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ABSTRACT
A FRET INVESTIGATION INTO MOLECULAR MECHANISMS OF
CARDIAC TROPONIN ACTIVATION IN RECONSTITUTED THIN FILAMENTS
MARIA ELENI MOUTSOGLOU
2016
Cardiomyopathies (CM) are the leading cause of death in America, and can
develop from mutations in sarcomeric proteins, leading to altered protein structure and
function. Current therapies target upstream signaling pathways to treat the symptoms of
heart failure, but are associated with increased mortality by affecting downstream
signaling pathways and other muscle types. Rational drug design can develop therapies to
treat CM at the protein level. However, a detailed knowledge of how sarcomeric proteins
regulate muscle contraction is required. Muscle contraction occurs through a cyclic
interaction between actin thin and myosin thick filaments, regulated by intracellular Ca2+
concentration. Troponin (Tn), the Ca2+-binding protein in muscle, allosterically regulates
actin and myosin interactions (crossbridge formation) by facilitating the release of two
troponin I (TnI) actin binding sites at high Ca2+, the inhibitory region (IR) and the second
actin binding site (SABS). The mechanism to remove TnI crossbridge inhibition is not
well understood. A multi-site Förster resonance energy transfer (FRET) assay in cardiac
Tn in reconstituted thin filaments was used to investigate the Ca2+-dependent structure
and dynamics of the SABS, and show current theories behind Tn activation are biased
using structures developed in isolated Tn. The SABS underwent large Ca2+-dependent
conformational changes, suggesting this region plays an important structural role in

xvii
muscle regulation. The mechanisms behind thin filament Ca2+ sensitivity were also
assessed to facilitate rational drug design. Titrations monitoring FRET efficiency (Tn
activation) by Ca2+ and myosin showed the drug bepridil works in a similar mechanism to
rigor myosin binding, which in native muscle increases Ca2+ sensitivity. The Ca2+desensitizing drug EGCG, however, does not work in a similar mechanism to protein
kinase A (PKA)-mediated phosphorylation of cardiac TnI, which in native cardiac muscle
disrupts residues in TnC responsible for binding Ca2+ at Site II. A single point drug
screen was developed for Tn in reconstituted thin filaments using a novel correlation
between the Ca2+-depleted FRET efficiency and Ca2+ sensitivity. This study shows the
utility of performing Tn structural studies in an environment that mimics native muscle.

1

THE CALCIUM-DEPENDENT STRUCTURE AND DYNAMICS OF THE CTERMINAL REGION OF CARDIAC TROPONIN I
ABSTRACT SECTIONS 1-3
Heart failure is the leading cause of death in the United States. To facilitate drug
design, the molecular mechanisms behind muscle regulation must be resolved. Cardiac
muscle contraction occurs through the Ca2+-dependent cyclic interaction between thin
and thick filaments, regulated by the heterotrimeric protein complex troponin (Tn). At
low Ca2+, the C-terminus of cardiac troponin I (C-cTnI) has two regions bound to actin to
inhibit myosin binding (crossbridge formation): the inhibitory region (IR) and the second
actin binding site (SABS). At high Ca2+, the Herzberg model of Tn activation suggests
the switch region binds an exposed hydrophobic pocket of N-TnC, dragging the IR off
actin to remove crossbridge inhibition. While structural studies have attempted to
describe the mechanism of Tn activation, the Ca2+-dependent nature of C-cTnI remains
elusive due to the complex inter- and intramolecular interactions between the proteins of
the thin filament. This study attempts to resolve the structure and dynamics of C-cTnI
within the reconstituted thin filament using a multi-site Förster resonance energy transfer
(FRET) assay. Epifluorescence imaging and fluorescence correlation spectroscopy were
used to monitor filament quality prior and during measurements. Ensemble time-resolved
FRET was used to derive the inter-dye distances with and without Ca2+. Regions of cTnC
displayed independent Ca2+ dynamics, most evident in the inter-lobe linker. The switch
region had minimal Ca2+-dependent dynamics (≈0.5 nm decrease in inter-dye distance
with Ca2+), and maintained a ≈5 nm distance from the regulatory core of Tn, ≈3 nm
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farther than predicted by the Ca2+-saturated crystal structure of cTn. Steady-state FRET
measurements performed on isolated cTn with donors on cTnI(151-189) and an acceptor
on cTnC89 showed good agreement with atomistic model-derived distances, suggesting
actin and tropomyosin (Tm) alter the overall architecture of cTn. Functional studies in
isolated rat ventricular fibers monitored force as a function of Ca2+, and showed
mutagenesis in the cTnI switch region and N-lobe of cTnC did not alter the native
function of cTn. cTnI177 appears to act as a pivot point separating the static switch
region and the highly dynamic C-terminal end of cTnI. Residues after cTnI177
underwent the greatest Ca2+-dependent changes (distances decreased by ≈1.5 nm),
leading to the designation of this region as the SABS. The binding of the SABS on actin
may account for the apparent displacement of the switch region from the cTn core. This
suggests the Hertzberg model may incorrectly assign the role of the switch region;
instead, some other mechanism may account for the removal of the IR and SABS from
actin.

3

1 INTRODUCTION
This dissertation is based on a study of the Ca2+-dependent interactions between
two thin filament regulatory proteins: troponins I and C. Mutations in the C-terminal
region of cardiac troponin I are known to cause cardiomyopathies through an interruption
in protein structure and function. However, the structure of this region of cardiac TnI is
not well defined due to its highly mobile nature and complex interactions with both actin
and troponin C. This author hypothesizes the C-terminal region of cardiac TnI plays a
dynamic role in muscle regulation. In this study, a Förster resonance energy transfer
(FRET) assay was developed to investigate the Ca2+-dependent structure and dynamics of
the C-terminal region of troponin I in reconstituted thin filaments. The presence of
tropomyosin and actin may influence the structure of cardiac troponin, and the
mechanisms of troponin activation currently presented in literature may be biased from
structural studies performed on troponin in isolation. An overview of basic muscle
contraction is given below to understand how proteins in the heart work together to
regulate myocardial activation.

1.1 An overview of cardiac muscle activation
In 2009, the Center for Disease Control (CDC) stated heart disease was the
leading cause of death in the United States.1 Cardiomyopathies result from functional
changes or a weakening in heart muscle, often as a result of mutations in sarcomeric
proteins. While current therapies attempt to slow the progression of heart disease by
addressing symptoms, direct therapies targeting sarcomeric proteins (called sarcomeric
modulators) would be more effective in reducing mortality by eliminating some of the
negative side effects of current therapies.2 In order to facilitate the development of
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informed drug design, the underlying mechanisms governing cardiac muscle regulation
must be resolved.
Cardiac muscle is striated muscle composed of fibrous myocytes (heart muscle
cells). Myocytes contain myofibrils comprised of bundles of sarcomeres. Sarcomeres are
the repeating contractile unit of muscle cells containing a network of proteins with two
types of filaments: thin and thick. Following a change in action potential (depolarization)
in myocytes, the sarcoplasmic reticulum (SR) releases Ca2+ into the myofibrils.
Intracellular Ca2+ regulates muscle contraction at the level of the thin filament by
interacting with the troponin (Tn) complex.3 When cytosolic [Ca2+] reaches ≈10 µM,
conformational changes in the thin filament cause thin and thick filaments to slide past
each other (contraction), mediated by crossbridge interactions between actin protomers
and myosin catalytic heads.4-5 This is known as the sliding filament model, coined by
Huxley and Hansen in 1954.4 Ryanodine receptors in the SR facilitate Ca2+ release and its
subsequent uptake via the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), leading
to muscle relaxation.6 A schematic view of the relaxed and contracted sarcomere is
shown in Figure 1.
Thin filaments are repeating structural units, where each functional unit is
composed of seven actin monomers, one tropomyosin (Tm) dimer, and one Tn complex.
Tn is composed of troponin T (TnT, Tm-binding), troponin C (TnC, Ca2+-binding), and
troponin I (TnI, ATPase inhibition). Globular α-actin (G-actin) monomers polymerize to
form F-actin in a double helix with an axial rise of ≈27.6 Å.7
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relaxed
I-band

A-band

I-band

m-region

myosin head

z-disc

thin filament
thick filament
overlap region

non-overlap
region

overlap region

contracted

SARCOMERE
Figure 1. Organization of the sarcomere showing the interdigitation of the thin and
thick filaments. ATP hydrolysis by myosin motors causes filaments to slide past each
other, shortening sarcomere length. Intracellular [Ca2+] controls myosin heads, cyclically
attaching and detaching from actin during relaxation and contraction. Labeled are thin
filaments (green) composed of troponin, tropomyosin, and actin; thick filaments (red)
composed primarily of myosin; Z-discs, composed of α-actinin, define a sarcomere unit
and crosslink the thin filaments; overlap regions, where myosin overlaps actin thin
filaments; the non-overlap region, absent thin filaments; the I-bands, absent myosin; the
A-band, the length encompassing one thick filament; and m-region, portion of the thick
filament without myosin heads.
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The actin structure is divided into four subdomains: subdomains 3 and 4 in the
inner domain of one actin monomer interact with subdomains 3 and 4 of an adjacent
monomer; subdomains 1 and 2 in the outer domain face outward, where subdomain 1
provides the binding site for myosin heads.8 Actin filaments are anchored to the Z-discs
(Figure 1), which regulate the length of the thin filament.9 Tm is a rod-like coiled-coil
dimer that acts as a molecular ruler. Tm runs along F-actin, providing binding sites for
the N-terminal tail of TnT at every seventh actin protomer, ensuring an equal distribution
of Tn every ≈40 nm.10-11 Tm binds in the grooves of F-actin between subdomains 1 and 3
(close to the myosin binding site),12 with a tail-to-tail overlapping region between Tm
molecules.13
Thick filaments are composed of myosin-II, which is divided into two regions.
The N-terminal end is composed of two motor or catalytic domains (globular heads).
Each motor domain associates with two light chains (regulatory and essential) and a
heavy chain. The C-terminal end is composed of an α-helical tail that forms a coiled-coil
with the heavy chain.14 The motor domain is termed subfragment-1 (S1), and protrudes
outward from the rigid filamentous region of bundled myosin tails (Figure 2). S1 is an
ATPase catalyzing the hydrolysis of adenosine triphosphate (ATP) into adenosine
diphosphate (ADP) and inorganic phosphate (Pi). S1 binding to actin facilitates the
release of ADP and Pi.15
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Figure 2. A simplified schematic of Ca2+- and myosin-dependent activation of the
thin filament. One regulatory unit is composed of seven actin protomers (red circles),
one α-helical Tm dimer (blue), and one Tn complex composed of TnT (green), TnI
(cyan), and TnC (yellow). For simplicity, actin is depicted as a single, straight filament;
in native muscle, F-actin is a double helix composed of two strands of actin. When
muscle is relaxed (state 1) at low Ca2+, TnC has a Mg2+/Ca2+ ions (black stars) bound to
Sites III and IV. The TnI inhibitory region (IR) and second actin binding site (SABS) are
bound to actin, forcing Tm in a position to prevent myosin binding. The thick filament is
composed of myosin, where myosin tails are intertwined, and the catalytic heads (S1)
protrude outward. At state 1, myosin has ATP bound, and is not interacting with actin.
When intracellular Ca2+ increases at state 2, Ca2+ binds to Site II in TnC causing Ca2+dependent activation of the thin filament. Conformational changes propagate through Tn,
causing the release of the IR and SABS from actin, allowing Tm to move away from
myosin S1 binding sites. Actin activates the S1 ATPase, where crossbridge formation
leads to hydrolysis of ATP into ADP and inorganic phosphate (Pi), with Pi is still
associated with the S1 head. Energy from ATP hydrolysis forces S1 into a higher energy
conformation. S1 binding to actin is cooperative, allowing for downstream crossbridge
formation (state 3). When ADP and Pi are released from S1 (state 4), S1 changes
conformation to a lower energy state, dragging the thin filament to contract
(powerstroke). S1 then binds ATP and releases actin, and Ca2+ is released from TnC; the
thin and thick filaments thus to return to state 1.
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The schematic in Figure 2 describes the Ca2+-and myosin dependent activation of
the thin filament leading to contraction. At low Ca2+ (Figure 2, state 1), Tn is in an
inactive conformation, with the inhibitory region (IR) and second actin binding site
(SABS) of TnI bound to actin, forcing Tm in a position that blocks myosin binding sites
on actin to prevents crossbridge formation.16 At high Ca2+ (Figure 2, state 2), Ca2+ binds
to Site II of TnC, causing conformational changes in Tn that promote IR and SABS
release from actin.17-18
Tm is free to move away from the myosin binding sites, allowing crossbridge
formation. S1 hydrolyzes ATP, forcing the catalytic head into a higher energy
conformation, with both Pi and ADP still associated with S1.19-20 Myosin then binds actin
in this higher energy state. More myosin heads are cooperatively recruited to bind to actin
(Figure 2, state 3). Figure 2, state 4 shows the actin-activated release of ADP and Pi from
S1,21 causing S1 to change to a lower energy conformation, dragging the thin filament
along in the powerstroke (contraction).22 When ATP binds to S1, myosin releases actin,
leading to relaxation. This cycling of ATP by myosin and actin is known as the
crossbridge cycle.
The detailed mechanism of activation of the thin filament to promote myosin
binding is still under investigation. One proposed mechanism is the steric blocking
model: in the absence of Ca2+, Tm blocks myosin-binding positions on actin due to the
inhibitory properties of TnI (as described previously). When Ca2+ binds to TnC,
conformational changes in Tn cause TnI to remove its inhibitory properties, allowing Tm
to move away from the myosin binding site, promoting myosin binding and ATPase
activity. Another proposed mechanism is the cooperative/allosteric model, which
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emphasizes the importance of actin conformational changes during activation to promote
myosin binding.23-25 Further studies are needed to verify these mechanisms.
In the next section, more detail is given to the structure and function of the Tn
complex as understood and presented in contemporary scientific literature. This is useful
in understanding why this study utilized the entire thin filament to investigate TnI in an
attempt to mimic the native muscle environment. Some of the mechanisms of Tn
activation and TnI structure outlined in the Introduction will be revisited in the Results
and Discussion section to compare and contrast to the conclusions reached by this study.

1.2 Troponin: the command center for muscle activation
In the sarcomere, contracted and relaxed states exist in a dynamic equilibrium,
where Ca2+ transients and other modifications shift the balance. Muscle contraction
occurs when a certain fraction of Tn is in the active state. The components of cardiac Tn
dynamically interact to modulate muscle activation using allosteric and cooperative
mechanisms to translate the signal across the myofilament. Tn activation itself can be
modulated by covalent and non-covalent modifications, including Ca2+ binding,
crossbridge formation, post-translational modifications, mutations, and intracellular
acidification. Changes in these modifications contribute to the contractile dysfunction
associated with heart failure.26
Tn uses allostery to control activation: conformational changes in Tn are
propagated along the thin filament to promote crossbridge formation. Tn is able to fulfill
this role due to its two distinct subdomains: the N-terminal region of TnT, which grips
the Tn complex onto the Tm-actin filament; and the regulatory core of C-TnT, TnI and
TnC. These domains are mainly composed of α-helices connected by flexible linkers.27
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Figure 3 shows the Manning-Tardiff-Schwartz (MTS) molecular model, with certain
regions of TnT, TnI, and TnC discussed in more detail in the following sections. The
MTS model utilized the 52kDa cardiac crystal structure of Tn, and was used as a
reference in the Results and Discussion section. In the following text, “on” and “open”
may be used interchangeably to describe the active state of Tn, and “off” and “closed”
may be used to describe the inactive state of Tn.
Understanding how Tn translates on or off signals to actin during activation is
imperative to a complete understanding muscle regulation. Of particular importance are
the unique structure-function relationships between actin and TnI (the inhibitory protein),
and TnI and TnC (the Ca2+ binding protein). This assay was designed to monitor the
structural transition of C-TnI with respect to three specific sites on TnC, allowing for a
triangulation of the relative position C-TnI during activation, and broaden the
understanding of the Ca2+-induced dynamics between TnI and TnC. Though nuclear
magnetic resonance (NMR) spectroscopy and X-ray crystallography have given insights
into the Ca2+-saturated and Ca2+-depleted structural nature of Tn, this assay was designed
to directly probe the Ca2+-dependent dynamics of C-TnI in relation to TnC reconstituted
into thin filaments in solution. Using thin filaments as a simple biochemical model28 for
muscle activation yields insight into the behavior of Tn in the presence of Tm and actin.
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Figure 3. Structure of the Ca2+-saturated cTn core. Ribbon representation of the MTS
molecular model of Ca2+-bound cTn, where TnI (grey), TnT (T2) (cyan), and TnC (black)
are shown. Helices I and II of the T2 region of TnT and helices I-III of TnI are labeled.
For the C-terminal region of TnI, the inhibitory region (residues 138-149, red), the switch
region (residues 151-167, blue), the mobile domain (residues 168 to 189, green), and the
C-terminal end (residues 190 to 211, pink). The switch region is bound to the
hydrophobic pocket of the N-lobe of TnC.
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1.2.1 Troponin C: the Ca2+-binding subunit of the thin filament
Troponin C is an ≈18 kDa, 161-residue protein known as the Ca2+-sensitive
switch of the myofilament. Cardiac TnC is composed of two globular lobes connected by
a flexible linker.29 The N- and C-lobes (N: amino terminus; C: carboxy terminus) each
contain two EF-hand structural motifs (helix-loop-helix) that bind divalent cations at sites
numbered I-IV (N-ward to C-ward). Sites III and IV in the C-lobe constitutively bind
Mg2+ or Ca2+. Sites I and II in skeletal TnC (sTnC) bind Ca2+ at physiological levels,30
but only Site II in cTnC binds Ca2+.31 Site I is unable to bind Ca2+ due to mutations in two
acidic residues responsible for coordinating Ca2+ (D29L, D31A), and an insertion of a
valine at residue 28.32 The chelation residues coordinating Ca2+ at Site II are D65, D67,
E76, S69, and T71.33 When Ca2+ binds to Site II, the N-lobe of cTnC partially opens, as
opposed to a full opening in sTnC when two Ca2+ bind.34-35 This opening occurs through
a structural rearrangement of the B and C helices, revealing a hydrophobic cleft where
the switch region of TnI is thought to bind to stabilize the open conformation of the Nlobe of TnC.35-36 The C-lobe of TnC requires no other protein interactions to stabilize its
open conformation.29 Residues 44-66 of helix I of TnI bind to the C-lobe.27, 37 Due to the
lobes’ individual roles within TnC, the C-lobe has been termed the structural domain, and
the N-lobe the regulatory domain.

1.2.2 Troponin T: the tropomyosin-binding anchor of the thin filament
Troponin T is a ≈36 kDa protein responsible for anchoring the Tn complex onto
the thin filament through interactions with Tm. The N-terminus of TnT modulates
ATPase activity, and the C-terminus interacts with Tm in a Ca2+-sensitive manner.38-39
TnT is a flexible, elongated protein with two distinct regions: T1, the Tm-binding region
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(residues 1-181, human numbering); and T2, which interacts with the core of Tn
(residues 181-288, human numbering).40 Notably, T1 was removed to promote sample
stability in the Takeda crystal structure, as this region increases aggregation of isolated
Tn.27 T1 has an isoform-specific N-terminal extension (residues 1-76) that is negatively
charged due to its composition of mostly of aspartate and glutamate residues.41
Tobacman first suggested the N-terminal extension participates in Ca2+-dependent
regulation, where a deletion of the first 38 residues in bovine cTnT resulted in a decrease
in ATPase activity.42 Chandra et al. suggested the ATPase activity inhibition conferred by
the N-terminal deletion is due to changes in interactions at the Tm-Tm overlap region.43
Residues 98-136 (human numbering) in the central region (CR) in T1 interact
with the C-terminal region of Tm to affix Tn onto the actin filament,44 and the N-terminal
extension modulates this interaction.45 Residues 183-200 form a flexible linker
connecting T1 and T2 together. Helix II (residues 226 to 279) in T2 forms the I-T arm
with helix II of TnI.27 The C-terminal region of TnT in the I-T arm interacts with the Clobe of TnC27 and Tm.46-47 Interactions between the T2 region and TnI, TnC, and Tm
occur in a Ca2+-dependent manner,39 and T2 has been shown to play a role in both Ca2+dependent regulation and in length-dependent activation.45 The behavior of TnT during
muscle regulation is modulated by protein kinase C (PKC)-mediated phosphorylation
sites at Thr 194, 203, and 284, and at Ser 198, which can result in an increase or decrease
in thin filament sensitivity, depending on the site phosphorylated.48

1.2.3 Troponin I: the inhibitory subunit of the thin filament
Troponin I is a ≈24 kDa protein known as the inhibitory subunit of Tn. At
intracellular [Ca2+] = 10-6 M, TnI inhibits crossbridge formation by preventing myosin
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binding to actin (ATPase activity).49 Absent other Tn subunits, TnI is still capable of
inhibiting ATPase activity in the myofilament.50 However, regulation of this inhibition
requires the Ca2+ sensitivity of TnC.51-52 TnI and TnC interact in an antiparallel manner,
where the N-terminus (residues 35-72) of TnI interacts with the C-terminus of TnC.
Post-translational modifications on TnI in the form of phosphorylation primarily
down-modulate cardiac contractility. Cardiac TnI has an isoform-specific ≈32-residue Nterminal extension with two protein kinase A (PKA)-dependent phosphorylation sites at
serines at 23 and 24 (human numbering).53 Ser-23/24 can also be phosphorylated by
protein kinase D (PKD), causing reduced Ca2+ sensitivity of TnC.54 Yasuda et al. used
mice expressing non-phosphorylatable cTnI to show PKA-mediated phosphorylation at
Ser-23/24 contributes significantly to cardiac relaxation.55 When not phosphorylated, the
extension stabilizes the N-terminus of TnC.56 Phosphorylation increases Ca2+ release by
destabilizing Ca2+ binding through changes in the interactions between the N-TnI with NTnC.57-58 TnI also contains PKC-mediated phosphorylation sites at Ser-43/45, and on
Thr144 in the inhibitory region (IR).59 Phosphomimetic mutations at Ser-43/45 showed
reduced thin filament sensitivity to Ca2+.60 Under Ca2+-depleted conditions, Thr144 was
shown to be involved in strong crossbridge-dependent activation of ATPase activity,61
suggesting Thr144 modulates crossbridge formation.
C- and N-TnI domains play structural and regulatory roles, respectively. Helix II
(residues 91-136) of TnI forms a coiled-coil with helix II of TnT to form the I-T arm. The
I-T arm and helix I of TnI (residues 44-80) enclose the C-lobe of TnC.27 The regulatory
region of TnI comprises residues 138-211. Included is the inhibitory region (residues
138-149), which interacts with actin under Ca2+-depleted conditions17, 62 to inhibit myosin
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ATPase activity (muscle contraction).50 The structure of the IR for cTnI has not been
resolved using X-ray crystallography, though FRET studies in cTn have predicted the IR
switches from a β-turn coil into a quasi α-helix with Ca2+.63
Upon Ca2+ binding, the switch region (residues 151-167) binds to the partiallyexposed hydrophobic pocket of the N-lobe of TnC, stabilizing the fully open state of the
N-lobe. According to a model first developed by Herzberg, the binding of the switch
region drags the IR off actin, removing its inhibitory effects from actin-tropomyosin.64-65
Residues 168-211 are required for full ATPase inhibition through Ca2+-dependent
interactions with actin (termed the second actin binding site, SABS).66-67 This region is
composed of the mobile domain (residues 168-189) and C-terminal end (residues 190211), and has been the subject of numerous studies. However, the complete structure,
dynamics, and functional details of this region remain unresolved. The fly-casting
mechanism has been proposed to describe the role of TnI(168-211): under Ca2+ saturating
conditions, these residues are an intrinsically disordered region (IDR), and able to sample
multiple potential binding sites on actin that catalyze a return to the off state upon Ca2+
release.68 Deletion experiments, where the last 17 residues of sTnI were removed,
showed the affinity of TnI for the thin filament decreases in the absence of this Cterminal region, suggesting interactions with actin and TnC are in a Ca2+-dependent
equilibrium.69
The next sections include a brief overview of some of the proposed structures of
different isoforms of C-TnI, and the mechanism in which C-TnI binds to either actin or
TnC as understood in literature. This is helpful in discovering some of the drawbacks of
the current methodology, and why structural biology investigations benefit when
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performed in a more native environment. Also noted are the unresolved portions of
cardiac and skeletal TnI structures. Of particular importance is the unresolved C-terminal
region, the subject of this study.

1.2.4 Sample stability and resolution limits: barriers to resolving native
protein structure and dynamics
A number of studies on skeletal and cardiac Tn have attempted to reveal the
structure and dynamics of C-TnI, and identify specific interactions with TnC and actin.
Unfortunately, due to sample stability issues or the resolution limits of the selected
method, many studies were performed on free Tn, individual Tn subunits, or on Tn with
amino acid deletions. This gives rise to the question of whether the Ca2+-depleted
structure/dynamics of the C-TnI can be fully understood in the absence of actin. X-ray
crystallography is a useful method that provides high resolution 3D protein structure at
atomic resolution. Progress in resolving the crystal structure of the entire cTn complex
and Ca2+-depleted cTn has been impeded by practical issues, such as sample aggregation
or growing high quality crystals. To grow crystals, proteins are exposed to a non-native
environment, where pH, ionic strength, temperature, and detergents used differ
dramatically to the native muscle environment.70 Solution conditions could promote
proteins to settle into non-native structures. Additionally, more mobile regions of proteins
cause disorder in the crystal lattice, altering X-ray diffraction and preventing resolution.71
NMR spectroscopy can resolve protein structure and dynamics in solution. However,
NMR can only be used for proteins or peptides <40 kDa.72 Tn itself is a 75 kDa complex,
and only an incomplete complex can be studied using NMR. To overcome the barriers in
X-ray crystallography and NMR spectroscopy, this study utilized FRET spectroscopy to
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resolve TnI-C structure and dynamics in solution. There is essentially no size limitation
with FRET, therefore allowing the incorporation of FRET-labeled Tn into reconstituted
thin filaments. Additionally, FRET can resolve large-scale conformational changes (≈10
Å) in large assemblies.73 More detail into developing a FRET assay to study structural
biology is given in the Results and Discussion section.
Equating skeletal Tn structure and function to cardiac Tn can also be problematic.
While the amino acid sequences between cardiac, fast skeletal, and slow skeletal Cterminal regions of TnI are highly conserved,74 there are some substantial structural
differences in TnT, TnC, and TnI isoforms. cTnT has an 18 residue N-terminal extension
that may affect the cooperative activation of the thin filament.75 Comparing the results of
deletion experiments in rabbit sTnT76 and bovine cTnT42 shows the N-terminal extension
in cTnT alters Ca2+-dependent ATPase activity. In addition, sequence heterogeneity
between fast skeletal (fs)TnT and cTnT suggests variations in structure impose a tissuespecific function for TnT.77 As mentioned previously, cTnC does not bind Ca2+ at Site I,
which effects the kinetics of the Ca2+-sensitive inhibitory properties of TnI (switching of
TnI off actin to TnC).78 Ca2+ binding to cTnC induces only a partial opening of the Nlobe, compared to a full opening in sTnC. sTnI has no N-terminal extension, which
includes PKA-mediated phosphorylation sites at Ser-23/24 in TnI, important for
modulating the Ca2+ sensitivity of the TnC.79
Structural studies performed in isolated or fragmented Tn or in individual Tn
subunits can still give insight into the mechanism of activation. Of concern to molecular
and atomistic modeling, however, is the inherent bias introduced by incorporating
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structures developed from isolated Tn. Proposed models for both skeletal and cardiac CTnI structure and function will be reviewed as presented in the literature.

1.2.5 Crystal structures and proposed atomistic models of Tn
The Takeda crystal structure of the Ca2+-saturated cTn core
Takeda et al. solved Ca2+-bound human cTn structures using X-ray
crystallography in 2003 (human numbering will be used in this section).27 In total, four
structures were resolved: two 46 kDa structures (A and B, PDBID 1J1D), and two 52
kDa structures (A and B, PDBID 1J1E). The N-terminal extension of TnI and T1 region
of TnT were removed to promote sample stability. TnI Helix III comprises residues 150159 of the switch region, which is bound to the hydrophobic cleft of the Ca2+-bound Nlobe of TnC. Helix III is followed by a flexible linker, where a glycine at residue 160
kinks helix IV (residues 164-189) to protrude rigidly outward from the core domain.
Glycine is a small amino acid that destabilizes α-helices. Insufficient electron density
prevented resolving the IR (138-147) and C-terminal end (192-211) most likely due to
their mobile nature. At high Ca2+, the IR is in an extended conformation to allow the
switch region to interact with the N-lobe of TnC, suggesting under Ca2+-depleted
conditions, the IR changes both its position and potentially its conformation in order to
bind to actin.
The Vinogradova fsTn crystal structures with and without Ca2+ bound
In 2005, Vinogradova et al. solved the Ca2+-saturated and Ca2+-depleted crystal
structures of chicken fast skeletal (fs) Tn at 3.0 and 7.0 Å resolutions, respectively.80 The
disordered C-terminal region (last 40 residues) juts perpendicularly away from the Tn
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core. In the absence of Ca2+, the IR forms an α-helix and binds to actin. When Ca2+ binds
to TnC, the IR helix extends to a loop, allowing the switch region to reach the
hydrophobic cleft of the TnC N-lobe, corresponding to an ≈8 Å movement. The linker
between the C- and N-lobes forms an α-helix. Vinogradova and colleagues suggest the
disordered inter-lobe linker for TnC seen in the Takeda structure may be due to the
absence of stabilizing interactions from the cardiac-specific N-terminal extension.
The Murakami atomistic model of sTn
In 2005, Murakami et al. used NMR to analyze a ≈52 kDa ternary sTn complex,
showing the mobile domain (human cTnI160-210) of sTnI as a ß-sheet flanked by two
short α-helices.81 The mobile domain tumbled independently of the Tn core around a
pivot point between TnI Gly160 and Lys164 (human cardiac numbering), suggesting a
capacity for this domain to interact with actin under Ca2+-depleted conditions. Under
Ca2+-saturated conditions, the C-terminal end was less mobile due to contact of the
switch region with N-TnC. This is in agreement with anisotropy measurements in
reconstituted thin filaments by Zhou et al., who showed the flexibility of C-TnI decreases
when Ca2+ binds.82 Using the ratio of chemical shift differences at high and low Ca2+,
Murakami et al. showed there was greater mobility in residues sTnI170-180 (mcTnI199211), with less mobility in sTnI140-169.
The Pirani/Vinogradova atomistic model of the Ca2+-saturated and Ca2+-depleted thin
filament
In 2006, Pirani and Vinogradova et al. reconstructed the Ca2+ bound and unbound
atomistic models of the thin filament using Tm, actin, and the Vinogradova fsTn crystal
structures.80 The model was aligned to electron microscopy (EM) images of isolated
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skeletal thin filaments.83 The EM/atomistic reconstruction of the thin filament showed an
“extra appendage” that extended outward from Tn under Ca2+-depleted conditions; this
was attributed to C-TnI. This region branched outward from the I-T arm to form a bridge
between two actin monomers. How this extension was connected to the rest of TnI was
not resolved. The authors claim the N-lobe of TnC is positioned relatively remotely from
the actin surface both with and without Ca2+. This suggests if the switch region is tethered
away from N-TnC by the IR bound to actin, the switch region would have to travel an
appreciable distance (more than 1 nm) to bind to the N-TnC at high Ca2+.
The Manning-Tardiff-Schwartz (MTS) atomistic model of the thin filament
In 2012, Manning, Tardiff, and Schwartz presented molecular models of the thin
filament at high and low Ca2+.84 The 52 kDa cTn crystal structure,27 Pirani atomistic
model of the thin filament,83 and fsTn80 were used to predict Tn and Tm/actin
intramolecular interactions. Tn relaxation was a result of reduced interactions between
the N-lobe of TnC and switch peptide of TnI, resulting in favored interactions between
the IR and SABS regions with actin. This supports the fly-casting mechanism and
Herzberg model of Tn activation. Under low Ca2+, the mobile domain had a “rigid”
conformation favoring actin binding that forced Tm in a position to block myosin binding
sites on actin, which supports the steric blocking model. Additionally, as a result of TnC
N-lobe conformational changes, the I-T arm rotated, translating a deactivating structural
change to Tm through TnT. The greatest Ca2+-dependent dynamics were seen in the I-T
arm, the cTnT T1-T2 linker, and mobile domain of TnI. This study’s FRET-derived
distances at high Ca2+ were compared to MTS model distances in the Results and
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Discussion section, as the MTS model includes the crystal structure cTn core with
molecularly-derived residues for the C-terminal end (mcTnI189-211).

1.3 Mutations in C-TnI associated with heart failure
Molecules that modulate the Ca2+ sensitivity of the thin filament are a therapeutic
option to improve contractile function. Resolving the mechanism of thin filament
activation could lead to rational structure-based drug design. Sarcomeric protein
mutations are responsible for cardiomyopathies by interrupting the regulatory functions
governed by those proteins.2 Cardiomyopathies (CM) develop when myocytes “sense”
changes in contractility due to amino acid mutations that disrupt protein structure; the
myocytes alter signaling cascades to initiate compensatory mechanisms, resulting in a
CM phenotype.85 Familial hypertrophic cardiomyopathy (HCM),86 restrictive
cardiomyopathy (RCM),87-88 and familial dilated cardiomyopathy (DCM)89 are the three
most common forms of heart failure associated with mutations in genes encoding for
sarcomeric proteins. Here, mutations in TNNI3, the gene encoding cTnI, will be
discussed briefly to highlight the importance of cTnI’s IR and SABS (C-terminal end) for
normal cardiac function. RCM is distinguished by impaired ventricular filling and
reduced end diastolic volume due left ventricular wall stiffness, with preserved
myocardial wall thickness and systolic function.90 Mutations in hcTnI that cause RCM
are primarily focused in the IR (Leu144Gln, Arg145Trp) and C-terminal end (Ala171Thr,
Lys178Glu, Asp190Gly, Arg192His, Arg204His).88, 91 These mutations increase the Ca2+
sensitivity of force development, decrease ATPase activity, and decrease ATPase
inhibition.92-93 HCM is characterized by contractile dysfunction, a thickened left ventricle
(hypertrophy), and arrhythmia.86 HCM is primarily a genetically inherited disease, as
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opposed to RCM and DCM, which are both acquired and genetically inherited.94 Four of
the 29 total TNNI3 mutations causing HCM are found in the IR, with the majority (22)
found at the C-terminal end.95-97 These mutations have shown contrasting effects on Ca2+
sensitivity and Ca2+-activated force of myofibrils.98 DCM causes a thinning of the left
ventricle (dilated) and poor systolic function.99 DCM mutations have been discovered in
the N-terminus of cTnI: a mutation near the Ser-23/24 phosphorylation site (Arg21Cys)
decreases phosphorylation rates in vitro, while a Ala2Val caused decreased TnT/TnI
interactions.89 As of yet, no mutations in the C-terminal region of TnI have been
discovered that cause of DCM.
The high density of HCM- and RCM-causing mutations in C-TnI demonstrate the
essential role of the two actin binding sites in this region to maintain normal cardiac
muscle function. A greater understanding of the Ca2+-dependent structure and dynamics
of this region, particularly of the second actin binding site of TnI, would yield insight into
why these site mutations yield such dramatic phenotype changes to reduce mortality.

1.4 A multi-site FRET assay in a most native environment
A multi-site FRET assay was developed to resolve the Ca2+-dependent structure
and dynamics of the C-terminal region of cTnI in reconstituted regulated actin. The interdye distances derived at high and low Ca2+ clarify the role of cTnI in modulating muscle
activation. Other studies lack the exhaustive assessment of filaments involving a
combination of biochemical and spectroscopy methods that ensure a high degree of
confidence in sample quality. Solution conditions mimicking the native environment of
the sarcomere yield a more accurate assessment of Tn structure, as opposed to structures
derived from isolated Tn.28 This is the first assay designed to use FRET to map the
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position of C-cTnI with respect to the N-lobe, inter-lobe linker, and C-lobe of cTnC, and
to confirm the hypothesis that the SABS of cTnI plays a vital structural and functional
role in regulating muscle activation. Here, the switch region (helix III) of cTnI was
shown to have minimal Ca2+-dependent dynamics, and most likely is a rigid helix
comprising residues 151-177 that maintains a distance of ~5 nm away from the cTn core.
This is surprising considering the Herzberg model predicts switch binding to N-TnC upon
Ca2+ binding. Helix III is connected by a short loop to a more mobile helix (called helix
IV). The SABS consists of residues 189-211, and is the most dynamic region of C-cTnI.
cTnC undergoes region-dependent Ca2+-induced movement. This study has shown at low
Ca2+, the SABS is bound to actin; when Ca2+ binds to cTnC at Site II, the SABS is
displaced from actin, where the regulatory region of cTn would translate this activating
signal to TnT(T1), Tm, and finally actin to promote cooperative activation of the thin
filament. The binding of the switch region to cTnC may require further thin filament
modifications, such as myosin binding or phosphorylation. The surprisingly long
distances resolved between the switch region and the N-lobe of cTnC compared to
previous studies may be due to the displacement of the C-terminal region away from the
core of cTn by the SABS binding to actin.
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2 METHODS
2.1 Native protein purification
2.1.1 Acetone powder from bovine left ventricle tissue
Acetone powder was prepared from fresh bovine hearts at 4°C as described.100
Connective tissue, blood vessels, and blood were removed, and the left ventricle was
ground in a pre-chilled meat grinder. The minced meat was soaked in 0.1 M KCl and
0.15 M potassium phosphate (pH 6.5) for 10 min, then filtered through pre-soaked
cheesecloth. The mince was stirred in 0.05 M NaHCO3 (sodium bicarbonate) for 10 min
and filtered, then stirred in 1 mM EDTA (pH 7.0) for 10 min, filtered, and stirred again in
the same buffer for 5 min. Mince was filtered, then stirred in deionized and distilled H2O
(ddH2O) for 5 min, and filtered. Mince was stirred in 1 L of acetone for 10 min at 25°C,
filtered, and repeated four times. The mince was then dehydrated overnight in the hood,
and stored at -20°C for up to a year. Purity was assessed using sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE, 12% bis/acrylamide, monomer to crosslinker ratio 29:1) with Precision Plus Protein Kaleidoscope Protein Standards (Bio-Rad,
Hercules, CA).

2.1.2 Purification of tropomyosin from acetone powder
Tm was purified from acetone powder as described.101 Briefly, about 100 g of
acetone powder was extracted with a high salt solution (1.0 M KCl, 0.5 mM
diothiothreitol [DTT]) at pH 7.0, filtered through cheesecloth, and the residue extracted
again with the high salt solution. After adjusting the pH to 4.6 for 30 min, the solution
was centrifuged for 20 min at 6,000 xg, and the pellet was dissolved in the high salt
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buffer with pH 7.0. The insoluble material was removed using centrifugation at 6,000 xg
for 10 min. This procedure was repeated twice, with the final pellet dissolved in ddH2O
supplemented with 0.5 mM DTT. Ammonium sulfate (0-53%, mass calculated with
http://www.encorbio.com/protocols/AM-SO4.htm) was added slowly to the solution,
with pH maintained at 7.0 at 4°C with stirring for 30 min. The precipitate was removed
with centrifugation for 30 min at 11,000 xg, and the supernatant was brought to 65%
saturation with ammonium sulfate, with pH maintained at 7.0. The precipitate was
pelleted with centrifugation, dissolved in 0.5 mM DTT, and dialyzed against 2 mM 2mercaptoethonol (BME). Tm consisting of a native mixture (9:1) of α:β isoforms was
aliquoted, lyophilized, and stored at -80°C for up to 1 year. Purity was assessed using
SDS-PAGE. Gels were stained using GelCode™ Blue Safe Protein Stain (Fisher
Scientific Company, LLC, Hampton, NH).

2.1.3 Purification of actin from acetone powder
Actin was purified from acetone powder as described.100 Briefly, 5 to 10 g of
acetone powder was dissolved in Buffer A (2 mM Tris-HCl [Trizma® hydrochloride,
Tris(hydroxymethyl)aminomethane hydrochloride] (pH 8.0), 0.5 mM BME, 0.2 mM
CaCl2, 0.005% sodium azide, and 0.2 mM Na2ATP) (20 mL/g acetone powder) and
stirred for 30 min. Extract was filtered through sterilized cheesecloth. The filtrate was
then centrifuged at 20,000 xg for 1 hour at 4°C. The supernatant was polymerized by
adding drop-wise (the same volume as the supernatant volume) a solution of 50 mM KCl,
2 mM MgCl2, and 1 mM ATP to the filtrate at 4°C while stirring, with continued stirring
for two hours. Solid KCl was added to the solution to reach a concentration of 0.8 M and
stirred for 30 min. The solution was centrifuged at 150,000 xg for 1.5 hours, and the
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pellet was resuspended in Buffer A supplemented with 0.8 M KCl, 2 mM MgCl2, and 1
mM ATP. The sample was centrifuged at 150,000 xg for 1.5 hours, and the pellet was
resuspended in Buffer A at 1.5 mL/g acetone powder. The pellet was homogenized with a
Dounce homogenizer, and dialyzed against Buffer A for 16 hours, with three additional
buffer exchanges for a total of 48 hours. Globular actin (G-actin) was clarified with
centrifugation at 150,000 xg for 1.5 hours. The supernatant containing G-actin was then
polymerized with 50 mM KCl, 2 mM MgCl2, and 1 mM ATP added drop-wise with
stirring, and stirred for 2 hours at 4°C. Filamentous (F-actin) was stored at 4°C in Buffer
A for up to four months. Purity was confirmed using SDS-PAGE.

2.2 Mutagenesis and DNA amplification and purification
Wild type (WT) rat cardiac troponin T (TnT) and WT rat cardiac troponin C
(TnC) plasmids were obtained from the Herbert C. Cheung lab (University of Alabama).
WT mouse cardiac troponin I (TnI) and myc-tagged mouse cardiac TnT plasmids were
gifts from the R. John Solaro lab (University of Illinois at Chicago). Primers were
ordered from Integrated DNA Technologies (Coralville, IA), diluted to 1 µg/mL with
ddH2O, and stored in -20°C. Cysteine-less (Cys-less), Cys-lite (removal of one native
Cys), and single Cys mutations in TnC and TnI (Table 1) were made using QuikChange
Lightning Site-Directed Mutagenesis kits (Agilent Technologies, Santa Clara, CA) by
following the protocol provided. PCR products were transformed into XL10-Gold
Ultracompetent Cells (Agilent Technologies, Santa Clara, CA) following the protocol
provided. 100 µL of cells were inoculated onto lysogeny broth (L-B, Fisher BioReagents,
Hampton, NH) agar plates supplemented with the appropriate antibiotic (100 µg/mL), and
incubated overnight at 37°C. Minipreps were prepared in triplicate with 2 mL of L-B
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supplemented with the appropriate antibiotic (100 µg/mL). Single colonies were
inoculated into the medium, and grown overnight with shaking at 37°C. Plasmids were
purified using Wizard Plus SV Minipreps DNA Purification System kits (Promega
Corporation, Madison, WI) following the protocols provided. Purified plasmids were
sequenced using single pass DNA sequencing by ACGT, Inc. (Wheeling, IL). Upon
sequence confirmation, plasmids were stored at -20°C.
Table 1. Recombinant troponin proteins expressed in Escherichia coli and purified.
Protein

Mutation/Modification

Species

Vector

troponin T

N-terminal His-tag
none
none
C84S
C35S, C84S, S89C
C35S, C84S, T127C
none
C81I, C98S, S151C
C81I, C98S, L160C
C81I, C98S, S167C
C81I, C98S, L174C
C81I, C98S, V177C
C81I, C98S, I182C
C81I, C98S, V189C
C81I, C98S, I196C
C81I, C98S, S200C
C81I, C98S, G204C
C81I, C98S, K208C
C81I, C98S, G211C

mouse cardiac
rat cardiac
rat cardiac

pSBETa
pET-3d
pET-3d

Antibiotic
Resistance
kanampamp-

mouse cardiac

pET-3d

amp-

troponin C

troponin I

Cloning Sites
NdeI-BamHI
NcoI-BamHI
NcoI-BamHI

NcoI-BamHI

2.3 Bacterial expression and recombinant protein purification
2.3.1 Preparation of troponin C
WT rat cardiac TnC, Cys-lite TnC (C84S), and Cys-less TnC (C35S, C84S) were
sub-cloned into the pET-3d vector with ampicillin (amp) resistance for expression. The
plasmids were thawed on ice, and 0.5 µL of plasmid were added to 50 µL of BL21 (DE3)
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competent Escherichia coli cells (New England Biolabs, Ipswich, MA). Cells were
transformed using heat shock (42°C, 42 sec), and incubated with 250 µL S.O.C. medium
(Super Optimal broth with Catabolite repression, 2% tryptone, 0.5% yeast extract, 10 mM
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) shaking for 1 hour
at 37°C. 100 µL of cells were inoculated onto L-B agar plates supplemented with 100
µg/mL ampicillin and incubated at 37°C overnight. Pre-cultures were prepared by
selecting a single colony, and inoculating 3 mL of L-B broth supplemented with 100
µg/mL ampicillin. The pre-culture was incubated at 37°C under shaking for 6 hours.
Bacteria were overexpressed in large growths, where 500 µL of cells from the pre-culture
were inoculated into 500 mL of Terrific Broth (TB, Fisher BioReagents) (typically total 2
L growths) supplemented with 100 µg/mL ampicillin under shaking for 18 hours at 37°C.
Troponin C was purified from cells as described with some modifications.102-104
Briefly, cells were harvested with centrifugation at 8,000 rpm for 9 min with a JA-10
rotor, and used immediately or stored at -80°C for up to a month. Cells were resuspended in less than 100 mL of 2.5 mM EDTA, 0.5 mM PMSF, 50 mM Tris-HCl (pH
8.0), and 15 mM BME with a stir bar at 4°C for 30 min. Cells were lysed on ice with
ultrasonification in a Misonix ultrasonix liquid processor (power, 50; 10 sec on, 20 sec
off) for 25 min of “on” time. Cellular debris was removed from the lysate with two
rounds of centrifugation. First, the lysate was centrifuged at 18,000 rpm for 25 min using
a JA-20 rotor. The supernatant was then centrifuged at 35,000 rpm for 45 min in a
Beckman XL-90 ultracentrifuge using a Ti-45 rotor. Ammonium sulfate (0-60%, mass
calculated with http://www.encorbio.com/protocols/AM-SO4.htm) was added slowly
with stirring to the supernatant at 4°C over the course of an hour, then centrifuged for 30
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min at 10,000 rpm with a JA-14 rotor. Ammonium sulfate was added to the supernatant
(60-80%) and centrifuged for 30 min at 10,000 rpm with a JA-14 rotor. The pellet was resuspended in and dialyzed against 1 L Buffer A-TnC (50 mM Tris-HCl (pH 7.5), 50 mM
NaCl, 5 mM CaCl2, 1 mM MgCl2, and 1 mM DTT) overnight.
TnC was purified from the lysate using hydrophobic interaction chromatography.
The lysate was loaded onto a column with a matrix of Phenyl Sepharose 6 Fast Flow
(High Sub) (GE Healthcare Life Sciences) equilibrated with Buffer A-TnC using a fast
protein liquid chromatograph (FPLC, ÄKTAprime, GE Healthcare Life Sciences) and a
UV lamp to monitor absorption at 280 nm. Non-specific proteins with weak hydrophobic
interactions were removed with 50 mM Tris-HCl (pH 7.5), 1 M NaCl, 0.1 mM CaCl2,
and 1 mM DTT. TnC was eluted from the column with 50 mM Tris-HCl (pH 7.5), 1 mM
EDTA, and 1 mM DTT. SDS-PAGE was used to analyze peaks from absorbance at 280
nm. Fractions containing purified protein were combined, lyophilized, and stored at 80°C for up to three years.

2.3.2 Preparation of troponin I
WT mouse cardiac TnI and cysteine-modified TnI (see Table 1) were purified
similarly to TnC, with some modifications. The pelleted cells were re-suspended in CM
buffer supplemented with 0.5 mM PMSF. The ammonium sulfate precipitations were 027% and 27-60%, and the pellet from the second cut was re-suspended in and dialyzed
against 1 L of CM buffer overnight. TnI was purified from the lysate using weak cation
exchange chromatography. The lysate was loaded onto a column with a matrix of CM
(carboxymethyl) Sepharose Fast Flow (GE Healthcare Life Sciences) equilibrated with
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CM buffer. TnI was eluted with a gradient elution of 0 to 100% mixtures of CM buffer
and CM buffer supplemented with 300 mM NaCl.

2.3.3 Preparation of troponin T
WT rat cardiac TnT and mouse cardiac TnT with an N-terminal polyhistidine
myc-tag (amino acid sequence, N-EQKLISEEDL-C) were purified similarly to TnC, with
some modifications. Cells were grown for 36 hours at 37°C with shaking. The pelleted
cells were re-suspended in CM buffer (6 M urea, 30 mM citric acid (pH 6.0), 1mM
EDTA, and 1 mM DTT) supplemented with 0.5 mM PMSF. The ammonium sulfate
precipitations were 0-35% and 40-60%, and the pellet from the second cut was resuspended in and dialyzed against 1 L of DEAE buffer (6 M urea, 50 mM Tris-HCl (pH
8.0), 1 mM EDTA, 1 mM DTT) overnight. TnT was purified from the lysate using weak
anion exchange chromatography. The lysate was loaded onto a column with a matrix of
DEAE (diethylaminoethyl) Sepharose Fast Flow (GE Healthcare Life Sciences)
equilibrated with DEAE buffer. TnT was eluted with gradient elution from 0 to 100%
mixtures of DEAE buffer and DEAE buffer supplemented with 500 mM KCl.

2.4 Development of FRET assay
2.4.1 Calculation of the Forster critical distance
The Förster distance (R0) is the distance at which 50% of the donor molecules
decay by energy transfer, and 50% decay by radiative and non-radiative processes.105 For
each FRET pair (AF546, FRET donor-ATTO655, FRET acceptor; ATTO550, FRET
donor-ATTO655, FRET acceptor), R0 was determined using excitation and emission
spectra provided by Life Technologies and ATTO-Tec GmbH using105
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𝑅"#

9000 ln 10 𝜅 + 𝑄=
128𝜋 + 𝑁𝑛3

6
"

𝐹- 𝜆 𝜀8 𝜆 𝜆3 𝑑𝜆,

(1)

where 𝜅 + is the relative orientation in space of the donor and acceptor transition dipoles,
assumed 2/3; N is Avogadro’s number = 6.023 × 10+@ mol-1; n is the refractive index,
assumed to equal 1.4 for biological particles in an aqueous solution; QD is the quantum
yield of the donor in the absence of an acceptor, obtained from product literature; FD(λ) is
the corrected fluorescence intensity of the donor from wavelength range λ to λ+∆ λ, with
the total intensity normalized to 1; εA(λ) is the acceptor molar extinction coefficient at its
maximum absorption wavelength λabs (see Figure 6B-C).

6
𝐹"

𝜆 𝜀8 𝜆 𝜆3 𝑑𝜆 is the

spectral overlap integral in units of M-1 cm-1 (nm) between the donor emission and the
acceptor absorption normalized to one.105 A MatLab script (MatLab and Statistics
Toolbox Release 2015a, The MathWorks, Inc., Natick, MA) was used to calculate R0,
and the code can be found in the Appendix.
Table 2. Sarcomeric proteins (gene), their molecular weights, and molar extinction
coefficients ε at 280 nm.
Species

Molecular Weight (kDa)

ε (M-1 cm-1)

rat cardiac

18.4

4,480

Troponin I (TNNI3)

mouse cardiac

24.3

11,460

Troponin T (TNNT2)

rat cardiac

35.7

15,470

reconstituted cardiac

78.4

31,410

α-Tropomyosin (TPM1)

bovine cardiac

32.7

21,760

β-Tropomyosin (TPM2)

bovine cardiac

32.8

Actin (ACTC1)

bovine cardiac

42.0

43,960

Myosin subfragment-1

chicken skeletal

110

90,850

Myosin (MYSS)

chicken skeletal

500

0.56*

Protein
Troponin C (TNNC1)

Troponin

*units are mL/mg cm

-1
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2.4.2 Dye labeling of proteins
Cys residues of proteins were selectively labeled with maleimide-containing
fluorescent dye molecules. Lyophilized fluorophores were briefly centrifuged, and stock
solutions were prepared at 10 mM in dimethyl sulfoxide (DMSO for UV-spectroscopy
≥99%, Sigma-Aldrich, St. Louis, MO) and stored at -20°C for up to six months. Cys
residues were reduced by dialysis against labeling buffer (LB: 50 mM MOPS (pH 7.2), 3
M urea, 100 mM KCl, 1 mM EDTA) containing 5 mM DTT. DTT was removed with
three dialysis steps against LB. Reduced proteins (100 µM) were reacted with a 5-fold
excess of dye molecule for 12 hr at 4°C under nitrogen with stirring. Labeling was
terminated with 5 mM DTT. The labeling was repeated for a total of three reactions to
increase the labeling efficiency (fA, molar concentration of dye relative to total
concentration of protein). Unreacted dye molecules were removed by size exclusion
FPLC (Sephacryl S-100 HR, ÄKTAprime Plus, GE Life Sciences) in LB. Single-cysteine
modified proteins will be abbreviated as TnXYC, where X is either the troponin protein I
or C, and Y is the modified Cys residue. TnC35C, TnC89C, and TnC127C were labeled
with ATTO655. TnIX1C, where X1 is either 151, 160, 167, 174, 177, 182, and 189 were
labeled with Alexa Fluor® 546. TnIX2C, where X2 is either 196, 200, 204, 208, and 211
were labeled with ATTO550. Protein and dye concentrations were determined by
absorption spectroscopy using the extinction coefficients (M-1 cm-1) in Tables 2 and 3.
The concentration of dye-labeled proteins was determined by absorption
spectroscopy using
𝑝𝑟𝑜𝑡𝑒𝑖𝑛 = 𝐴+H" − 𝐶𝐹+H" 𝐴KLM

𝜀,

(2)
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where Amax is absorption maximum of the dye and CF280 is the correction factor for dye
absorption at 280 nm. The labeling efficiency fA is the concentration of dye divided by
the concentration of the protein.
Table 3. Maleimide fluorophores, where ε is the molar extinction coefficient at 280 nm,
CF is the correction factor at 280 nm, Q is the quantum yield, λabs and λem are the
absorption and emission maximum wavelengths, respectively.
Fluorophore
Alexa Fluor® 546 (AF546) (donor)1
ATTO 550 (donor)

2

ATTO 655 (acceptor)

2

1

Life Technologies, Cincinnati, OH

2

ATTO-Tec GmbH, Siegen, Germany

Molecular
Weight
(g/mol)
1034

ε (M-1 cm-1)

CF280

Q

λabs (nm)

λem (nm)

104,000

0.08

0.79

532

554

816

120,000

0.12

0.80

554

576

812

125,000

0.08

0.30

663

684

2.5 Troponin and regulated actin reconstitution
Tn was reconstituted as described49 with some modifications. TnC, TnI, and TnT
were combined in the following molar ratios: for WT, unlabeled, and donor-labeled Tn,
1:1.2:1.4, respectively; for donor-acceptor-labeled Tn, 1.2:1:1.4, respectively. Individual
Tn components were dialyzed against DEAE buffer for 3 hours at 4˚C, and combined in
glass vials and incubated at room temperature with gentle shaking for 2 hours. Tn was
then stepwise dialyzed for 2 hours at 4˚C against 50% DEAE and 50% high salt buffer
(HSB: 1 M KCl, 20 mM MOPS (pH 7.0), 1.25 mM MgCl2, 1.25 mM CaCl2, 5 mM DTT),
HSB, WB supplemented with 625 mM KCl, 425 mM KCl, 225 mM KCl, and 75 mM
KCl. Tn was aliquoted and stored at -80˚C for up to one year. After thawing prior to
measurements, uncomplexed TnI and TnT were removed using centrifugation at 10,000
xg for 1 min. Donor-only Tn (Tn-D) was prepared from TnIX1C labeled with AF546 or
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ATTO550. Donor/acceptor Tn (Tn-DA) was prepared from TnIX2C labeled with AF546
or ATTO550 and TnCXC labeled with ATTO655. An asterisk (*) represents dyeconjugated proteins, e.g., TnI151C*AF546.
Regulated actin filaments (rAc) were prepared by incubating Tn, Tm, and F-actin
(7 µm in protomer) at a molar ratio of 1:5:7 in WB at 4˚C on ice. The order of protein
addition was F-actin, Tm, then Tn. rAc were incubated at 4˚C for at least a week prior to
use, and stored for up to three months.

2.6 Steady-state fluorescence spectroscopy
Steady-state (ss) ensemble FRET spectroscopy was performed on paired D-only
and DA samples of Tn containing donors labeled with AF546 on TnI residue 151, 160,
167, 174, 177, 182, and 189, or containing a donor and an acceptor labeled with
ATTO655 on TnC residue 89. Paired samples were donor concentration-matched using
absorption spectroscopy, where ε and λabs used are shown in Table 3. Tn was diluted to
500 nM (in donor concentration) in WB supplemented with 75 mM KCl into a 50 µL
Quartz Fluorometer Cell (Starna Cells, Inc., Atascadero, CA), and incubated at room
temperature (RT, 22°C) for 10 min. Emission spectra were collected at RT on a
Fluorolog-3 spectrofluorometer (Horiba), with 530 nm excitation, and emission
monitored from 540 to 630 nm (monochromator slit width 4 nm, 1 sec integration time).
Energy transfer E was calculated using
𝐸=

1
𝐼-8
1−
,
𝑓8
𝐼-

(3)

where fA is the acceptor labeling efficiency, IDA is the intensity at 570 nm for the donor in
the presence of an acceptor, and ID is the intensity at 570 nm for the donor in the absence
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of an acceptor. Inter-dye distance (R) between the donor and acceptor dyes was
calculated using the Förster relation
𝑅 = 𝑅"

1−𝐸
𝐸

Q

#

,

(4)

where R0 is the Förster distance of the donor/acceptor dye pair. The R0 for FRET pair
AF546-ATTO655 was 5.5 nm.

2.7 Epifluorescence imaging of regulated actin filaments
All regulated actin filaments were imaged post-reconstitution. rAc, or rAc stained
with phalloidin*AF488 (Life Technologies, Cincinnati, OH) at a 1:35 actin:phalloidin
were diluted to 10 nM in WB and deposited on glass coverslips (25 mm, ThermoFisher
Scientific, Pittsburgh, PA). Fluorescence images were collected on an inverted
microscope (IX71, Olympus USA, Center Valley, PA) with a TE cooled interline CCD
camera (Clara, Andor) with a 100x (N.A. 1.4) oil immersion objective (UPlanSApo,
Olympus). A xenon lamp (X-Cite 120PC, Lumen Dynamics) was used for excitation. For
AF488, the filters 475/35: 495: 550/88 (Semrock) (excitation: dichroic: emission) were
used. For AF546 and ATTO550, the filters 545/25: 565: 605/70 (Chroma) were used. For
ATTO655, the filters 620/60: 660: 700/75 (Chroma) were used. Images were pseudocolored and merged using ImageJ 1.47v (National Institutes of Health, Bethesda, MD).
Length was calibrated by imaging a dual axis linear scale (Edmund Optics, Barrington,
NJ).
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2.8 Time-resolved fluorescence spectroscopy
2.8.1 Time-correlated single photon counting (TCSPC)
TCSPC measurements were performed at room temperature (20±2˚C) using 500
nM (in Tn) donor-only rAc (rAc-D) and donor/acceptor rAc (rAc-DA) in WB, or WB
supplemented with 3 mM CaCl2 using a MicroTime 200 confocal fluorescence lifetime
microscope (PicoQuant GmbH, Berlin, Germany) based on an inverted microscope
(IX71, Olympus USA, Center Valley, PA). Samples were placed on glass coverslips (25
mm width, ThermoFisher Scientific, Pittsburgh, PA) or in glass-bottomed microwell
plates (96-well SensoPlate Plus, 175 µm heighth, glass bottom, E&K Scientific, Santa
Clara, CA), and incubated at room temperature for 30 min prior to measurements.
Excitation light from a 532 nm pulsed diode laser (LDH-P-FA-530-B, PicoQuant) was
passed, respectively, through a quarter wave plate, a single mode fiber optic, a laser
cleanup filter (534/635-25, Semrock, Lake Forest, IL), a principle dichroic mirror (DC1)
(ZT532/638rpc, Chroma, Bellows Falls, VT), and a 100x (N.A. 1.3) oil immersion
objective (UPlanFLN, Olympus). Emitted light was passed through the objective and
DC1, then through a 550 nm long pass filter (HQ550lp, Chroma), 50 µm pinhole, a
secondary dichroic (ZT532/638PC, Chroma), a bandpass filter (HQ580/70, Chroma), and
recorded on an avalanche photodiode (MPD PDM series ϕ=100 µm, Micro Photon
Devices, Italy), respectively. Data were collected until the maximum count per channel
exceeded 10,000 (typically 10 min). Background intensity averaged 80 counts/sec.
The photon counting histograms of TCSPC data were convolved with the
instrument response function (IRF), and fit to a two-exponential decay model 𝐼 𝑡 =
𝑎Q 𝑒 ST

UV

+ 𝑎+ 𝑒 ST

UX

, where I(t) is the intensity of the donor as a function of time t, and ai
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is the fraction of fluorophores with lifetime τi (SymphoTime Version 5.2, PicoQuant).
Amplitude-weighted mean lifetimes 𝜏 =

Z 𝑎Z 𝜏 Z

Z 𝑎Z

of the donor in the presence of

the acceptor dye 𝜏-8 and the donor in the absence of the acceptor dye 𝜏- were used to
obtain the FRET efficiency E
𝐸=

1
𝜏-8
1−
,
𝑓8
𝜏-

(5)

where fA is the labeling efficiency of the acceptor. The distance R between the donor and
acceptor dyes is given by the Förster relation in Eq. 4. The R0 for FRET pair AF546ATTO655 was 5.5 nm, and for 6.4 nm for FRET pair ATTO550-ATTO655.

2.8.2 Fluorescence correlation spectroscopy
FCS measurements and analysis were performed by Dr. Gi-Ho Kim on rAc, TnC,
and dyes in WB, or on Tn in WB supplemented with 75 mM KCl. Freely-diffusing TnC
and Tn at 500 pM, and rAc filaments at 500 nM (in Tn) were examined using the time
resolved confocal microscope described above, with a 0.4 fL effective confocal volume
positioned 50 µm above the top surface of the glass coverslip. The effective confocal
volume was determined by fitting the autocorrelation function of free AF546 dye (1 nM
in ddH2O) with fixed correlation time (0.029 msec).106 Excitation from the pulsed 532 nm
laser was attenuated to 50 µW. Photon arrival times were collected for approximately 10
min. Data were analyzed by calculating the autocorrelation function107
𝐺 𝑡 =

𝐹 𝑡 𝛿𝐹 𝑡 + ∆𝑡
,
𝐹 𝑡 +

where 𝛿𝐹 = 𝐹(𝑡) + 𝐹 is the fluctuation in fluorescence from the temporal average
𝐹(𝑡) =

Q `
𝐹
` "

𝑡 𝑑𝑡 (SymphoTime Version 5.2, PicoQuant). To recover the

(6)
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translational correlation times, the data were fit to a pure diffusion model with one or two
species
b

𝐺 𝜏 =
ZcQ

where

b
Z 𝜌Z

𝜏
𝜌Z 1 +
𝜏Z

SQ

𝜏
1+
𝜏Z 𝜅 +

SQ +

,

(7)

= 1 𝑁 , 𝑁 is the average number of molecules in the confocal volume;

𝜅 = 𝑧" 𝜔" , where z0 = 1.4 µm and 𝜔" = 0.22 µm are the radial and axial radii,
respectively, of the Gaussian beam profile at 1/e2 of its maximum intensity; and τi is the
lateral diffusion time of the ith diffusing species.

2.8.3 Statistical analysis
The standard error of the mean (SEM) was calculated for n = 3 FRET efficiencies
for each donor residue determined from rAc filaments reconstituted on different days.

2.9 Functional characterization of mutated Tn
2.9.1 Tn exchange into skinned cardiomyocytes
All animal protocols were approved by the Animal Care and Use Committee at
Loyola University School of Medicine, and conducted according to the NIH Guidelines
for Care and Use of Animals in Research (NIH Publication No. 85-23, revised 1996).
Cardiac myocytes were isolated from left ventricles of rats, detergent skinned, and
subjected to Tn exchange as previously described.108 Briefly, myocytes were isolated
from rat left ventricular tissue, snap frozen, and stored at -80°C. Frozen tissue was
homogenized and filtered through a 70 µm cell strainer, then pelleted by centrifugation at
120 xg for 1 min at 4°C. Cells were skinned by resuspending the cell pellet in relaxing
solution (97.92 mM KOH, 6.24 mM ATP, 10 mM EGTA, 10 mM Na2CrP, 47.57 mM
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potassium propionate, 100 mM BES, and 6.54 mM MgCl2) supplemented with 1% Triton
X-100, and incubated on a rocking table (room temperature, 15 min). Triton was removed
through two rounds of washing: myocytes were pelleted by centrifugation (300 xg, 5 min,
4 °C), then suspended in 1 mL of ice cold relaxing solution. To replace endogenous Tn
with recombinant Tn constructs, skinned myocytes in relaxing solution were coincubated (4°C, overnight) with exogenous Tn (2 mg/ml). Unbound Tn was removed
with two rounds of washing through the pellet/suspension sequence just described.
Myocytes were placed on ice and used within 8 hrs.
To determine the efficiency of Tn exchange, a portion of the myocyte preparation
was analyzed by Western blot as previously described.109 Briefly, total protein
homogenates were resolved by 12% SDS-PAGE and blotted onto a nitrocellulose
membrane. Blots were probed with a mouse monoclonal antibody against cardiac TnT
(Clone JLT-12, Sigma), which detects both native and exogenous myc-tagged TnT. A
secondary anti-mouse HRP-conjugated antibody (Promega W402B) allowed the relative
TnT content (native vs. exogenous) to be quantified by chemi-luminescence (ECL,
BioRad).

2.9.2 Muscle mechanics experiments
Myocytes with clear striation patterns were selected and attached to a force
transducer (Aurora Scientific Inc. 403A transducer, Aurora, ON, Canada) and a highspeed piezo translator (Thor Labs, Newton, NJ). Cells were perfused with a closely
placed pipette through a constant perfusion control system (VC-8M Eight Channel MiniValve Perfusion System, Warner Instruments, Hamden, CT). Cells were perfused with
solutions of varying calcium concentrations (pCa 10.0–pCa 4.5). In each perfusate,
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developed force was measured at two sarcomere lengths (1.9 μm and 2.3 μm). Cells were
perfused with maximally activating Ca2+ solution at the beginning and the end to
calculate time-dependent run down. Any cell showing more than 20% run down in
maximal force was discarded. All data were acquired by custom-made LabView software
and analyzed using Origin Pro 8.0. Individual force-pCa curves were fit to a modified
Hill equation (P/Po)=[Ca2+]nH/( Ca50 nH + [Ca2+] nH)), where nH is the Hill coefficient. All
force data were normalized by the cross sectional area of the cell. Cell cross-sectional
elliptical area was calculated using a calibrated on-screen monitor as described
previously.108

2.9.3 Statistical analysis
Non-linear regression and statistical analysis were performed using GraphPad
Prism ver. 6.0 (La Jolla, CA). The mean ± SEM of the parameters recovered from the
fitting are reported. The recovered parameters from different samples were compared
using two-way ANOVA. Statistical significance was defined as P<0.05.
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3 RESULTS & DISCUSSION
3.1 Designing a FRET assay on troponin
The sequence of rat cTnC is identical to hcTnC, except for residue 119, which is
an isoleucine in human and methionine in rat. Figure 4A shows the sequence alignment
for rc and hcTnC. The 52 kDa Takeda crystal structure resolved the hcTnC structure to a
3.3 Å resolution, except for two residues in the central linker.27 Figure 4C shows the
secondary structure of cTnC, with FRET acceptor residues highlighted: 35 is in the Nlobe, 89 is in inter-lobe linker, and 127 is in the C-lobe. None of the residues selected are
involved in Ca2+ or Mg2+ binding.
mcTnI is a 211 residue protein, and Figure 4B shows the sequence alignment
between mc and hcTnI (210 residues). Figure 4C shows the secondary structure of cTnI
with donor residues highlighted in green. hc and mcTnI residues differences in C-TnI are
marked in yellow. Two of the three residue variances in the C-TnI were mutated to Cys
for modification with fluorescent probes (mouse I182C and G211C). All donor residues
and acceptor residues were visualized using the MTS molecular model of Ca2+-bound Tn
(Figure 5).84 Donor positions span the C-terminal region of cTnI, beginning at TnI151 in
the switch region, and acceptor positions are located on the N-lobe, the inter-lobe linker,
and the C-lobe of cTnC.
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Figure 4
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Figure 4. Mouse cTnI and rat cTnC sequence alignment with human. Highlighted in
blue are residues resolved in the Ca2+-saturated 52 kDa core of human cardiac Tn
(PDBID 1J1E).27 (A) A sequence alignment was performed using the Basic Local
Alignment Search Tool (BLAST) for hc TnC (gene name TNNC1, UniProt identifier
P63316) and rcTnC (UniProt identifier Q4PP99). hcTnC, aligned, and rcTnC residues are
shown in the top, middle, and bottom lines, respectively. Residue variances are shown in
yellow. The residues selected for acceptor labeling are highlighted in red: C35, S89, and
T127. (B) BLAST alignment of the amino acid sequences of hcTnI (gene name TNNI3,
UniProt identifier P19429) and mcTnI (UniProt identifier P48787). The C-terminal
region (residues 151-211 in mouse numbering) is identified by the magenta line, with
amino acid residue differences between hc and mc in C-TnI highlighted in yellow.
Residues selected for donor labeling are highlighted in green: S151, L160, S167, L174,
V177, I182, V189, I196, S200, G204, K208, and G211. (C) Schematic showing the
domain organization of cardiac TnC and TnI. Helices are depicted as blue rectangles.
Sites III and IV of TnC bind Mg2+ constitutively. Site II of TnC binds regulatory Ca2+.
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Figure 5. Multi-site FRET assay on troponin. Ribbon representation of MTS model
resolved from the 52 kDa core of Ca2+-saturated Tn. Single Cys mutants with covalentlybound donor dyes span the switch (151, 160, 167), mobile (174, 177, 182, 189), and Cterminal (196, 200, 204, 208, 211) domains of TnI (green spheres). Acceptors dyes are
covalently bound to single Cys mutants (red spheres) on TnC between the A and B
helices (35) in the N-lobe, the linker between the N- and C-lobes (89), and between
helices F and G (127) in the C-lobe.

3.1.1 Donor and acceptor fluorophore selection
The qualifications for designing a FRET pair were: fluorophores must (i) be
excited and emit at visible wavelengths (400-700 nm), (ii) have low molecular mass ≈1
kDa, (iii) have a long carbon linker (Cx, x ≤ 5), (iv) have an extinction coefficient >100K
(bright), (v) and be thiol-reactive.
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Labeling with low molecular weight fluorophores reduces potential tertiary
structure perturbations. A long carbon linker, the carbon group spacer between the
fluorescent moiety and the reactive moiety, increases the ease of the reactive moiety
reaching the specific residue for labeling, leading to a higher degree of labeling. All
fluorophores used had a five-carbon linker, where C5 = ≈7.7 Å for AF546, ATTO550,
ATTO655. This introduced a threshold to the derived inter-dye distances, where
distances have an inherent error range of ±1.54 nm. Time-resolved FRET measurements
were repeated in triplicate to gauge the error range. The linker also allows for free
rotation of the dyes to reduce steric hindrance,111 which could cause variations in the
assumed orientation factor (κ2 = 2/3) that would influence the rate of energy transfer E.
Additionally, the quantum yield can be reduced when the dye linker is too short.112 A
high extinction coefficient ε, which is the capacity for the fluorophore to absorb a photon
of light, is important for both donor and acceptor excitation (either directly-excited for
the former or from sensitized emission for the latter). Molecular brightness, or the
fluorescence output per fluorophore, is proportional to the product of ε and the quantum
yield (Q), which is the number of photons emitted per photon absorbed.105 Cysteine was
chosen as the reactive residue due its low native prevalence (two in both TnC113 and
TnI114). Thiol-reactive fluorophores covalently bind to cysteine residues with high
efficiency and specificity within a certain pH range.115 Maintaining a pH below 8 in the
labeling reaction buffer ensured amine groups remained protonated, and did not undergo
nucleophilic attack by maleimide moieties.
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Figure 6. Emission spectra of FRET dye pairs, inter-Cα distances, and theoretical
FRET efficiencies for troponin. (A) Cα (Rmod) bond lengths between donor residues on
TnI and acceptor residue 35C on TnC (green), 89C (red), and 127C (blue) determined
using the MTS model84 and VMD.116 Dashed grey lines at 5.5 and 6.4 nm indicate the R0
for AF546/ATTO655 and ATTO550/ATTO655, respectively. (B) Normalized absorption
and emission spectra for AF546 (magenta) and ATTO655 (blue) used to determine the
spectral overlap needed to calculate R0. Dashed lines indicate absorption; solid lines
indicate emission. The confocal time-resolved microscope used in this study has an
excitation wavelength at 532 nm (green dashed line). (C) Normalized absorption and
emission spectra for ATTO550 (pink, donor) and ATTO655 (blue, acceptor). 532 nm
excitation (green dashed line). (D) Theoretical FRET efficiencies E calculated from Cα
bond lengths in (A). A consistent coloring scheme is used in panels A and D.
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3.1.2 Theoretical FRET efficiencies and Cα distances
The carbon-α (Cα) distances between TnI donor residues (151, 160, 167, 174,
177, 182, 189, 196, 200, 204, 208, 211) and TnC acceptor residues (35, 89, 127) were
estimated using the MTS molecular model in VMD version 1.9.2.116 Figure 6A shows the
Cα distances (Rmod), which range from ≈2 nm to ≈8 nm. The Förster critical distance (R0)
between the donor and acceptor fluorophores was an important consideration in the
design of this FRET assay. The R0 is the distance at which resonant energy transfer is
50% efficient,105 and should be close to the theoretical Cα distances to ensure both small
and large conformational changes can be resolved. The FRET efficiency strongly
depends on inter-dye distance when close to the R0.105 The broad range of distances in
this assay required a selection of two FRET pairs, one with R0 = 5.5 nm (donor-acceptor,
AF546-ATTO655), and the other with R0 = 6.4 nm (ATTO550-ATTO655). TnI residues
151-189 were labeled with AF546, and residues 196-211 were labeled with ATTO550.
TnC residues were labeled with ATTO655.
Figures 6B-C show the excitation and emission spectra for the FRET pairs
(donor-acceptor) AF546-ATTO655 and ATO550-ATTO655 provided by Life
Technologies (Alexa Fluor® dyes) and ATTO-Tec, Gmbh (ATTO dyes). To measure
energy transfer, the donor must be promoted to its excited state. The confocal setup was
equipped with a picosecond pulsed laser at 532 nm to excite the donor (λexc). The peak
absorption (excitation) wavelengths λabs for AF546 and ATTO550 are 532 and 554 nm,
respectively; therefore, the fluorophores are adequately excited at λexc. The probability of
directly exciting ATTO655 is low at λexc (< 3%), compared to AF546 (≈100%) and
ATTO550 (≈40%). Figure 6D shows the theoretical FRET efficiencies for each acceptor,
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calculated using Eq. 4 from Rmod and the R0 for each donor/acceptor FRET pair.
Particularly for acceptor position TnC35, some of the theoretical E appear too close to 1.0
to provide accurate estimations of inter-dye distances. If the conformation of Tn within
thin filaments is similar the MTS model (and by association, the Takeda structure), the
experimentally-derived E should closely follow Figure 2D.

3.1.3 Preparing the FRET assay in regulated actin
Single Cys mutants were introduced on a Cys-less TnI with native Cys 81 and 98
mutated to isoleucine and serine, respectively, and a Cys-less TnC plasmid with native
Cys 35 and 84 mutated to serines. The complete list of single Cys TnI and TnC plasmids,
in addition to the WT plasmids for TnI, TnC, and TnT, are shown in Table 1. Plasmids
were sequenced prior to purification to confirm mutagenesis. Henceforth, proteins will be
identified by their single Cys residue (e.g., TnI151C or TnI151). Plasmids were
transformed into E. coli, and purified using fast protein liquid chromatography (FPLC).
Figures 7-9 show representative results for recombinant TnC, TnI, and TnT purification.
SDS-PAGE 12% (29:1) was used to analyze the purity of the Tn subunits. Panel C in
Figures 7-9 shows the fractions containing purified Tn subunits. When a lane is
overloaded, contaminant protein bands may appear. Figure 10, shows a representative
SDS-PAGE gel loaded with 5 µM of Tn subunits, where contaminant proteins were too
diluted to resolve. Since measurements will be performed using nanomolar
concentrations of Tn, the likelihood of contaminant proteins in the sample solution is
small. The staining intensity difference between equimolar-loaded subunits is due to the
differences in molecular mass; higher molecular mass proteins provide more binding sites
for Coomassie dye, and consequently stain more intensely.

50

Figure 7. Purification of rcTnC. Representation of results from purification of
recombinant rcTnC127C. (A) SDS-PAGE (12%, 29:1) of the cell lysis of BL21(DE3)
competent E. coli cells and subsequent clarification using centrifugation and (NH4)2SO4
precipitation. Molecular weight markers (M), E. coli grow (G), supernatant (S) and pellet
(P) from 18 K rpm, 35 K rpm, 0-40% (NH4)2SO4 precipitation 14 K rpm, and 40-60%
(NH4)2SO4 precipitation 14 K rpm sedimentation. (B) Resolution of TnC on Phenyl
Sepharose. Absorbance at 280 nm (purple), conductivity (red), and fraction collection
(grey box) are shown. The pellet containing TnC from the second (NH4)2SO4
precipitation in (A) was loaded in the presence of 5 mM CaCl2. Weak hydrophobic
products from the lysate were removed in the presence of 0.1 mM CaCl2 and 1 M NaCl.
TnC was eluted with a Ca2+-free buffer. (C) Detection of purified TnC from the elution
peak (around 0.9 L) from the absorbance at 280 nm. Molecular weight marker (M),
sample loaded (L), and samples from the eluted fractions with purified TnC are shown.
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Figure 8. Purification of mcTnI. Representation of results from purification of
recombinant mcTnI167C. (A) SDS-PAGE (12%, 29:1) of the cell lysis of BL21(DE3)
competent E. coli cells and subsequent clarification using centrifugation and (NH4)2SO4
precipitation. Molecular weight markers (M), E. coli grow (G), supernatant (S) and pellet
(P) from 18 K rpm, 35 K rpm, 0-27% (NH4)2SO4 precipitation 14 K rpm, and 27-60%
(NH4)2SO4 precipitation 14 K rpm sedimentation. (B) Resolution of TnT on DEAE
Sepharose. Absorbance at 280 nm (purple), conductivity (red) and 500 mM KCl gradient
(green), and fraction collection (gray box) are shown. The pellet containing TnI from the
second (NH4)2SO4 precipitation in (A) was loaded in a buffer containing no salt. (C)
Detection of purified TnI around the 30% gradient mixture from the absorbance at 280
nm. Molecular weight marker (M), sample loaded (L), and samples from the eluted
fractions with purified TnI are shown.
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Figure 9. Purification of rcTnT. Representation of results from purification of WT
rcTnT. (A) SDS-PAGE (12%, 29:1) of the cell lysis of BL21(DE3) competent E. coli
cells and subsequent clarification using centrifugation and (NH4)2SO4 precipitation.
Molecular weight markers (M), E. coli grow (G), supernatant (S) and pellet (P) from 18
K rpm, 35 K rpm, 0-35% (NH4)2SO4 precipitation 14 K rpm, and 35-60% (NH4)2SO4
precipitation 14 K rpm sedimentation. (B) Resolution of TnT on DEAE Sepharose.
Absorbance at 280 nm (purple), conductivity (red) and 500 mM KCl gradient (green),
fraction collection (gray box) are shown. The pellet containing TnT from the second
(NH4)2SO4 precipitation in (A) was loaded in a buffer containing no salt. (C) Detection of
purified TnT from elution peak 1 (around 0.9 L, 30% gradient) from the absorbance at
280 nm. Molecular weight marker (M), sample loaded (L), and samples from the eluted
fractions with purified TnT are shown.
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Figure 10. Purified troponin subunits. SDS-PAGE (12%, 29:1) showing purified TnT
(T), TnI (I), and TnC (C) loaded at 5 µM. Also shown are molecular weight markers (M).

Cys residues were site-specifically labeled with maleimide-containing
fluorophoresin a denaturing high urea buffer (6 M) to reveal Cys residues buried in
globular protein form. The labeling reaction was at pH 7.2 to reduce non-specific amine
labeling, and unbound dye was removed using size-exclusion chromatography. The
degree of labeling (labeling ratio, fA) was determined using Eq. 2. Typically, the labeling
ratios for TnI*AF546 exceeded 95%; unfortunately, labeling ratios were at or below 80%
for proteins labeled with ATTO dyes, although the labeling reaction was repeated three
times. Labeling ratios were determined immediately prior to Tn reconstitution to ensure
the highest degree of accuracy. Labeled proteins will henceforth be written as
TnX###C*fluorophore, where X is the Tn subunit, ### is the Cys residue, and
*fluorophore denotes covalent modification (e.g., TnC151C*AF546).
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TnI, TnC, and TnT were combined to form reconstituted Tn through serial
dilutions against high molar urea, to high salt, to low salt (150 mM KCl) for storage. Tn
was stored for no longer than 6 months at -80°C, as these samples visibly precipitated
(precipitate settled to bottom of tube), and were discarded. Tn reconstituted with a donor
labeled on TnI, WT TnC, and WT TnT will henceforth be written as Tn-D, and Tn
reconstituted with a donor on TnI, an acceptor on TnC, and WT TnT will henceforth be
written as Tn-DA. Cardiac Tm and actin were purified from acetone powder from bovine
left ventricle tissue. Figure 11 resolves the two Tm isoforms, α and β. Around 15-20% of
skeletal Tm is in the β-isoform in adult larger mammals (such as bovine and human),
whereas cardiac Tm is primarily composed of the α isoform.117 Tm and actin were
resolved at 37 and 48 kDa, respectively, using SDS-PAGE.

Figure 11. Tropomyosin and F-actin purified from bovine left ventricle muscle.
Molecular weight markers (M), tropomyosin (Tm) consisting of α and β isoforms, and Factin (Actin) are shown.
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3.2 Quality assessment of singly- and doubly-labeled regulated
actin
The sarcomere in striated muscle is composed of a highly ordered structural array
of muscle proteins arranged in filaments. To maintain the physiological function of thin
filaments in vitro, preserving filament structure after reconstitution is imperative to
maintaining a native-like environment. In muscle, there is generally one Tn bound for
every one Tm dimer that lies across 7 actin monomers.3 Regulated actin filaments (rAc)
were reconstituted at a ratio of 1:5:7 (Tn:Tm:Actin) with an ionic strength of 75 mM
KCl. Filaments reconstituted with Tn-D, Tm, and actin will henceforth be written as rAcD, and with Tn-DA, Tm, and actin will be written as rAc-DA. Epifluorescence imaging
was used as the primary control to monitor thin filament morphology, as there were
various conditions (buffer composition, incubation time, concentration of thin filament
proteins) that influenced the integrity of rAc. All measurements on rAc were performed
in working buffer (WB: 75 mM KCl, 50 mM MOPS pH 7.0, 5 mM MgCl2, 2 mM EGTA,
5 mM BME), unless otherwise stated.

3.3 Epifluorescence imaging reveals stability of filaments under
various conditions
3.3.1 Tn binding to Tm-actin is dependent on ionic strength
rAc-DA was reconstituted with TnI182C*AF546, TnC89C*ATTO655, and with
actin labeled with phalloidin-AF488 in WB with 75, 150, 225, or 300 mM total KCl, and
incubated for 1 hour at 4°C. Filaments were deposited at 10 nM (in Tn) on glass
coverslips, and imaged using epifluorescence microscopy. Figure 12 shows the directlyexcited emission from TnI182C*AF546, TnC89C*ATTO655, and actin*phalloidin-
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AF488. As ionic strength increases from 75 mM, the amount of Tn in solution increases,
evident by an increase in background points of fluorescence. The amount of Tn bound to
actin and Tm decreases, evident by the decrease in white signal from the merged images.
White indicates a co-localization of green, red, and blue signals. The approximate length
of actin, and the emission intensity from phalloidin-AF488, remains relatively constant
across all ionic strengths. Therefore, an ionic strength of 75 mM promotes Tn binding to
Tm and actin. However, Tn was still not congruently bound across actin, evident by large
gaps in co-localized signal across the actin filaments.

Figure 12

57
Figure 12. Tn binding to actin and Tm depends on ionic strength. rAc with Tn-DA
(TnI182C*AF546, TnC89C*ATTO655) was reconstituted with Tm and actin stained
with phalloidin-AF488 at a ratio of 1:1:7 (Tn:Tm:Actin) at a total ionic strength of 75,
150, 200, and 300 mM KCl, and incubated for 1 hour at 4°C. Filaments were diluted to
10 nM, and deposited on glass coverslips. Emission from AF546 (excitation, 545/25;
emission 605/70), ATTO655 (excitation 620/60; emission 700/75), AF488 (excitation,
475/35; emission 550/88), and merged images are shown. With higher ionic strength
(>75 mM KCl), Tn is dissociated from Tm and actin, evident by the appearance of points
of fluorescence in the AF546 and ATTO655 images, and the disappearance of
colocalized Tn on actin (decrease in white from merge images). The scale bar is 5 µm.

3.3.2 Incubation time affects Tn binding to Tm and actin
rAc-D reconstituted with TnI211C*ATTO550, Tm, and actin stained with
phalloidin-AF488 (1:1:7) was imaged after incubation at 4°C for 1 day, 1 week, and 3
months. Figure 13A shows the emission from labeled TnI and actin, and the merged
images. A 1 day incubation yielded short filaments with sparse Tn binding, and isolated
Tn was visible in the background. Filaments showed congruently bound Tn and
elongated filaments (5-10 µm) after 1 week, with little to no Tn in the background. A 3month incubation yielded even longer filaments (>10 µm), though the amount of Tn
bound appears relatively unchanged from the 1 week incubation. The presence of
congruently bound Tn-DA, suggested by the co-localized emission from TnI (green) and
TnC (red), indicates Tn incorporated onto Tm and actin as an intact assembly.
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Figure 13
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Figure 13. Physical characterization of labeled regulated actin filaments. (A)
Incubation time affects filament remodeling. Epifluorescence images of rAc-D with Tn-D
(TnI211*ATTO550, TnC, TnT) and actin stained with phalloidin*AF488 was diluted to
10 nM in WB 1 day, 1 week, and 3 months after reconstitution at 4°C. Emission from
ATTO550 (excitation, 545/25; emission 605/70), AF488 (excitation, 475/35; emission
550/88), and merged images show filament remodeling with time. Filaments appear
longer, less dense, and more continuously decorated with Tn after 1 week. The scale bar
is 5 µm. (B) The quantity of Tm affects filament stability. Epifluorescence images of
rAc-DA with Tn-DA (TnI189C*AF546, TnC127C*ATTO655, TnT) showing aggregated
(bundled) filaments reconstituted with a 1:1:7 mixture of Tn:Tm:actin. Single (nonbundled) filaments made with a 1:5:7 mixture of Tn:Tm:actin with rAc-D with Tn-D
(TnI189C*AF546) and rAc-DA are shown. Emission from AF546 (excitation 545/25;
emission 605/70), directly-excited ATTO655 (excitation 620/60; emission 700/75), and
the merged images are shown. The scale bar is 5 µm.

3.3.4 The quantity of Tm affects filament stability
Filaments reconstituted with Tn:Tm:Act at a ratio of 1:1:7 had a 25% chance of
bundling. Bundling was evident in epifluorescence imaging by the appearance of thicker
filaments, with the tails showing multiple “single” filament threads. Figure 13B shows
an example of bundled rAc-DA reconstituted from Tn-DA (TnI182C*AF546,
TnC127C*ATTO655). Increasing the Tm concentration in solution during reconstitution
dropped the bundling rate to <10%. Figure 13B shows the emission from rAc-D
reconstituted with Tn-D (TnI182C*AF546) and rAc-DA reconstituted with Tn-DA
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(TnI182C*AF546) at a ratio of 1:5:7 Tn:Tm:Act. Filaments appear non-bundled and
single. All rAc reconstitutions were therefore performed with a Tn:Tm:Act ratio of 1:5:7,
unless otherwise stated, and incubated for at least 1 week prior to measurements.

3.3.5 Proteins did not undergo proteolysis after reconstitution and
incubation
Sample purity and protein integrity of reconstituted filaments were assessed using
SDS-PAGE. Figure 14 shows rAc reconstituted with WT Tn at a ratio of 1:1:7, and the
pre-spin mixture and sedimented pellet of rAc reconstituted at a ratio of 1:5:7. The
proteins showed minimal to no degradation after both Tn and rAc reconstitution. TnC had
a faint band due to its low molecular mass. When rAc is sedimented, the pellet should
show actin at a ≈7 times higher intensity than Tn subunits. Therefore, the intensity of Tm
in the pellet should be similar to the Tn subunits, and similar to Tm in rAc reconstituted
with a ratio of 1:1:7. The similarities in the Tm band intensities for the reserved (W) and
pellet (P) of 1:1:7 and 1:5:7 rAc, respectively, showed the amount of Tm bound to actin
remains unchanged regardless of the amount of Tm present in solution.

3.3.6 Ca2+ does not affect the physical characterization of regulated
actin filaments
This assay was designed to monitor Ca2+-dependent conformational changes in
Tn. To determine if changes were coming from Tn structural changes or filament
instability with Ca2+, filaments were imaged with and without Ca2+. rAc-DA reconstituted
with Tn-DA (TnI182C*AF546, TnC127C*ATTO655) was diluted to 500 nM, and
imaged at 10 nM (no Ca2+, apo). rAc-DA was then supplemented with 3 mM CaCl2 and
imaged at 10 nM after 10 min, 2 hours, and 5 hours to determine if Ca2+ affected filament
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morphology. Figure 15 shows Ca2+ had no effect on filament morphology, evident by
similar emission profiles, suggesting Ca2+-induced changes in dynamics or structure are
not due to filament dissociation.

Figure 14. Assessment of sample purity of reconstituted rAc. SDS-PAGE (12%, 29:1)
of rAc reconstituted with WT Tn, Tm, and actin at a ratio of 1:1:7 or 1:5:7. TnI, TnC,
TnT, Tm with α and β isoforms, and actin are resolved. A pre-spin mixture (W) of 1:1:7
rAc (5 µM in actin protomer), and the W and pellet (P) of sedimented 1:5:7 rAc (5 µM in
actin protomer) are shown. Molecular weight markers are not shown.
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Figure 15. Calcium does not affect the physical morphology of regulated actin. rAcDA filaments reconstituted with Tn-DA (TnI182C*AF546, TnC127C*ATTO655) were
diluted to 500 nM, then imaged at 10 nM (no Ca2+, apo). rAc-DA was then supplemented
with 3 mM CaCl2 and imaged after 0, 2, and 5 hours. Emission from AF546 (excitation
545/25; emission 605/70), directly-excited ATTO655 (excitation 620/60; emission
700/75), and the merged images are shown. The scale bar is 5 µm.
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3.4 FCS as a filament screening tool
Fluorescence correlation spectroscopy (FCS) can be used to estimate the mobility
of molecules in solution.118 The primary parameter in FCS is not the emission from the
fluorophore, but the fluctuations in the emission intensity at thermodynamic equilibrium
over time. These fluctuations can be quantified by temporally autocorrelating the
recorded intensity signal,105 and the fluctuations depend on the rate of diffusion of a
fluorophore though the confocal volume. Assuming the fluorescent properties of AF546
and ATTO550 do not change with time, and assuming a constant excitation power and a
three-dimensional Gaussian intensity profile,119 the translational correlation time τC and
diffusion coefficient D can be determined for a sample.
FCS was used during data collection to assess filament diffusion. To determine if
the sample contained Tn bound to Tm-actin or unbound Tn, the fluorescence emission
from isolated AF546, TnC127C*AF546, Tn-D (TnC127C*AF546), and rAc-D
(TnC127C*AF546), called rAcC*, were analyzed using FCS. As the FRET assay was
designed with donors on TnI, a representative data set of rAc-D (TnI211C*ATTO550),
called rAcI*, was also included in the normalized autocorrelations shown in Figure 16.
rAc were fit to a model of two diffusing species (Eq. 7), and all other traces were fit to a
model of a single diffusing species. AF546, TnC, and Tn had translational correlation
times of 0.03, 0.10, and 0.16 msec, respectively. The translational correlation times
(fractional amplitude) for rAcC* were 2.48 (0.44) and 18.23 (0.56) msec, and for rAcI*
were 4.16 (0.46) and 81.61 (0.54) msec.
The faster time components for rAc samples are most likely due to shorter
fragments of rAc filaments, and not free Tn or TnI, as the correlation times for these

64
shorter components are more than an order of magnitude longer than correlation times for
free Tn and TnI. Aggregates of TnI and Tn may account for this shorter correlation time
component; however, the low prevalence of aggregates evident in epifluorescence
imaging would not support that claim. The second or slow components for rAc samples is
attributed to longer filaments, which are visible in epifluorescence images, and range
between 5-15 µm in length.

Figure 16. Fluorescence correlation spectroscopy estimates the molecular weight of
a freely-diffusing particle. Correlation times correlate to sample molecular weights. The
normalized autocorrelation function of free AF546 dye (500 pM, ¡), labeled TnC
(TnC127*AF546, 500 pM, ✕), Tn reconstituted with TnC127C*AF546 (100 nM, r),
rAc reconstituted with TnC127C*AF546 (rAcC*, 100 nM, Ç), and rAc reconstituted with
TnI211C*ATTO550 (rAcI*, 100 nM, ¯) are shown. Solid lines represent fits of AF546,
TnC, and Tn samples to a model of a single diffusing species with translational
correlation times of 0.03, 0.10, and 0.16 msec, respectively, or rAc fit to a model of two
diffusing species to determine correlation times (fractional amplitudes), where rAcC* has
2.48 (0.44) and 18.23 (0.56) msec, and rAcI* has 4.16 (0.46) and 81.61 (0.54) msec.
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Molecular diffusion D and friction F are related by 𝐹 = −𝑓𝑣, where f is the
translational frictional coefficient and v is velocity. Friction and molecular size are
related by Stokes’ equation, where 𝑓 = 6𝜋𝜂𝑎 for a smooth sphere with a minimal
hydrodynamic radius a for a molecule of a certain molecular weight, and 𝜂 is the
viscosity of the solution. Einstein’s relation
𝐷=

𝑘j 𝑇
𝑘j 𝑇
=
,
𝑓
6𝜋𝜂𝑎

(8)

shows the diffusion coefficient is inversely proportional to size, where kB is Boltzmann’s
constant, and T is temperature. The radius a can be calculated from the molecular mass M
of the molecule using
𝑎=

n

3𝑀 𝑁8
,
4𝜋𝜌

(9)

where NA is Avogadro’s number = 6.023 × 10+@ mol-1, and 𝜌 is the mean density of the
molecule, assumed to be ≈1 g/mL for globular proteins. The diffusion coefficient is
therefore proportional to M-1/3, giving a proportionality constant of ≈-0.33. Translational
correlation times are related to diffusion coefficients by
𝜏o =

𝜔" +
,
𝐷

(10)

where 𝜔" = 0.22 µm is the axial radius of the confocal detection volume.120 The
dependence of the diffusion coefficient on the molecular mass of the labeled sample is
shown in Figure 17 for molecules of known molecular mass, which are 1.0, 18.4, and
78.3 kDa for AF546, TnC, and Tn, respectively. The experimental data were fit using
linear regression (log scale). The slope yielded a proportionality constant of -0.40, which
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differs by 18% from the theoretical value. This difference may come from a
misestimation of the confocal volume.
FCS gives molecular mass properties of a sample by monitoring the translational
correlation times. rAc was analyzed using FCS from TCSPC measurements, which
allowed for rejection of samples showing large populations of non-incorporated Tn, free
TnC, or an excess of free dye. Using epifluorescence imaging and FCS provided means
of examining only reconstituted rAc filaments that met certain quality standards: i)
labeled Tn should be congruently bound to the filaments, ii) there should be no
aggregates of Tn and TnI, iii) filaments should not be bundled, iv) there should not be a
large population of unbound Tn or TnI (donor) in solution. These standards were in place
to assure reconstituted filaments replicate native filament conditions by reducing artifacts
introduced in the complex sample preparation.
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Figure 17. Dependence of the diffusion coefficients on molecular mass. Free AF546
dye (red), TnC127C*AF546 (black), and Tn-D (TnC127C*AF546) (green) were
analyzed using FCS, and the autocorrelation was fit to a model of a single diffusing
species. The translational correlation times were converted to diffusion coefficients and
plotted against known molecular masses. The data were fit using linear regression (log
scale) (black line), which yielded a slope and Y-intercept of -0.40 and -0.39, respectively.
R2=0.98.

3.5 TCSPC measurements of regulated actin filaments
Ensemble lifetime measurements were performed using time correlated single
photon counting (TCSPC). Following excitation by a pulse of light, the donor
fluorophore absorbs the photon, and the lifetime is the average amount of time the
fluorophore remains in this excited state.105 The sample is excited thousands of times, and
the lifetimes are compiled into a histogram of intensity with respect to time. One benefit
of using time-resolved methods to perform FRET measurements is the lifetime of a
sample is not dependent on the concentration of fluorophores in the confocal volume,
thereby removing the need for donor concentration-matching in paired D and DA
samples. Lifetime is calculated from a multiexponential fit to the TCPSC histogram, and
the peak intensity value does not affect the lifetime. Lifetimes are also independent of
static quenching. Static quenching is the formation of a non-fluorescent complex between
the donor and acceptor, creating a population of “invisible” donors that upon excitation
do not release a photon during relaxation.105, 121 In steady-state FRET measurements,
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where the emission intensity of the donor is used to calculate transfer efficiency, these
“dark” complexes can yield falsely higher transfer efficiencies.
The donor lifetime was collected in filaments absent an acceptor (rAc-D,
reconstituted with Tn-D with TnI151C*AF546, TnI160C*AF546, TnI167C*AF546,
TnI174C*AF546, TnI177C*AF546, TnI182C*AF546, TnI189C*AF546,
TnI196C*ATTO550, TnI200C*ATTO550, TnI204C*ATTO550, TnI208C*ATTO550, or
TnI211C*ATTO550, for a total of 12 donor positions), and in the presence of an acceptor
(rAc-DA, reconstituted with Tn-DA with either TnC35C*ATTO655,
TnC89C*ATTO655, or TnC127C*ATTO655 as the acceptor, for a total of 36 unique
FRET pairs). rAc filaments were diluted to 500 nM in WB (apo), or WB supplemented
with saturating Ca2+ (+Ca, 3 mM). The laser power and collection time were adjusted to
reach a peak of >10,000 counts to ensure reasonable photon counting statistics,122 which
typically took ≈10 min. An average background of 80 counts/sec for the avalanche
photodiode (APD) detector indicated a good signal to noise ratio. Fluorescence decays
were convolved with the instrument response function (IRF, at FWHM = 85 ps), and
amplitude-weighted lifetimes were recovered from a nonlinear least-squares multiexponential fitting. χ2 values show goodness of fit, with a value = 1 indicating a perfect
fit. To confirm reproducibility, measurements were repeated at least three times on
separately reconstituted filaments. Figure 18 shows a typical set of fluorescence decays
for ATTO550 in rAc-D (Tn-D, TnI208C*ATTO550) and rAc-DA (Tn-DA,
TnI208C*ATTO550, TnC127C*ATTO655) under apo and +Ca conditions.
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Figure 18. Lifetime measurements of donor-only and donor/acceptor rAc filaments.
Representative lifetime decay data from TCSPC analysis showing the normalized
emission intensity decay from the donor in rAc-D reconstituted with Tn-D
(TnI208C*ATTO550) and rAc-DA reconstituted with Tn-DA (TnI208C*ATTO550,
TnC127C*ATTO655) diluted to 500 nM in WB or WB supplemented with 3 mM CaCl2
(+Ca). (A) ATTO550 lifetime decays for rAc-D (blue), rAc-D +Ca (red), rAc-DA (cyan),
and rAc-DA +Ca (magenta). Black lines represent fits to a multi-exponential decay
model to the data convolved with the instrument response function (IRF, dotted line).
Amplitude-weighted mean lifetimes 𝜏- are 3.30, 3.28, 3.01, 2.64 nsec, respectively. (B)
Weighted residuals from fits in (A) with χ2 values shown. A consistent coloring scheme
is used in (A-B).

A representative table of lifetime (fractional amplitude), amplitude-weighted
mean lifetime, χ2, and E for rAc-D, and for rAc-DA with an acceptor attached to TnC
residue 35, 89, or 127 can be found in Tables A1-4. Donor-only lifetime decays were fit
to three-exponential fit for samples labeled with AF546, and two-exponential fits for
samples labeled with ATTO550. The inverse lifetime is the sum of rates that depopulate
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the excited state, and therefore a fluorophore in solution (ideally a donor-only filament)
should single exponential decay lifetimes, indicating no competing paths for excited state
depopulation.105 The heterogeneous character of the donor-only lifetime decays,
particularly those with a three-exponential fitting, may be due to self-quenching from
interactions between the dye and protein residues (dynamic quenching). Because the
decay is heterogeneous, the amplitude-weighted mean lifetime was used for calculating E
to remove any assumptions as to the nature of the individual decay rates.123 rAc—DA
lifetime decays were always fit to a three exponential function. For most fits, 𝜏Q was less
than 1 ns, and accounted for less than 20% of the total lifetime, and is attributed to
scattering from the glass coverslip or the solution.

3.6 Calculating FRET efficiency and inter-dye distance
The donor dye was not sensitive Ca2+, evident from the comparison of donor
lifetimes in rAc-D filaments under apo and +Ca conditions. Table A1 shows the lifetimes
of donor-only filaments from one reconstitution set. The average Ca2+-induced lifetime
change

𝜏-

poL

− 𝜏-

Lqr

± SEM is 0.02 ± 0.01 ns (n = 12). Although the change is

not significant, apo and +Ca E were calculated from 𝜏- and 𝜏-8 collected in the
absence or presence of 3 mM CaCl2, respectively, to maintain similar environmental
conditions around the donor dye.
The amplitude-weighted mean lifetime of the donor in the absence 𝜏- and
presence of an acceptor 𝜏-8 was used to calculate transfer efficiency E using Eq. 5. The
inter-dye distance R between D and A dyes was calculated using the Förster relation (Eq.
4). Due to the dependence on distance of resonant energy transfer, an increase in transfer
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efficiency corresponds to a decrease in the inter-dye distance. To account for absent
acceptor fluorophores in rAc-DA filaments (i.e., a donor-only population), E were
corrected using the acceptor labeling efficiency fA. The FRET efficiency E is typically
calculated using
𝐸=

𝜏- − 𝜏-8 / 𝜏- .

(11)

The amplitude-weighted mean lifetime of the donor in rAc-DA filaments is
𝜏-8 = 𝑓8 𝜏-8 ′ + 1 − 𝑓8 𝜏- ,

(12)

where 𝜏-8 ′ is the lifetime of the donor in the presence of an acceptor, and 𝜏- is the
lifetime of the donor in the absence of an acceptor determined from TCSPC
measurements of rAc-D filaments. 1 − 𝑓8 𝜏- and 𝑓8 𝜏-8 ′ are the contributions to
donor lifetime from populations of Tn-D and Tn-DA within rAc-DA filaments,
respectively. To correct 𝐸 for the presence of this donor-only population, 𝜏-8 is
substituted with 𝜏-8 ′ =

Uuv
wv

−

Uu
wv

+ 𝜏- from Eq. 12 to yield Eq. 5.

The presence of a donor-only population in rAc-DA samples inflates 𝜏-8 ,
resulting in lower transfer efficiencies and longer inter-dye distances. To emphasize
confidence in utilizing fA as a correction factor for calculating E from lifetime decays, a
representative example of uncorrected E and R and fA-corrected E and R obtained from
three separately reconstituted rAc-D (Tn-D, TnI211C*ATTO550) and rAc-DA (Tn-DA,
TnI211C*ATTO550, TnC127C*ATTO655) are shown in Table A5. The data were
chosen due to the large variation in fa, where fa ranges from 0.33 to 0.85. Table A6 shows
the average E and R ± SEM. Figure 19 shows the changes in E and R when using fA
correction, where values for E increase and R decrease. This suggests fA can be used to
correct for a population of donors absent an acceptor in rAc-DA samples. Even with
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diverse sample conditions in separately reconstituted filaments, the mean E and R show a
smaller variance compared to the uncorrected data. The Ca2+-depleted and Ca2+-saturated
FRET efficiencies for the three acceptor positions were plotted for each donor residue
(Figure 20). Tables A7, A8, and A9 show the E and R with and without Ca2+ for all
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Figure 19. Correcting the FRET efficiency with the acceptor labeling efficiency
removes the influence of a donor-only population in Tn-DA-decorated filaments.
Representative data for separately reconstituted rAc-D (Tn-D, TnI211C*ATTO550) and
rAc-DA (Tn-DA, TnI211C*ATTO550, TnC127C*ATTO655) filaments. (A) The noncorrected (raw) and fa-corrected mean FRET efficiency E for rAc (apo, black), and rAc
supplemented with 3 mM CaCl2 (+Ca, grey). Error bars represent SEM (n = 3). (B) The
mean inter-dye distance R calculated from E (raw) and Ec (corrected) for rAc, and rAc
supplemented with 3 mM CaCl2. Error bars represent SEM (n = 3). A consistent coloring
scheme is used in panels A-B.
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Figure 20. FRET efficiencies in Tn within thin filaments with and without Ca2+. rAc
filaments were diluted to 500 nM in WB (apo, open circles and dotted line) or WB
supplemented with 3 mM CaCl2 (+Ca, solid circles and solid line). Transfer efficiencies
were calculated from the amplitude-weighted mean lifetime of the donor, and the donor
in the presence of the acceptor on TnC35C (green), TnC89C (red), or TnC127C (blue).
Increases in E with Ca2+ indicate the donor on TnI moving closer to TnC. Average E ±
SEM (n = 3) is shown.
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Studies utilizing FRET as a structural biology method should take heed of the
influence on E (and R) by the orientation of the fluorophores. This influence depends on
the constrained nature of the covalently attached dyes, and the influence on the emission
and absorption dipole moments of the donor and acceptor fluorophores, respectively.124
In calculating FRET efficiency, the orientation factor κ2 was assumed to be 2/3, as both
the donor and acceptor have C5 linkers that should allow for free rotation of the dyes to
sample random orientations.111 If there is not free rotation, an error of up to 35% could
be introduced to R calculations.105 To completely remove any doubt about the distances
obtained, fluorescence anisotropy measurements, which determine whether or not
covalently attached fluorophores are freely rotating in solution, would need to be
performed on both the donors and acceptors in the future to determine whether the
fluorophores are constrained.105 Anisotropy values would give a tailored R0 for each
FRET pair (instead of using a universal R0 based on isolated fluorophore emission
spectra), which would theoretically produce more accurate calculation of R. These
experiments are time-consuming and sample intensive, and thus would be more
appropriate for a future study. Conveniently, Xing et al. published anisotropy results for
an AEDANS (5-(iodoacetamidoethyl)amino-naphthalene-1-sulfonic acid) fluorophore
covalently bound to mcTnI residues 151C, 160C, 167C, 188C, and 210C in thin
filaments, and reported no change in fluorophore mobility across all TnI residues.125 This
provides a small level of insight into the protein environment of some of the donor
residue positions.
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3.7 Inter-dye distances reveal the dynamics of the C-TnI
3.7.1 Dynamics of the C-TnI with respect to the N-lobe of TnC
The Ca2+-depleted and Ca2+-saturated R for rAc with acceptor TnC35 are plotted
for each donor residue (Figure 21A). The Ca2+-induced change in inter-dye distance (∆R
= R+ca - R-Ca) is shown in Figure 22B, with the corresponding change in E for reference in
Figure 22A. A comparison between recovered +Ca R and Rmod is shown in Figure 22D.
Average ∆E and ∆R values ± SEM (n = 3) are shown in Table A10. Negative ∆R values
indicate the donor and acceptor fluorophores move closer together in space due to Tn
conformational changes.
The switch region (residues 151-167) maintained a distance of ≈5.3 nm from the
N-lobe of TnC, ≈3 nm farther than predicted by the MTS model. TnI167 had an
appreciable ∆R = -0.60 nm, though other residues in the switch region had minimal ∆R.
TnI167 may be in a portion of the switch region moving closer to the N-lobe; however,
the switch region and N-TnC are too far apart to be interacting. ∆R were greater in the Cterminal end (residues 182-211) than in the switch region, suggesting a more dynamic
nature probably corresponding to the second actin binding site (SABS) lifting off actin
when Ca2+ binds to N-TnC. Because apo and +Ca R values increased sharply after
TnI177, the N-TnC may be positioned in the middle of the switch region, with TnI177211 extending laterally away from N-TnC.
The minimal Ca2+-induced movements in the switch region are slightly surprising,
though not a novel discovery. Cordina et al. used paramagnetic relaxation enhancement
NMR in a recombinant binary complex of rcTnC/TnI to show movement in the switch
region (residues 151 and 159) and IR (residue 143) was small, suggesting the switch

76
region remains close to the N-lobe of TnC to increase the probability the switch region
will bind to the incompletely open N-lobe.126 They averaged the Ca2+-induced distance
changes for TnI residues 151 and 159 with respect to the N-lobe, and observed ∆Rav = 0.95 nm. The FRET-derived ∆Rav for TnI151, 160, and 167 is -0.33 nm. Differences may
be due to the influence on TnC and TnI structure from TnT, Tm, and actin that force the
switch region away from N-TnC; a binary TnC/TnI complex may retain a more compact
structure.
Ca2+-induced distance changes with respect to the N-TnC were smaller than those
in the inter-lobe linker (acceptor TnC89C) and C-lobe (acceptor TnC127C). This
suggests the change in distance was due to TnC movement, not TnI movement. One of
the novel benefits of this study was maintaining the same donors on TnI and altering the
acceptor positions on TnC, allowing for insights into both TnC and TnI dynamics, as all
Ca2+-induced ∆R would be the same if TnC was immobile. NMR has shown N-TnC has
independent dynamics,127 though the results presented here show N-TnC has only
minimal dynamics compared to the rest of TnC. The partial opening of this N-lobe when
Ca2+ binds does not cause dramatic movement of the lobe in space. However, spatial
movement may not be resolved using FRET if TnC35C moves orbitally with respect to a
donor on TnI—movement space would not translate to a change in distance. These
inquiries could be clarified in the future by applying the resolved distance constraints
from all acceptors towards molecular modeling.
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Figure 21. Inter-dye distances in Tn reconstituted in thin filaments with and without
Ca2+. The inter-dye distance (R) was calculated from E in the absence (apo, open circles
and dotted lines) and presence of 3 mM CaCl2 (+Ca, closed circles and solid lines). (A) R
with acceptor TnC35C (green) vs. TnI donor. (B) R with TnC89C (red). (C) R with
TnC127C (blue). (D) +Ca FRET-derived R (l, solid lines) and MTS model-derived84
Rmod (Ð, dotted lines) for acceptor position 35C, 89C, and 127C. (E) +Ca E derived from
steady-state ensemble FRET of isolated Tn (500 nM in Tn) in WB +3 mM CaCl2 (p,
solid line) from n = 1 reconstitution, +Ca E from trFRET of rAc (l, solid line) from
Figure 19B, and theoretical E derived from the MTS model (Ð, dotted line) from Figure
6D. (F) R calculated from E in (E), where Rmod is from Figure 6A, and rAc R is in (D).
Color scheme and symbols are preserved from (A-F).
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Figure 22. Relative FRET efficiency and inter-dye distance changes upon Ca2+
binding to Tn within the thin filament. (A) The change in E was obtained by
subtracting the mean +Ca E from the mean apo E. The positive values indicate a closer
proximity of the donors on TnI and acceptors on TnC. Changes in E for acceptor position
35, 89, and 127 are in red, green, and blue, respectively. (B) Inter-dye distances (R) were
obtained by subtracting the +Ca mean distances from apo distances. The negative values
indicate a closer proximity of the C-TnI to TnC35C (green), TnC89C (red), or TnC127C
(blue).
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3.7.2 Dynamics of the C-TnI with respect to the inter-lobe linker of TnC
The +Ca and apo R with acceptor TnC89 are plotted for each donor residue
(Figure 21B). The Ca2+-induced ∆R is shown in Figure 22B, with the corresponding
change in E for reference in Figure 22A. In switch region, +Ca R were longer compared
to Rmod; however, the MTS model seemed to predict with some accuracy the +Ca R for
TnI(182-211), seen in a superposition of the red solid (R) and dotted (Rmod) lines in
Figure 21D. The switch region maintained a distance ≈5 nm from the inter-lobe linker,
with a sharp increase after TnI177 in both R (distance) and ∆R (dynamics). Without Ca2+,
the C-terminal end extended away from the inter-lobe linker beyond TnI177.
Interestingly, at high Ca2+, R dropped to ≈6 nm at the C-terminal end, as opposed to ≈7
nm for TnC35C, indicating both the inter-lobe linker of TnC and the C-terminal end of
TnI may dynamically move towards each other. This is consistent with NMR studies in
sTnC127 and human cTnC,29, 35 and in the MTS modeling.84
The longer inter-dye distances between the switch region and the core of Tn
compared to Rmod are dramatically pronounced with respect to TnC89C. Robinson et al.
performed time-resolved measurements on cTn alone, cTn-Tm, and cTn in rAc using the
FRET pair TnI151C*AEDANS-TnC89C*DDPM, and showed a Ca2+-induced ∆R = -0.4
nm for Tn in rAc.49 This is two times larger than the ∆R = -0.19 nm from this study.
Robinson et al. also showed the recovered Ca2+-depleted distances increased by 0.4 nm
from Tn and Tn-Tm to rAc, suggesting structural changes in Tn are influenced by actin.
Robinson et al. reported a +Ca R in rAc of 2.42 nm, not dramatically different from Rmod
= 1.40 nm in isolated Tn. There is an important point to consider when comparing
Robinson et al.’s results to those presented in this study: the ionic strength of their sample
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buffer was 150 mM KCl, compared to 75 mM KCl in this study. When imaging rAc with
an ionic strength of 150 mM, a large population of unbound Tn was present in solution
(Figure 12). Free Tn could falsely decrease distances derived from Tn in rAc.
To determine if distances recovered in isolated Tn using this study’s FRET
constructs would correspond more closely to both Robinson’s and the Rmod distances,
steady state FRET was performed in Tn with donor residues TnI(151-189) (donor
AF546) with acceptor TnC89C. Figure 22E and 22D show the comparison of FRETderived E and R, respectively, from Tn alone and Tn within rAc, and the E and Rmod
predicted by the MTS model. Values are shown in Table A11. R for isolated Tn clearly
correlate to Rmod, where the switch region and TnI(174-189) are in close proximity to the
Tn core. However, for R derived from Tn within rAc, there is a clear structural influence
on TnI and TnC from the presence of Tm and actin. Importantly, this shows a more
native environment is necessary to define the structure-function role of Tn. Utilizing
epifluorescence imaging and FCS can give confidence in filament integrity, where
samples with unbound Tn in solution are discarded prior to measurement.

3.7.3 Dynamics of the C-TnI with respect to the C-lobe of TnC
Apo and +Ca R with acceptor TnC127 are plotted for each donor residue (Figure
21C). ∆R is shown in Figure 22B, with the corresponding change in E for reference in
Figure 22A. Apo R in the switch region maintained a distance of ≈6 nm, compared to ≈5
nm with acceptors on TnC35 and 89. Of particular interest are the ∆R at TnI151 and 160
(∆Rav = -0.8 nm), which differ from the almost non-existent ∆R at those TnI residues
with acceptors on TnC35 and 89. Because NMR relaxation studies have shown the Clobe has intra-lobe dynamics,127 this author concludes the entire C-lobe must alter its
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position in space when Ca2+ binds, moving closer to the C-terminal region of TnI. This is
in agreement with reports of a Ca2+-dependent rotation of the I-T arm around the actin
filament, shown in MTS modeling.84 With Ca2+, R only increased ≈0.8 nm from the
switch region to residue 211, indicating the C-lobe and TnI182-211 both alter their
conformation/position such that the C-lobe becomes “enclosed” in space by the Cterminal region of TnI. TnI177 still appears to still behave as a pivot point for greater
Ca2+-induced dynamics in the C-terminal end, with ∆R values increasing from ≈-0.5 to ≈1.2 nm N- to C-ward, respectively (Figure 22B).
Cordina et al. monitored the Ca2+-induced distance changes in the IR (TnI151 and
159) with respect to the C-lobe in a binary complex of TnC/TnI, where ∆Rav = 0.97 nm,
indicating the switch region moved farther away from the C-lobe with Ca2+.126 Averaging
this study’s ∆R from TnI 151, 160, and 167 showed ∆Rav = -0.44 nm, suggesting in the
presence of Tm and actin, the switch region and the C-lobe move closer together.
Therefore, both TnC and TnI may undergo spatial rearrangement when in reconstituted
thin filaments that are not observed in a binary TnC/TnI complex.
In this section, the dynamics and distances with respect to each region of TnC
were described. It appears that the MTS model predicted the position of the C-lobe with
some accuracy at high Ca2+, but appears to have incorrectly predicted the position of the
N-lobe with respect to C-TnI. In the next section, the structure and general dynamics of
cTnI with respect will be discussed in greater detail, with comparisons to literature
reports of C-TnI dynamics.
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3.7.4 The majority of Ca2+-dependent dynamics are within TnI residues
182-211
A pictorial summary of Figure 22B is shown as a primary sequence color map in
Figure 23A, with a secondary structure model in Figure 23B. A cursory glance across all
acceptor positions shows large Ca2+-dependent dynamics are focused at the C-terminal
end (from residues 182-211). The largest changes were seen in TnI196 and 200, located
in the second actin binding region of TnI. These results are consistent with those by
Jayasundar et al., who proposed a molecular model with constraints from FRET-derived
distances in free cTn. The second actin binding site, which they predicted was in the
mobile domain (TnI182-189), underwent greater conformational changes than the
inhibitory region.128 Structural studies such as those by Jayasundar may have been
focusing on the wrong “mobile” domain, however, as the results in this study predict the
greatest dynamics are in TnI196-211.
Observing the trend in R in C-TnI with respect to the three acceptor positions can
give some insight into the secondary structure of the C-TnI. The MTS model predicted an
extended α-helix comprising TnI158-189 (predicted from the Takeda crystal structure
1J1E), and a denatured C-terminal end (residues 190-211). A FRET study by Dong et al.
showed the switch region in mcTnI150-165 maintains an α-helix both with and without
Ca2+.129 The results of study suggest the switch region may be part of a helix-loop-helix
motif, where the switch region is helix III (residues 151-177), with a loop connecting
helix IV (residues 180-189). The loop allows for the relatively rigid switch region to
connect to the dynamic helix IV. There may be similarities in the structure and dynamics
of the two actin binding sites in TnI. The SABS comprises residues TnI189-211, and is
slightly C-ward from where Murakami predicted the SABS in sTnI.81 Dong et al. used
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intra-molecular FRET on TnI to show when Ca2+ binds, the IR experiences a ≈9 Å
increase in length, and the conformation changes from a β-turn coil to a quasi α-helix
with Ca2+.63 The SABS may undergo a similar conformational change, where the Cterminal end becomes more extended when not bound to actin, evident from the Ca2+dependent disappearance in an apparent “kink” at residue TnI196. RKKK is a critical
amino acid sequence for actin binding found in the IR,130 and this sequence is also found
in the SABS at TnI(205-208). Peak inter-dye distance and Ca2+-dependent dynamics were
observed around TnI196, where glycines at TnI190, 201, and 204 could be responsible
for imparting mobility. In summary, the switch region (helix III) is an α-helix with minor
Ca2+-dependent dynamics; a pivot point at residue TnI177 leads into a dynamic α-helix
(helix IV) and the dynamic SABS (189-211). This is illustrated in Figure 23B.

Figure 23
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Figure 23. Dynamics of the C-terminal region of TnI (residues 151 to 211) in
reconstituted thin filaments. (A) Primary sequence map of the Ca2+-induced dynamics
of C-TnI compared to the N-lobe, flexible linker, and C-lobe of TnC. The color-coded
results of the Ca2+-induced distance changes (∆R) from Table A11. The number of
residues represented by each box is three, with the residue attached to the donor in the
middle (e.g., for donor position 151, the box represents residues 150, 151, and 152). (B)
The model depicts a helix-loop-helix motif, where helix III (151-177) and helix IV (180189) are shown. Helix III remains relatively static in the absence of Ca2+ (apo) and with
Ca2+ bound, with a pivot point near residue 177 leading into helix IV. Residues 182 to
211 comprise the second actin binding site (SABS). The SABS has the greatest Ca2+dependent dynamics.

A simplified approach to the results presented in the previous sections is shown in
Figure 24 as a highly schematic model of the Ca2+-dependent activation of Tn within the
thin filament. For simplicity, only one actin strand is shown in a “straightened”
formulation without helical twisting; in native muscle, two actin chains form a double
helical strand, each with its own Tm dimer and evenly-spaced Tn complex. TnC is
positioned perpendicularly relative to the actin filament,131-132 above the interface
between two adjacent actin protomers. The C-terminal region of TnI bridges two actin
monomers, with the inhibitory region bound on one monomer, and the SABS bound on
the other.81 In the absence of Ca2+, the IR and the SABS are bound to actin, displacing the
switch region away from the N-lobe. When Ca2+ binds to Site II, the inhibitory region
and SABS move off actin; the switch region, however, undergoes minor Ca2+-induced

86
movements towards the N-lobe and does not bind to the partially-exposed hydrophobic
pocket. The SABS undergoes major Ca2+-induced movements towards TnC. TnC itself
has independent dynamics, with the greatest dynamics evident in the inter-lobe linker.

Figure 24
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Figure 24. Schematic model of the structure and displacement of the switch region
and SABS with respect to TnC under Ca2+-saturated and Ca2+-depleted conditions.
(A) The thin filament under low Ca2+, with actin (red), Tm (blue), TnT (purple), TnI
(cyan), and TnC (yellow) shown. For TnI, the N-terminal phosphorylation sites at Ser23/24 (P), helix I, the I-T arm (helix II), helix III (switch region), and the actin binding
sites (black dotted circles) consisting of the IR and second acting binding site (SABS) are
shown. For TnC, the N-lobe and Sites III and IV occupied by Mg2+/Ca2+ (blue circles) on
the C-lobe are shown. For TnT, the T1 and T2 regions are shown. (B) Close-up from (A)
showing TnI, TnC, TnT, and the actin surface under low Ca2+. Yellow stars represent the
12 donor positions spanning from TnI(151-211). TnI(151-177) form helix III, known as
the switch region; TnI(180-189) form helix IV; and TnI(189-211) form the SABS. The
three acceptor positions are shown on TnC35 (N-lobe), 89 (flexible linker), and 127 (Clobe). TnC lies across actin, where the N-lobe is positioned out of the page, and the Clobe into the page. Helix I of TnI and the I-T arm are in the plane of the page. (C) Same
as (B), but under +Ca conditions, where Ca2+ is bound to Site II on the N-lobe of TnC
(blue circle). Black arrows depict Ca2+-induced movement. The IR has moved off actin.
Movement in the switch region is minimal. The N- and C-lobes move towards actin,
where the inter-lobe linker is the most dynamic region of TnC. TnI177 acts as the pivot
point, bridging the non-dynamic switch region and dynamic SABS, which lifts off actin,
moving ~1-1.4 nm towards TnC. TnC35, 89, and 127 are positioned such that they are
~equidistant from residue 151 of TnI.
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The physiological importance of C-TnI is supported by myocardial stunning, a
phenomenon where cTnI(193-211) is selectively degraded,133 resulting in contractile
dysfunction.134 Functional studies have predicted the importance of these residues in
inhibiting thin filament activation. Tachampa et al. exchanged recombinant cTn
containing mcTnI(1-193) and hcTnI(1-192) into skinned rat cardiac trabeculae, and
showed a resulting ≈50% decrease in maximal force and cooperative activation. Actinactivated ATPase activity also dropped by ≈50%.135 Importantly, they showed a ≈50%
increase in Ca2+ sensitivity, but only when cTn was reconstituted into thin filaments. This
author hypothesizes the SABS is responsible for the reduction in Ca2+ sensitivity when
Tn is reconstituted into thin filaments136 due the the displacement of the switch region
away from the N-lobe of TnC.

3.8 Functional characterization of a FRET pair in the switch region
and N-lobe of TnC
Tn containing TnI151C and TnC35C was selected to determine whether potential
functional or structural effects from mutagenesis could account for the unexpectedly
large distance between switch region and the N-lobe of TnC. Mutant Tn containing
mcTnI (C81I, C98S, S151C), rcTnC (C84S), N-terminal myc-mcTnT and WT Tn
containing mcTnI, rcTnC, and N-terminal myc-mcTnT were exchanged into isolated rat
myofibrils. The efficiency of exchange of WT Tn (53.73±3.94%) and mutant Tn
(43.64±6.23%) were estimated from Western blots of the exchanged cells (Figure 25AB). Figure 25C shows measurements of force at different Ca2+ concentrations. During
measurements, the sarcomere length (SL) was maintained at either 1.9 µm or 2.3 µm.
Two sarcomere lengths were used to determine if mutagenesis had any effect on the Ca2+
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sensitivity of force development, as sarcomere length determines the Ca2+ response of the
sarcomere.137
At 1.9 µm and 2.3 µm SL, peak force (Figure 25D) and Ca2+ sensitivity (pCa50)
(Figure 25E) were not statistically different between fibers exchanged with WT and
mutant Tn (P > 0.05). The mutagenesis required for this FRET pair negligibly affected
the Ca2+-dependent regulatory activity of the mutant Tn compared to WT Tn, suggesting
no significant structure or functional perturbations of the switch region by the
mutagenesis required for this FRET pair. In the future, these experiments should be
repeated with FRET-labeled Tn in order to determine if dye modification affects the
native function of Tn. Ideally, these measurements would be performed on all paired
D/DA Tn.
The previous sections have attempted to explain and give credence to the
surprising observation of C-TnI structure and dynamics in reconstituted thin filaments. In
the next section, the importance of actin and Tm on Tn structure will be discussed, along
with a comparison between results derived from this FRET assay and current
mechanisms of Tn activation proposed in literature.
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Figure 25
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Figure 25. Functional characterization of wild type and mutated Tn. WT Tn
consisting of myc-mcTnT, mcTnI, rcTnC and mutant Tn consisting of myc-mcTnT,
mcTnI151C, rcTnC35C were exchanged into skinned cardiomyocytes isolated from rat
ventricles. (A) Western blot analysis of reserved fibers. Exchanged myc-TnT was
compared to native TnT to determine the Tn exchange efficiency. (WT: n = 3 hearts;
mutant: n = 3 hearts) (B) Shown is the mean exchange efficiency from samples in (A) ±
SEM. Differences were not significant (P > 0.05, two-way ANOVA). (C) Pooled data
(mean ± SEM, WT: n = 9 fibers; mutant: n = 9 fibers) from force-pCa measurements of
fibers at short (red, 1.9 µm) and long (blue, 2.3 µm) sarcomere lengths (SL). Lines for
mutant (dotted line) and WT (solid) exchanges are drawn using the mean Ca2+-sensitivity
pCa50 and maximum force Fmax recovered from individual fits of fibers. (D) Average
maximum force ± SEM from (C) for SL at 1.9 µm (white) and SL 2.3 µm (grey). (E)
Average pCa50 ± SEM from (C). A consistent coloring scheme is used in (D-E).

3.9 Actin ultimately determines Tn structure and dynamics during
activation
The muscle field emphasizes the importance of the switch region as the molecular
toggle for cardiac muscle regulation, responsible for dragging the IR and SABS off actin
to remove myosin binding inhibition. This may be a biased view, however, as the switch
region/N-lobe interactions are based on isolated or fragmented Tn structures solved using
NMR or X-ray crystallography. In reconstituted thin filaments, the switch region was
around 5 nm from the N-lobe (both apo and +Ca), too far to promote an interaction. Other
modulatory modifications to the thin filament (like crossbridge formation) may be
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required to push the switch region into the hydrophobic pocket of N-TnC in native
muscle, whereas for Tn in the absence of actin, the fully active conformation is
energetically preferred. Hence, why some of the previously-mentioned studies in Tn
reported limited Ca2+-induced movements of the switch region due to its close proximity
to the N-lobe, as Tn was already in an active-like conformation, even at low Ca2+.126, 128
Temporarily averting full binding of the switch region may be a stopgap mechanism to
prevent hyperactivation from Ca2+ binding, where full thin filament activation requires
additional steps. Therefore, the Herzberg model of TnC activation may still hold true,64
though Ca2+ alone may not promote switch region binding to N-TnC. Conversely, the
inability of the N-lobe to fully open due to the inactivity of Site I may indicate the switch
region evolved out of vogue in cardiac muscle as the major Tn structural change; instead,
SABS and IR lift off actin in an isoform-specific mechanism.

3.9.1 The role of TnI in the steric blocking mechanism of thin filament
activation
The steric blocking mechanism for muscle activation dictates that the IR inhibits
Tm movement under low Ca2+, where Tm blocks myosin binding sites and prevents
ATPase activity. Under high Ca2+ conditions, TnC competes with actin, causing liftoff of
the IR to allow Tm movement away from myosin binding sites.51, 138-139 A three-state
model of activation branching from the steric blocking model has been proposed by
McKillop and Geeves,23 and this mechanism is consistently discussed in terms of Tm
position correlated to the activation level. However, some studies have shown Tm
undergoes minor Ca2+-140-141 and myosin-induced141 movement on actin. A mechanism
proposed by Patchell et al. stated IR-dependent actin conformational changes are
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responsible for promoting myosin binding, and not the position of Tm on actin.24 Using
electron microscopy (EM) on filaments reconstituted with actin, Tm, and the C-terminal
half of hcTnI (residues 132-210), Galinska-Rakoczy et al. showed this fragment of TnI
lies across two adjacent actin protomers.11 Murakami et al. developed their atomistic
model based those results,81 where sTnI-IR binds to the N-terminal region of actin,142 and
SABS binds to the DNase-I loop (interface between actin protomers) near the N-terminal
region of actin and a region in the C-terminal region of actin.81 The DNase loop may
facilitate interactions between actin protomers in the thin filament that promote myosin
crossbridge formation.143-144
The three-state model in terms of Tn would dictate: 1) in the absence of Ca2+, Tn
is in an inactive state, with complete ATPase inhibition due to IR/SABS bound to actin
(blocked); 2) when Ca2+ binds, Tn is in a semi-inactive state, where TnI may have
removed some of its inhibitory properties from actin, but the switch region is not bound
to N-TnC, and myosin may weakly bind (closed); 3) myosin binds to actin in the
presence of Ca2+, causing the fully-activated state, pushing the switch region into the
hydrophobic pocket of N-TnC, and inducing cooperative activation of the thin filament.
The second half of this of dissertation goes into greater detail of Tn activation by myosin
binding.

3.9.2 Minimal switch region dynamics: implications on the “drag and
release” mechanism
Since most of the Ca2+-dependent dynamics appear to be focused in the Cterminal end of TnI instead of the switch region, the “drag and release” mechanism145
may not be relevant to TnI when in the cardiac thin filament, as this study has shown the
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switch region does not bind to the hydrophobic pocket of N-TnC when Ca2+ is bound to
Site II. The dramatic difference in distance from the switch region to the inter-lobe linker
between isolated Tn to Tn in rAc should be compelling evidence to prompt a discussion
towards a modified theory of thin filament activation. Functional in situ studies have
attempted to support the “drag and release” mechanism, but may still be biased in their
analysis of results. A study monitoring simultaneous FRET and force in skinned cardiac
fibers showed strong crossbridge formation stabilized the N-lobe opening, evident from
an increase in the ensemble-averaged FRET in the presence of myosin and Ca2+.146 In a
2014 follow-up study, time-resolved FRET was used to monitor the effect of sarcomere
length on N-lobe opening, where N-lobe opening was sensitive to Ca2+ binding,
crossbridge state, and sarcomere length.147 Unfortunately, the FRET assay in both studies
only monitored intra-N-lobe conformational changes; the authors were essentially blind
in monitoring switch region binding to the N-lobe. Removing the assumption that Ca2+
causes switch region binding to N-TnC, the results from both of studies can instead be
explained using conclusions presented in this dissertation: the N-lobe may experience
minor opening with Ca2+, but crossbridge formation is ultimately responsible for pushing
the switch region into the hydrophobic pocket. As crossbridge formation is a function of
sarcomere length, N-lobe opening would correlate to sarcomere length. In order to truly
determine the role of the switch region, simultaneous force and time-resolved
fluorescence should be performed on one of the FRET constructs developed in this study,
where the donor is in the switch region and the acceptor in the N-lobe of TnC. The in
vitro behavior of the switch region with Ca2+ or myosin binding could thus be compared
to in situ behavior.
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Other FRET studies in rAc lend credence that myosin binding promotes N-TnC
and switch region interactions. Xing et al. used trFRET to show the Ca2+-saturated R
between donor residues in the switch region of mcTnI(151, 160, 167) and Cys374 in actin
in reconstituted thin filaments increased by as much as 0.7 nm upon S1 binding,
indicating S1 causes the switch region to move farther from actin,125 and potentially into
the hydrophobic pocket in the N-lobe of TnC. Wang et al. developed a multi-site steadystate FRET assay in rAc with five donor positions ranging from TnI(108-211) (mouse
cardiac numbering) on hcTnI and an acceptor on Cys374 in actin.148 Like Xing et al.,
Wang and coauthors saw an increase in inter-dye distance with S1 binding at TnI residue
152C.

3.9.3 The order in the disorder: the fly-casting mechanism of C-TnI
The fly-casting mechanism states a highly disordered SABS participates in longrange sampling of the thin filament to catalyze TnI binding to actin upon Ca2+
dissociation.68 This mechanism is based on the assumption that the SABS is an
intrinsically disordered region, and does not undergo conformational switching similar to
the IR. Julien et al. attempted to discover nascent structure in the IDR using NMR on an
sTnC/TnI chimera comprised of the N-lobe of sTnC and sTnI(126-211).149 They reported
no secondary structure, contrary to the skeletal Murakami and cardiac MTS models
already discussed. Again, these minimalistic structural studies raise concerns regarding
their physiological relevance to native cardiac protein structure and function in vivo. The
fly-casting mechanism may still apply in part; perhaps the potential absence of secondary
structure in the SABS after TnI189 still allow this region to participate in sampling the
actin surface for potential binding sites.
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3.10 Mutations in the C-TnI emphasize its functional importance
As outlined in the introduction, RCM- and HCM-causing mutations in TNNI3 are
found at a high density in the C-terminal region.97 Most of the mutations are missense,
meaning one amino acid has been substituted for another. The structure and dynamics of
this region found using this multi-site FRET assay could potentially give insight into the
mechanisms behind the disease-causing mutations. Notably, mutations in hcTnI around
the pivot point (K178E in human, K179E in mice) and a residue in the SABS (R192H in
human, R193H in mice) have been implicated in patients with RCM.88 Both cause a
dramatic increase in Ca2+ sensitivity and decrease in ATPase inhibition.92-93 This suggests
both residues play essential roles in regulating muscle contraction. Yumoto et al. utilized
circular dichroism and NMR to show K178E in an hcTnI129-210 peptide imparted a
small structural change in residues hcTnIK177-T181.93 Structural perturbations around
the pivot point could result in a loss of mobility in the C-terminal region, affecting the
ability of the SABS to bind actin. The arginine to histidine substitution at 193 results in a
loss of TnI inhibitory function, potentially due to the loss of a positive charge potentially
important for maintaining actin associations.150 Davis et al. showed exchange of
mcTnI(R193H) into mouse myocytes promoted shortened sarcomere lengths in a Ca2+independent manner, possibly due to a heightened contracted state as a result of increases
in myosin-actin interactions even at low intracellular Ca2+.150 Deletion mutations at
hcTnI177 and 178 result in HCM again emphasize the importance of the pivot point for
conferring mobility to the second actin binding site.151 Of the 29 HCM mutations in
TNNI3, 12 are found after hcTnI195.97 This supports the conclusion that the SABS of
TnI plays an essential role in regulating muscle contraction. Alterations of this binding

97
site could either hinder SABS binding to actin, or enhance SABS release; either way,
changes in the binding of this region result in dramatic changes in the muscle phenotype
and function leading to the development of cardiomyopathies.
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MECHANISMS OF ACTION OF INOTROPIC AGENTS, MYOSIN BINDING, AND
PKA-MEDIATED PHOSPHORYLATION OF TNI TO MODULATE CARDIAC THIN
FILAMENT ACTIVATION AND CALCIUM SENSITIVITY
ABSTRACT SECTIONS 4-7
To pump blood, the heart fills and empties through periods of relaxation and
contraction regulated by Ca2+ binding to cTnC and myosin binding to actin. Activation is
further tuned by protein kinase A (PKA)-mediated phosphorylation of Ser-23/24 in cTnI.
Small molecules that target the thin filament to affect cardiac output by altering
activation by Ca2+ and myosin are called cardiotonic agents, used to improve cardiac
function in heart failure patients. This study hypothesized these agents may mimic
mechanisms of myosin binding and TnI phosphorylation to modulate Tn activation.
Steady-state FRET was used to monitor structural changes in Tn in reconstituted thin
filaments, a physiologically relevant model of cardiac activation. Ca2+ and rigor-S1
titrations were performed as a two dimensional screening method to assess the effects on
cooperativity and sensitivity from bepridil and levosimendan, Ca2+ sensitizers that target
the N-lobe of TnC, and EGCG, a green tea compound with potential for Ca2+
desensitizing effects that targets the C-lobe of TnC. Filaments were treated with PKA to
determine if compounds acted in a similar mechanism to TnI Ser-23/24 phosphorylation.
For Ca2+ titrations, bepridil and S1 increased the level of active Tn, induced negative
cooperativity, and increased Ca2+ sensitivity. Notably, bepridil eliminated S1-induced
activation of Tn, suggesting bepridil and S1 activate the thin filament with a similar
mechanism, where both work by stabilizing the open conformation of the N-lobe of TnC.

99
While both EGCG and PKA treatment reduced Ca2+ and myosin sensitivity, EGCG
decreased the level of active Tn under Ca2+-depleted conditions, while Ser-23/24
phosphorylation did not alter the level of active Tn. This suggests independent
mechanisms for conferring Ca2+ desensitivity to the thin filament. A correlation was
discovered between the Ca2+-depleted FRET efficiency and Ca50. This study shows proof
of concept of a high throughput screen (HTS) to discover and develop small molecule
compounds that target sarcomere proteins to modulate cardiac output in the treatment of
heart failure.
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4 INTRODUCTION
Muscle contraction is mediated by the Ca2+-triggered cyclic interaction of myosin
motors with regulated actin filaments, where ATP hydrolysis by myosin enables thick
and thin filaments to slide past one other, causing shortening.152 Thin filaments are
composed of troponin (Tn), tropomyosin (Tm), and actin. Cardiac Tn is a heterotrimer
composed of troponin I (TnI), which inhibits actin-activated ATPase through interactions
with actin; troponin T (TnT), which binds to Tm and TnI to tether Tn to the thin filament;
and troponin C (TnC), which binds Ca2+. Cardiac TnC is composed of two EF hand
globular domains (lobes) connected by a flexible linker.27 The C-lobe (structural domain)
has two high-affinity divalent cation binding sites always occupied by Ca2+ or Mg2+,
stabilizing the open conformation of the structural domain.27 The N-lobe (regulatory
domain) has one low-affinity binding site (Site II). When Ca2+ floods the sarcomere
during diastole (relaxation), Ca2+ binds to TnC at Site II, causing conformational changes
in Tn-Tm that modulate myosin binding to actin (crossbridge formation), leading to
systole (contraction).64-65
Historically, the mechanism of activation has been thought to occur through a
structural rearrangement in the B/C helices in the N-lobe of TnC, which exposes a
hydrophobic pocket where the switch region of TnI binds, stabilizing the open
conformation of the regulatory domain.36 The inhibitory region (IR) and the second actin
binding site (SABS) of TnI come off actin as a result of Ca2+-dependent conformational
changes in Tn, allowing for a Tn-Tm-actin conformation that promotes crossbridge
formation and muscle contraction. While Ca2+ binding is a critical step in initiating
contraction by stabilizing the active state of Tn, Ca2+ alone does not account for the
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activation-dependence of the contractile properties of the myocardium. Strong (rigor)
crossbridge formation also plays a prominent role in activation itself: the strong forcegenerating crossbridge positively and cooperatively activates the thin filament,153
affecting the activation of Tn and its affinity for Ca2+.49, 154
In addition to the regulatory effects by Ca2+ and myosin on myofilament
activation, post-translational modifications of sarcomeric proteins also modulate
activation by changing the response of the myofilament to Ca2+. Kinase-mediated serine
and threonine phosphorylation of cTnI can alter myofilament properties in response to
stress or exercise.155 cTnI contains a ≈33 residue, isoform-specific N-terminal extension,
which contains two serines at residues 23 and 24.53 To meet changes in circulatory
demands requiring variations in contraction and relaxation, enhanced β1-adrenergic
stimulation causes an increase in the production of cAMP-dependent protein kinase A
(PKA).156 PKA phosphorylates cTnI Ser-23/24, promoting Ca2+ release (Ca2+
desensitivity) and increased crossbridge cycle kinetics to facilitate muscle relaxation
(lusitropy).157-158 Ser-23/24 phosphorylation is thought to disrupt interactions between the
N-terminal extension of TnI (residues 16-29) and TnC that promote Ca2+ binding to Site
II of TnC.56 In transgenic animals expressing non-phosphorylatable TnI (either mutant
S23A/S24A or slow sTnI, which lacks the ≈33 amino acid N-terminal extension), a
decrease in Ca2+ sensitivity following β1-stimulation is abolished, and its lusitropic effect
is reduced in isolated myocytes, isolated hearts, and in vivo.159-161 While the effects of
Ser-23/24 phosphorylation on the myofilament are known, the molecular mechanism
behind the decrease in Ca2+ sensitivity remains elusive.
Resolving the mechanisms behind Ser-23/24 phosphorylation-induced Ca2+
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desensitivity in Tn, and Ca2+- and myosin-dependent activation of Tn, can yield valuable
insight into the molecular mechanisms behind muscle regulation, facilitating the path to
create targeted drug therapies for heart failure. Heart failure, or cardiomyopathy (CM),
comprises changes in cardiac contractility, electrical conduction, Ca2+ transients, and
energy metabolism, leading to a failure of the heart to meet altered circulatory
demands.162-163 Sympathetic nervous system (SNS) activation is normal with heart
failure, but the myocardial response to SNS signaling is blunted by down-regulation of
the β-receptor-cAMP-PKA pathway.164-165 This causes reduced phosphorylation of cTnI,
leading to an increase in Ca2+ sensitivity; in the failing heart, Ser-23/24 phosphorylation
decreases by 33-80%.166-167 Restrictive cardiomyopathy (RCM) is a form of heart failure
associated with altered diastolic function and impaired ventricular filling due to increased
muscle stiffness, with normal systolic function and ventricular muscle wall thickness.90
An arginine to histidine mutation at residue 192 (R192H in human, R193H in mice) in
the second actin binding site (SABS) of cTnI has been implicated in RCM.88 Though
other forms of CM are associated with increases in myofilament Ca2+ sensitivity,
mutations associated with RCM are thought to cause the most dramatic increase in Ca2+
sensitivity compared to other forms of CM.93 Skinned fibers from failing human hearts
exhibiting increased sensitivity to Ca2+ and impaired diastolic function can be corrected
when the fibers are treated with PKA, enhancing Ca2+ desensitivity and promoting
relaxation.168-170 Unfortunately, the pitfalls of pharmacologically augmenting cAMPPKA signaling are illustrated by the negative survival benefit of treatment with the
phosphodiesterase III inhibitor milrinone.171 A PKA-mediated hyperphosphorylation of
the ryanodine receptor results in diastolic Ca2+ leak and impaired Ca2+ re-uptake by
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SERCA2a.172 An increase in cytosolic Ca2+ causes arrhythmias, stimulates maladaptive
Ca2+-dependent signaling cascades, and stimulates altered energy metabolism.173
Increased Ca2+ sensitivity due to R192H has been reversed in skinned muscle
fibers by desensitizing Tn to Ca2+,174 and in mice treated with EGCG,175 a green tea
compound targeting TnC to reduce Ca2+ sensitivity.176 This suggests a promising
approach to develop CM therapies by directly altering the Ca2+ sensitivity of Tn,
bypassing altered Ca2+ handling through increased cAMP-PKA signaling. Small
molecule compounds that target the thin filament (sarcomeric modulators) and mimic the
effect of PKA-dependent phosphorylation of TnI Ser-23/24 may be a viable therapeutic
strategy promoting myofilament relaxation in persons with RCM. Since the N-terminus
of TnI is unique to the cardiac isoform, pharmacotherapies that mimic the effect of N-TnI
bisphosphorylation are likely to be specific for the myocardium.
Here, the effects on Ca2+- and myosin-dependent activation by small molecules
and PKA treatment were investigated using a FRET-labeled Tn assay in reconstituted
thin filaments. This FRET assay monitored the activating structural change in Tn, with a
FRET donor in the SABS of TnI, and a FRET acceptor in the C-lobe of TnC. Ca2+ and S1
titrations were performed as a 2D screening method to assess the effects on cooperativity
and sensitivity with bepridil and levosimendan, proposed as Ca2+ sensitizers targeting the
thin filament,177-178 and EGCG.176 These small molecules were hypothesized to mimic
effects from myosin binding or TnI Ser-23/24 phosphorylation, giving insight into their
molecular mechanism. Results suggest TnI Ser-23/24-dependent desensitization to
myofilament force and ATPase to Ca2+ may be due to enhanced inhibition, where the
phosphorylated N-TnI is released from TnC to prevent IR displacement from actin, even
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with Ca2+ and myosin binding. Bepridil and S1 appear to have a similar mechanism of
increasing Ca2+ sensitivity in the thin filament, where bepridil stabilizes the open
conformation of the N-lobe, and myosin binding enhances cTnI switch region binding to
stabilize the open conformation of the N-lobe. EGCG and PKA-mediated Ser-23/24
phosphorylation appear to not share a mechanism to desensitize the thin filament for
Ca2+, evident by monitoring the level of Tn activation under Ca2+-depleted conditions. A
correlation was discovered between the deactivated (Ca2+-depleted) Tn state and Ca2+
sensitivity. The capacity of this FRET assay as a possible high-throughput screening
method (HTS) was demonstrated for small molecules targeting cardiac thin filaments to
treat heart failure.
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5 METHODS
Native and recombinant protein purification, fluorescent dye conjugation, labeling
ratio determination, epifluorescence imaging, and force-pCa experiments were described
in the Methods (Section 2).

5.1 Purification of myosin from chicken pectoralis major muscle
Skeletal myosin was purified from chicken pectoralis major muscle as
described,179-180 with some modifications. Breast tissue from a freshly slaughtered young
chicken was sliced into strips and ground in a food processor. Ground muscle was
extracted with 0.3 M KCl, 0.15 M KH2PO4 (pH 6.5), 20 mM EDTA, 5 mM MgCl2, and 1
mM ATP at 3x w/v at 4°C with stirring for 10 min. Remaining tissue was sedimented
with centrifugation at 8,000 rpm using a Beckman J2-Mi centrifuge with rotor JA-10 for
25 min. The supernatant was diluted slowly with stirring with 10x v/v of cold ddH2O.
The precipitate was settled for a minimum of 1 hour. The supernatant was siphoned off,
and the myosin precipitate was pelleted with centrifugation at 8,000 rpm for 45 min using
a Beckman centrifuge with rotor JA-10. The pellets were re-suspended in in 1 M KCl, 25
mM EDTA, and 60 mM KPO4 (pH 6.5) at 0.25 mL/g of original muscle mass and
dialyzed against 0.6 M KCl, 25 mM KPO4 (pH 6.5), 10 mM EDTA, and 1 mM DTT
overnight. Ammonium sulfate (0-30%, mass calculated with
http://www.encorbio.com/protocols/AM-SO4.htm) was added slowly to the solution with
stirring for a minimum of 30 min. The precipitate was pelleted with centrifugation at
12,000 rpm for 30 min using a Beckman centrifuge with rotor JA-14. The pellet was resuspended and dialyzed against 0.6 M NaCl, 10 mM NaPO4 (pH 7.0), 1 mM EDTA, and
1 mM DTT overnight.
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Myosin was stored in 50% glycerol in -20°C for up to six months, and purity was
confirmed using SDS-PAGE.

5.2 Myosin digest into subfragment-1
Myosin subfragment-1 (S1) was prepared as described181 with some
modifications. Myosin was dialyzed against 20 mM MOPS (pH 7.0), 50 mM KCl, 1 mM
EDTA and digested with 0.64 units chymotrypsin/1 mg myosin (α-chymotrypsin, TLCK
treated, Worthington Biochemical Co., Lakewood, NJ) for 10 minutes with stirring on
ice. The digestion was terminated with 5 mM phenylmethylsulfonyl fluoride (PMSF). 5
mM MgATP was added, and insoluble components were pelleted by centrifugation at
180,000 xg for 15 min. Soluble S1 in the supernatant was dialyzed into working buffer
(WB: 75 mM KCl, 50 mM MOPS pH 7.0, 5 mM MgCl2, 2 mM EGTA, 5 mM BME) and
stored at 4°C for up to 1 week. Catalytically inactive S1 (dead heads) were removed by
ultracentrifugation in a Beckman TL-100 ultracentrifuge at 64,000 rpm for 15 minutes
(TLA-100 rotor) in the presence of 5 mM ATP and F-actin at a molar ratio of 1 S1: 2
actin. ATP was removed using dialysis against WB (Spectra/Por 2 Dialysis Membrane,
MWCO 12-14 kDa, Spectrum Laboratories, Irving, TX). S1 was used within 24 hours of
dead head removal. Purity was confirmed using SDS-PAGE.

5.3 Phosphorylation of TnI in regulated actin
Serines 22 and 23 of TnI in rAc were phosphorylated using the protein kinase A
(PKA) catalytic subunit from bovine heart (Sigma-Aldrich, St. Louis, MO). Stock
solutions of PKA were prepared at 500 units/mL (50 µg/mL) in ddH2O with 6 mg/mL
DTT, and stored at 4°C for up to 1 week. Literature provided by Sigma-Aldrich indicated
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a 15% loss of activity after 8 days when stored at 4°C.182 PKA was incubated for three
hours at room temperature with rAc in WB supplemented with 5 mM MgATP at a ratio
of 125 units of PKA/mg of TnI.183 To remove unreacted ATP, rAc was sedimented by
ultracentrifugation at 64,000 rpm for 15 min (Beckman TLA-100 rotor). Pellets were
washed twice with WB, and reconstituted by Dounce homogenization.
The extent of phosphorylation was quantified using phosphate affinity SDSPAGE with PeppermintStick phosphoprotein molecular weight markers (Life
Technologies). Markers were loaded at 1 µg. The markers contain ovalbumin, which has
two phosphorylation sites, and β-casein, which runs close to TnI. Gels were stained
successively with Pro-Q Diamond phosphoprotein and SYPRO Ruby total protein stains
(Life Technologies), and scanned with UV excitation (Gel Logic 112, Kodak) with an
exposure time of 14 sec. Images were pseudo-colored using ImageJ 1.47v (National
Institutes of Health, Bethesda, MD). The amount of loaded TnI was adjusted to 1 µg by
multiplying the TnI SYPRO Ruby (SI) and TnI Pro-Q (DI) intensities by (𝑆y /𝑆z ), where
Sβ is the SYPRO Ruby band intensity of β-casein. The ratio of the Pro-Q Diamond and
SYPRO Ruby band intensities (abbreviated D/S ratio) of ovalbumin (𝐷{ 𝑆{ ) was
normalized to 2, and used as the maximum normalization factor. The number of sites in
TnI phosphyorylated (NP.) was found using
𝑁| =

𝐷z ′ 𝑆z ′
,
𝐷{ 𝑆{ /2

(13)

where 𝑆z ′ and 𝐷z ′ is the corrected SYPRO Ruby and Pro-Q Diamond band intensities of
TnI.
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5.4 Steady state fluorescence spectroscopy
5.4.1 Calcium titrations
Steady-state measurements were performed at 22°C on a Fluorolog-3
spectrofluorometer (Horiba) equipped with a MicroLab500 syringe dispenser (Hamilton)
and Versa water bath temperature control (ThermoFisher Scientific). Singly- and doublylabeled reporter filaments, rAc-D (with Tn-D, TnI189C*AF546, TnC127C, TnT) and
rAc-DA (with Tn-DA, TnI189C*AF546, TnC127C*ATTO655, TnT), respectively, were
prepared in WB (250 nM in Tn). Stock solutions of (-)epigallocatechin gallate (EGCG,
Sigma-Aldrich), bepridil hydrochloride (bepridil, Sigma-Aldrich), and levosimendan
(Sigma-Aldrich) were prepared at 25 mM in DMSO, aliquoted, and stored at -20°C for
up to six months. Stock solutions were monitored for precipitation, and vortexed for 30
sec prior to use.
Fluorescence emission from the FRET donor was monitored (530 nm excitation,
570 nm emission, monochromator slit width 4 nm, 1 sec integration time) following 25
serial injections (2 µL) of +Ca buffer into 1 mL of sample. +Ca buffer consisted of WB
supplemented with 50 mM CaCl2. A mixing time of 3 sec was applied after the addition
of each aliquot. Following the titration, the sample was denatured with 3 M guanidine
hydrochloride, and the donor emission was collected. This provided the relative
concentration of the donor dye. All intensity data were corrected for dilution. The
intensity of the rAc-DA sample was corrected for donor concentration mismatch using
∗
𝐼 } (𝐶𝑎)-8 = 𝐼(𝐶𝑎)-8 𝐼-∗ 𝐼-8
,

(14)
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∗
where 𝐼-∗ is the intensity of the denatured (+GnHCl) rAc-D sample and 𝐼-8
is the

intensity of the denatured rAc-DA sample. Ca2+-dependent FRET efficiency E was
calculated using
𝐸(𝐶𝑎) =

1
𝐼 } (𝐶𝑎)-8
(1 −
),
𝑓8
𝐼(𝐶𝑎)-

(15)

where fA is the labeling efficiency of the acceptor dye. Data were fit to the Hill equation
𝐸 = 𝐸S +

𝐸p − 𝐸S
,
1 + (𝐶𝑎•" 𝐶𝑎)b€

(16)

where nH is the Hill coefficient and Ca50 is the Ca2+ concentration that produces half
maximal activation, E− is the FRET efficiency without added Ca2+ and E+ is the FRET
efficiency with saturating Ca2+.
Calcium titrations were performed on rAc-D and rAc-DA, phosphorylated rAc,
and rAc supplemented with 0.5% (v/v) DMSO drug vehicle solvent, 200 µM bepridil,
200 µM levosimendan, 200 µM EGCG, and 750 nM S1. Control measurements were also
performed on rAc phosphorylated with PKA (125 units/mg TnI) and 5 mM ATP, with
PKA only (125 units/mg TnI), and with 5 mM ATP only.

5.4.2 Concentration of free calcium
The concentration of free Ca2+ was obtained using the titration protocol described
above with injections into 1 mL of Fluo-4FF pentapotassium salt (Life Technologies)
(250 nM) in WB. Fluorescence (490 nm excitation, 520 nm emission, 4 nm slit width,
0.25 sec integration time) was corrected for dilution. The concentration of free Ca2+ was
calculated using
[𝐶𝑎+p ]Z = 𝐾-

𝐹Z − 𝐹KZb
,
𝐹KLM − 𝐹Z

(17)
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where KD (9.7 µM) is the dissociation constant of Fluo-4FF, Fmin is the intensity under
Ca2+-depleted conditions, and Fmax is the intensity under Ca2+-saturating conditions.

5.4.3 Myosin S1 titrations
Steady-state measurements were performed on the instrument detailed above.
rAc-D and rAc-DA (250 nM in Tn) were suspended in WB or WB supplemented with 3
mM CaCl2. Fluorescence emission from the FRET donor was monitored following 200
serial injections (2 µL) of 5 µM S1 in WB. A mixing time of 3 sec was applied after the
addition of each aliquot. Intensity data were corrected for dilution, and intensity of the
rAc-DA sample was corrected for donor concentration mismatch. E was calculated using
Eq. 3, which includes the acceptor labeling efficiency correction. FRET efficiency data
were fit to the Hill equation
𝐸 = 𝐸S +

𝐸p − 𝐸S
,
1 + (𝜃•" 𝜃)b€

(18)

where nH is the Hill coefficient, 𝜃 is the total [S1]/[Actin], 𝜃•" is the [S1]/[Actin] ratio
that produces half maximal activation, E− is the FRET efficiency without S1, and E+ is
the FRET efficiency with saturating S1.
Myosin titrations were performed in triplicate on rAc, phosphorylated rAc, and
rAc supplemented with 200 uM bepridil and 200 uM EGCG.

5.4.4 Determining EC50 of EGCG
rAc-D and rAc-DA (250 nM in Tn) were suspended in 1 mL of WB. Fluorescence
emission from the FRET donor was monitored following 200 serial injections (2 µL) of
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WB supplemented with 5 µM EGCG. Intensity data were corrected as indicated above,
and E was calculated using Eq. 3. FRET efficiency data were fit to the Hill equation
𝐸 = 𝐸S +

𝐸p − 𝐸S
,
1 + (𝐸𝐶•" 𝐸𝐺𝐶𝐺)b€

(19)

where nH is the Hill coefficient, 𝐸𝐶•" is the [EGCG] that produces half maximal
activation, E− is the FRET efficiency without EGCG and E+ is the FRET efficiency with
saturating EGCG.

5.5 Cosedimentation assays
5.5.1 Chemomechanical binding assay
Mixtures of F-actin or rAc (10 µM in actin protomer) and S1 (20 µM) were
prepared in W or WB supplemented with 5 mM MgATP, then sedimented at 64,000 rpm
for 15 min in a TLA-100 rotor. Reserved sample, supernatant, and pellet were examined
by quantitative SDS-PAGE. Coomassie-stained gels (GelCode Blue Safe Protein Stain,
ThermoFisher Scientific) were scanned (Gel Logic 112, Kodak) for 14 sec using white
light epi-illumination. Intensities of S1 and actin bands were quantified using ImageJ.
Band intensities I were converted to the relative C using
𝐶 = 𝐼 − 𝐼j

𝛼,

(20)

where IB is the background intensity and α is the staining efficiency of the S1 relative to
actin. α was determined from the band intensity of the reserved sample, which contains
proteins of known concentration. Measurements were performed in triplicate.
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5.5.2 S1 binding to regulated actin with PKA treatment and small
molecules
Phosphorylated rAc, rAc (10 µM in actin protomer), or rAc supplemented with 8
mM bepridil or 8 mM EGCG were mixed with S1 (20 µM) in WB, sedimented, and
analyzed as described above.

5.6 Statistical analysis
Unless otherwise stated, parameters such as nH and Ca50 were recovered through
non-linear regression using the least squares method using GraphPad Prism ver. 6g
(GraphPad Prism Software, Inc., La Jolla, CA). For Ca2+ titrations, E is reported as the
maximum likelihood estimate, and recovered parameters are shown for n = 1 trial. For S1
titrations, data are plotted as the mean, with errors bars as SEM. E is reported as the
maximum likelihood estimate, and recovered parameters are shown for n = 3 trials,
except in control measurements with rAc mock-treated with PKA, where n =1 trial.
Standard errors obtained from the fitting are shown next to each value. The significance
(P > 0.05) between untreated rAc filaments and filaments treated with PKA or small
molecule compounds was determined using the Z-test on the mean and asymptotic SE for
each parameter recovered from fits of the data to the Hill equation.184 In the case of high
throughput drug screening trials, compounds not producing significant shifts in Ca50 and

θ50 using this test would be discarded.
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6 RESULTS
6.1 Two-colored FRET in regulated actin filaments
Samples containing only a FRET donor (D), and both a FRET donor and acceptor
(DA) are necessary to determine energy transfer from a directly excited donor to an
acceptor fluorophore. FRET efficiency E is calculated from paired D/DA samples using
𝐸 = 1 − (𝐼-8 𝐼- ), where IDA is the emission intensity of the donor in the presence of an
acceptor, and ID is the emission intensity of the donor in the absence of an acceptor. Due
to the sixth power dependence of distance on resonant energy transfer 𝑅 =
𝑅" 1 − 𝐸 𝐸

Q #

, where R is the inter-dye distance, R0 is the Förster radius of the FRET

pair, and E is FRET efficiency,105 an increase in E corresponds to a decrease in the interdye distance. FRET efficiency was used to report Tn activation in reconstituted thin
filaments, corresponding to the movement of the SABS of TnI from actin towards the Nlobe of TnC. From the multi-site FRET assay described in Sections 1-3, a FRET pair that
fulfilled the requirements to report the activation-dependent structural change in Tn was
chosen to pursue drug screen design. The FRET pair needed to exhibit a large Ca2+induced change in E to provide maximum resolution for discovering alterations to Tn
activation from phosphorylation or small molecule binding. Figure 26A shows the
engineered Tn, which contains a single Cys in the C-terminal end of the second actinbinding domain of TnI (residue 189) labeled with FRET donor AF546. A single Cys in a
loop in the C-lobe of rat cardiac TnC (residue 127) was labeled with the FRET acceptor
ATTO655. The loop has no role in coordinating Ca2+or Mg2+. TCSPC measurements of
rAc filaments showed a Ca2+-induced change of 21% (Table A10). The assay is sensitive
to structural movements of the mobile domain of TnI with respect to the C-lobe of TnC.
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Figure 26. A steady-state FRET assay for measuring Tn activation. (A) Molecular
model of the Ca2+-saturated 52 kDa core of Tn showing placement of FRET dyes.84 TnC,
TnI, and TnT are colored cyan, blue, and grey, respectively. The FRET donor, AF546,
and FRET acceptor, ATTO655, are attached to Cys 189 of TnI (green sphere) and Cys
127 of TnC (red sphere), respectively. Ser-23/24 of TnI are represented as VDW spheres.
(B) Fluorescence emission spectra from rAc reconstituted with the FRET donor
TnI189C*AF546 (rAc-D) or both the donor and FRET acceptor TnC127C*ATTO655
(rAc-DA). rAc-D (blue dashed), rAc-D supplemented with 3 mM CaCl2 (+Ca, red
dashed), rAc-DA (blue), and rAc-DA +Ca (red). Denatured samples of rAc-D (black
dashed) and rAc-DA (black) are shown. Inset, Sensitized emission.
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Figure 26B shows the steady-state emission spectra from rAc-D and rAc-DA
under Ca2+-depleted (no added Ca2+), Ca2+-saturated (with 3 mM CaCl2), and denatured
(with 3 mM CaCl2 and 3 M GnHCl) conditions. Denaturation with GnHCl allowed for a
correction in the differences in donor concentration between rAc-D and rAc-DA samples,
as donor intensity with 3 M GnHCl provided the relative concentration of the FRET
donor dye in the sample.
The emission intensity of rAc-D was relatively insensitive to 3 mM CaCl2, while
the emission intensity of rAc-DA showed a 34% decrease in the emission of the FRET
donor (575 nm peak), and a corresponding 21% increase in the emission from the FRET
acceptor (675 nm peak). Denaturation with 3 M GnHCl served to eliminate the emission
peak from the FRET acceptor in rAc-DA samples (Figure 26B, inset). This strongly
suggests the emission peak at 675 nm is fluorescence emission from the acceptor due to
photons transferred from the donor to acceptor dyes through sensitized emission (FRET).

6.2 Characterizing the binding of myosin subfragment-1
Purified myosin is shown under denaturating gel conditions, where the myosin
heavy chain (MHC) runs ≥ 250 kDa, and the essential light chains (ELC1/2) and the
regulatory light chain (RLC) are resolved (Figure 27). Other proteins are visible in the
lane with purified myosin (P2), and are most likely contaminant actin and tropomyosin.
Myosin was enzymatically digested into the catalytically active myosin head,
subfragment-1 (S1). Figure 28A shows how SDS-PAGE was used to monitor the
progress of digestion, resolve proteins, confirm molecular weights, and determine sample
purity. In the presence of EDTA, chymotryptic digestion eliminates the RLC, though
ELC1/2 are still resolved.185
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Muscle contraction is maintained through a steady cyclic interaction between
myosin motor proteins and actin filaments. Myosin binds to actin by successively
forming contacts through nucleotide- and actin-dependent reorientations of different
subdomains in myosin. An accurate assessment of the catalytic ability of purified S1
required the removal of all non-specific S1 binding due to catalytically inactive S1
(called deadheads), which bind irreversibly to actin in the presence of ATP. Figure 28B
shows the difference between rigor and deadhead binding to actin in the presence and
absence of ATP, respectively. Under rigor conditions, a 2:1 mixture of actin and S1
showed a high degree of S1 binding, evident from the pellet of the sedimented sample.
An interesting note is the presence of two bands near the ELC1 isoform, where only the
lower molecular weight band appears to bind to actin. The higher molecular weight band
cannot be attributed to TnI or TnC, which run higher and lower, respectively. In the
presence of 5 mM ATP, a small portion of S1 was bound to actin (deadheads), and a
majority of S1 remained in solution (catalytically active S1).

Figure 27
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Figure 27. Purification of myosin from chicken pectoralis muscle. Molecular weight
markers (M); the pellet containing myosin, contaminant actin (~48 kDa), and Tm (~37
kDa) from the water precipitation (P1); the supernatant (S) and pellet (P2) containing
purified myosin heavy chain (MHC), essential light chains 1 (ELC1) and 2 (ELC2), and
regulatory light chain (RLC) from the 0-30% (NH2)4SO4 cut are shown.

Figure 28. Chymotryptic digest of myosin into subfragment-1. (A) Myosin was
digested with chymotrypsin (1:100, chymotrypsin:myosin) in the presence of EDTA for
10 minutes. Molecular weight markers (M), and the supernatant (S) containing S1 and
pellet (P) containing undigested myosin are shown. (B) Removal of catalytically inactive
S1. Co-sedimentation of S1 (20 µM) and actin (10 µM) in WB (rigor) and WB
supplemented with 5 mM MgATP. Molecular weight markers (M), the pre-spin mixture
(W), the supernatant (S), and pellet (P) for both rigor and +ATP conditions are shown. S1
in complex with either essential light chain 1 or 2 (ELC1, ELC2), and actin bands are
resolved. Under rigor conditions, S1 binds actin >90%. In the presence of 5 mM MgATP,
only catalytically inactive S1 bind to actin, and the supernatant contains catalytically
active S1.
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6.3 PKA-mediated phosphorylation of TnI Ser-23/24
PKA treatment of Tn selectively bis-phosphorylates TnI Ser-23/24.170 TnI Ser23/24 within reconstituted rAc was selectively phosphorylated with the catalytic subunit
of PKA and ATP (co-factor), and these were removed by sedimentation, washing, and resuspension of filaments. Schulenberg et al. showed the utility of characterizing protein
phosphorylation using a fluorescent dual-staining approach.186 SDS-PAGE with
subsequent staining using Pro-Q Diamond (selectively stains phosphorylated proteins)
and SYPRO Ruby (stains all proteins) was used to quantify the degree of phosphorylation
in rAc. Phosphorylated ovalbumin (from the phosphoprotein standard) has two
phosphorylation sites,187 and was used as a control (Figure 29A). Figure 29B shows Ser23/24 phosphorylated to ≈100% efficiency after a 1.5 hour incubation with PKA.

Figure 29. Quantification of PKA-dependent TnI phosphorylation. (A) Time course
of PKA-treated WT rAc analyzed by 1D SDS-PAGE (12%, 29:1). Successive staining
with Pro-Q Diamond (left) and SYPRO Ruby (right) provided, respectively, the level of
TnI phosphorylation and total TnI. (B) Time-dependent efficiency of TnI
phosphorylation by PKA. The number of phosphorylated residues in TnI was estimated
from the intensity of TnI compared to ovalbumin (phosphorylation and molecular weight
standard) in (A).
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6.4 Physical characterization of regulated actin
To determine if the triple mutants required for the assay on TnI (C81I, C98S,
V189C) and TnC (C35S, C84S, T127C) affected the functional properties of Tn,
isometric force-pCa experiments were performed. WT (control) and mutant Tn were
reconstituted with mouse cTnT with an N-terminal myc sequence attached. The
efficiency of exchange of WT Tn (80.6±1.0%) and mutant Tn (69.2±3.5%) were
estimated from Western blots of the exchanged cells (Figure 30A-B). Figure 30C shows
measurements of force at different Ca2+ concentrations. During measurements, the
sarcomere length (SL) was maintained at either 1.9 µm or 2.3 µm. At 1.9 µm and 2.3 µm
SL, peak force (Figure 30D) and Ca2+ sensitivity (pCa50) (Figure 30E) were not
statistically different between fibers exchanged with WT and mutant Tn (P > 0.05). The
mutagenesis required as part of the FRET assay design did not significantly alter the
native function of Tn.
Regulated actin filaments (rAc) were reconstituted from Tn, tropomyosin (Tm),
and F-actin. rAc was reconstituted with Tn containing the FRET donor (rAc-D), and with
Tn containing the FRET donor and acceptor (rAc-DA). SDS-PAGE was used to assess
the purity of thin filament proteins, and show rigor-S1 binding did not perturb Tn or Tm
bound to actin (Figure 31). rAc was reconstituted with 5x more Tm than actin protomer
to promote filament stability, but the amount of Tm bound to actin remained unchanged
with excess Tm in solution, compared to rAc reconstituted with one Tm:actin protomer.
The chemical structure of the small molecule compounds bepridil, levosimendan,
and EGCG used in this study are shown (Figure 32). To assess the effect on filament
morphology from PKA treatment, S1 binding, DMSO, and small molecules, rAc-DA
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filaments were imaged using epifluorescence (Figure 33). Filament bundling is not
appreciated, and donor and acceptor dyes co-localize, suggesting Tn remains stably
bound to rAc as an intact assembly.

Figure 30
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Figure 30. Functional characterization of mutated Tn. WT Tn consisting of myc-TnT,
TnI, TnC and mutant (M) Tn consisting of myc-TnT, TnI189C, TnC127C were
exchanged into skinned cardiomyocytes from rat ventricles. (A) Western blot analysis of
reserved fibers. Exchanged myc-TnT (WT or M) was compared to native TnT to
determine the Tn exchange efficiency. (WT: n=3; mutant: n= 3) Also shown are lanes
containing native TnT (C). (B) Exchange efficiency from samples in (A). Shown are the
mean ± SEM (WT: n=3; mutant: n=3). Differences were not significant (P > 0.05, twoway ANOVA). (C) Pooled data (mean ± SEM, WT: n = 9; mutant: n = 9) from force-pCa
measurements of fibers at short (red, 1.9 µm) and long (blue, 2.3 µm) sarcomere lengths
(SL). Lines for mutant (dotted line) and WT (solid) exchanges are drawn using the mean
of Ca2+-sensitivity pCa50 and maximum force Fmax recovered from individual fits of
fibers. (D) Average maximum force ± SEM from (C) for SL at 1.9 µm (white) and SL 2.3
µm (grey). (E) Average pCa50 ± SEM from (C). A consistent coloring scheme is used in
(D-E).
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Figure 31. Assessment of sample purity of thin filaments and myosin subfragment-1.
SDS-PAGE (12%, 29:1) of reconstituted mutant Tn (TnI189C, TnC127C, TnT), Tm with
α and β isoforms, actin, and S1. Molecular weight markers (M) are shown. rAc (10 µM
in actin) reconstituted with mutant Tn, Tm, and actin at a molar ratio of 1:5:7 Tn:Tm:Act
was cosedimented with S1 (10 µM). The pre-spin mixture (W) and pellet (P) are shown.

Figure 32. Chemical structures of small molecules. Shown are bepridil, levosimendan,
and EGCG.
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Figure 33
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Figure 33. Filament morphology of rAc-DA with small molecules, myosin S1, and
PKA treatment. Epifluorescence images of PKA-treated rAc-DA and rAc-DA
supplemented with DMSO (0.5%, v/v), 200 µM bepridil, 200 µM levosimendan, 200 µM
EGCG, and 1.5 µM S1. Filaments were diluted to 10 nM in WB and imaged on glass
coverslips. Shown is the emission from directly-excited TnI189C*AF546, directlyexcited TnC127C*ATTO655, and the merged images. The scale bar is 5 µm.

6.5 Determining the concentration of free Ca2+
The concentration of free Ca2+ in solution was determined using the Ca2+ sensitive
dye Fluo-4FF. Figure 34A shows the emission from 500 nM Fluo-4FF in WB with serial
injections of the Ca2+ buffer utilized in subsequent Ca2+ titrations of rAc: WB
supplemented with 50 mM CaCl2. Ca2+ binds to Fluo-4FF in a 1:1 complex, and upon
binding, the dye molecule undergoes a conformational change that allows fluorescence
emission upon excitation with blue light with no spectral shift. Eq. 17 was then used to
convert emission intensity to [Ca2+]free (Figure 34B). WB alone did not have any
contaminant Ca2+, evident from the first point prior to injecting Ca2+ (injection #0). Using
a fluorescent Ca2+ indicator provided a direct measurement of Ca2+ in solution with fewer
variables, as opposed to Ca2+ calculators that give an indirect measurement of free Ca2+.
Ca2+ calculators that solve simultaneous equilibrium reactions require user-defined values
prone to inaccuracies, including the absolute concentration of buffer components that
compete for Ca2+ binding (e.g. EGTA) and instrument aliquot volume.188
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Figure 34. Calibration of the concentration of free Ca2+. The Ca2+-sensitive dye Fluo4FF was diluted to 250 nM in WB, and serially injected with 2 µL of WB supplemented
with 50 mM CaCl2. Left, emission from Fluo-4FF (excitation, 490 nm; emission, 520
nm). The * indicates the emission from the donor after adding 100 mM CaCl2. Right, data
were corrected for dilution, and the free Ca2+ was calculated from the fluorescence
intensities using Eq 2.5, with fmax equal to emission after addition of 100 mM CaCl2 (*).

6.6 Screening for Ca2+-induced activation
The effect of small molecules on Ca2+-induced activation of Tn was assessed with
Ca2+ titrations of rAc (250 nM in Tn) in the presence of the compound solvent (DMSO,
0.5%, v/v), bepridil (200 µM), levosimendan (200 µM), EGCG (200 µM), S1 (750 nM),
and in rAc with bisphosphorylated TnI Ser-23/24 (PKA-treated). The emission from the
donor in paired D/DA filaments was monitored with 2 µL serial injections of working
buffer (WB: 50 mM MOPS pH 7.0, 5 mM MgCl2, 2 mM EGTA, 5 mM BME)
supplemented with 50 mM CaCl2 (Figure 35A). Paired samples were donor
concentration-matched using 3 M guanidine hydrochloride (GnHCl) using Eq. 14. Tn
dissociation eliminated donor quenching through resonant energy transfer. The emission
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intensity of the donor from dissociated rAc-DA was corrected to match the donor
intensity from dissociated rAc-D. Intensity data from rAc-D/DA samples were also
corrected for dilution, then plotted again free Ca2+ (Figure 35A). FRET efficiency E was
then calculated from the corrected intensity data using 𝐸 = 𝑓8 SQ 1 − 𝐼-8 𝐼- , where fA
is the acceptor labeling efficiency, IDA is the intensity of the donor from rAc-DA, and ID
is the intensity of the donor from rAc-D.

6.6.1 Bepridil and S1 both increased Tn activation and Ca2+ sensitivity
Figure 35C and 35D show E and normalized E, respectively, vs. free Ca2+, with
fits to the Hill equation. Normalized E clearly shows an increase in Ca2+ sensitivity with
S1 and bepridil compared to untreated rAc with bepridil and S1, evident from the
leftward shift of the titration curves. Bepridil increased FRET efficiency both under Ca2+
depleted conditions (E-, apo) and Ca2+-saturating conditions (E+, ≈3 mM CaCl2), though
not as dramatically as S1 binding (Figure 35E). The recovered Ca2+ dissociation constant
Ca50 and Hill coefficient nH in Figure 35F show the similar effects induced by S1 binding
and bepridil: both reduced cooperativity and significantly increased Ca2+ sensitivity
compared to untreated filaments. Table A12 summarizes the recovered parameters from
fits to the Hill equation. The Ca2+ sensitivity of Tn was unchanged with levosimendan.
Ca50 and nH with levosimendan were not significantly different from non-treated rAc.
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Figure 35. Effect of small molecules, PKA treatment, and S1 binding on the Ca2+dependent activation of regulated actin. (A) Representative traces for Ca2+ titrations of
rAc-D (dashed) and rAc-DA (solid) at 250 nM. Fluorescence emission of the FRET
donor vs. injection #. (B) Fluorescence emission from (A) corrected for dilution, and rAcDA corrected for dilution and concentration vs. the concentration of free Ca2+. (C) rAc
(250 nM in Tn) (blue), PKA-treated rAc (magenta) and rAc supplemented with the drug
carrier (red, 0.5% DMSO, v/v), 200 µM bepridil (green), 200 µM levosimendan (purple),
200 µM EGCG (orange), and 0.75 uM S1 (cyan) were titrated with Ca2+. A consistent
coloring scheme is used in (C-G). FRET efficiency was calculated from titrations of pair
D/DA rAc filaments. Solid lines represent fits of the data to the Hill equation to recover
the Hill coefficient (nH) and Ca2+ dissociation constant (Ca50) (Table A12), FRET
efficiency under depleted Ca2+ (E-) and the FRET efficiency under saturating Ca2+ (E+).
(D) Normalized data from (C). (E) Recovered E- (open bars) and E+ (filled bars) from fits
in (C). Mean ± asymptotic SE (error bars) are shown. (F) Recovered nH and Ca50 from
fits in (C). Mean ± asymptotic SE (error bars) are shown. (G) Plot of recovered E- vs.
pCa50 = − 𝑙𝑜𝑔 𝐶𝑎•" for small molecule modulators of troponin activation. Solid line is
a fit of data to a first order polynomial (R2 = 0.97).
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6.6.2 EGCG and TnI phosphorylation reduced Ca2+ sensitivity
EGCG dramatically desensitized Tn to Ca2+, evident from the rightward shift in
the titration curve in Figure 35B, increasing the Ca50 from 1.12 µM for untreated rAc to
4.06 µM. PKA treatment induced a smaller, but still significant (P<0.05) desensitization
for Ca2+. Cooperativity significantly decreased with EGCG, but was unchanged with
PKA treatment. EGCG caused a ≈1.5-fold decrease in E-, but E+ recovered slightly
higher compared to untreated rAc. PKA treatment caused a small ≈1.1-fold decrease in E-

6.6.3 Ca2+ sensitivity is correlated to the Ca2+-depleted FRET efficiency
Figure 35G shows the FRET efficiency under Ca2+-depleted conditions E- plotted
against pCa50 = − 𝑙𝑜𝑔 𝐶𝑎•" , fit to a first order polynomial (R2 = 0.97). Filaments treated
with small molecules that increased Ca2+ sensitivity had higher E-, and treated filaments
with decreases in Ca2+ sensitivity had lower E-. E-, a property of Tn in the absence of
Ca2+, is correlated to a property of Tn under activating Ca2+.

6.7 Screening for myosin-induced activation
To assess myosin-induced activation of Tn, rigor-S1 titrations were performed on
PKA-treated rAc, and rAc supplemented with EGCG (200 µM) and bepridil (200 µM).
The emission from the donor in paired samples (250 nM in Tn) was monitored with 2 µL
serial injections of 5 µM S1 in WB (Figure 36A) under Ca2+-saturating (+Ca, 3 mM
CaCl2) and Ca2+-depleted conditions (apo). Donor intensity in paired rAc-D/DA samples
was concentration-matched and corrected for volume as previously described (Figure
36B), and used to calculate the FRET efficiency.
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6.7.1 S1-induced activation of Tn occurs independently of Ca2+
Figure 36C and 36D show the FRET efficiency and normalized FRET efficiency,
respectively, plotted against the ratio of the total amount of S1 added to actin in the
sample (θ50 = [S1]T/[Actin]T) for samples under apo and +Ca conditions. Figure 36E
shows the recovered FRET efficiencies with total S1 added (E+S1, +1.43 µM S1) and
without S1 (E-S1). E+S1 for apo rAc and E-S1 for Ca2+-saturated rAc were 45.9 and 43.6%,
respectively, indicating activation with S1 behaved like Ca2+-induced activation.
Figure 36F shows the recovered Hill coefficients nH and θ50 for apo and Ca2+
conditions, where θ50 is the stoichiometry that produces half maximal activation. Adding
Ca2+ increased myosin sensitivity in rAc and with EGCG, but myosin sensitivity
remained unchanged when rAc was treated with PKA. Table A13 summarizes the
recovered parameters.

6.7.2 Bepridil eliminates S1-induced activation of Tn
The FRET efficiency remained unchanged for rAc supplemented with bepridil
from E-S1 to E+S1, indicating no myosin-induced Tn activation. Ca2+-induced activation of
Tn was preserved, as seen in the Ca2+ titrations with bepridil.

6.7.3 EGCG and PKA treatment reduce myosin sensitivity
EGCG decreased E- as seen in the Ca2+ titrations; saturating S1, however,
recovered E+S1 greater than the for rAc. The E+S1 for both apo and +Ca with EGCG was
similar, indicating S1 activates Tn the same, regardless of the presence of Ca2+. So
although myosin sensitivity increased with Ca2+, the level of S1-induced activation was
unchanged with Ca2+. Myosin sensitivity significantly decreased under Ca2+ depleted
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conditions for both EGCG and PKA treatment, where θ50 was 0.55±0.05 and 0.59± 0.01,
respectively. When Ca2+ was added to rAc with EGCG, the myosin sensitivity recovered
to rAc under apo Ca2+ conditions, whereas Ca2+ did not change the myosin sensitivity of
PKA-treated rAc. PKA treatment induced a massive cooperativity compared to untreated
filaments, with Ca2+ increasing cooperativity from 28.1 to 50.7.
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Figure 36. The effect of small molecules and Ca2+ on the activation of thin filaments
by myosin. (A) Representative traces for S1-titrations of rAc-D (dashed) and rAc-DA
(solid) at 250 nM in Tn under Ca2+-saturated (+3 mM CaCl2, red) and Ca2+-depleted
(cyan) conditions. Fluorescence emission of the FRET donor from rAc serially injected
with 2 µL of 5 µM S1 in WB. (B) Fluorescence emission from (A) from rAc-D corrected
for dilution, and rAc-DA corrected for dilution and concentration relative to the total
concentration of [S1]/[Actin]. (C) rAc (blue) and rAc supplemented with 200 µM EGCG
(orange) or 200 µM bepridil (green) were titrated with S1. The calculated FRET
efficiency (mean ± SEM, n = 3) vs. the relative total concentration of [S1]/[Actin] is
shown. Measurements were performed with no Ca2+ (dashed lines) and with 3 mM CaCl2
(solid lines). Smooth lines represent fits of the data to the Hill equation. The fits to PKAtreated rAc are shown (magenta). (D) Normalized FRET efficiencies from (C) for PKAtreated rAc, rAc, and rAc supplemented with 200 µM EGCG. (E) Stacked bar plot
showing FRET efficiencies from the fits ± asymptotic SE at saturating S1 (total S1 added
1.43 µM, filled), and with no S1 (open) for samples in (C). (F) Scatter plot summarizing
the Hill coefficients (nH) and relative total concentrations of [S1]/[Actin] that produces
half-maximal activation ([S1]/[Actin])50 ± asymptotic SE from the fits in (C) for PKAtreated rAc, rAc, and rAc supplemented with 200 µM EGCG with no Ca2+ (apo, open)
and with Ca2+ added (3 mM CaCl2, filled). A consistent coloring scheme is used in (C-F).
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6.8 Control measurements for PKA treatment
To determine if PKA treatment and the removal of PKA and its co-factor ATP
from treated filaments influenced Tn behavior to Ca2+ and myosin binding, Ca2+and S1
titrations were performed on paired untreated rAc filaments, PKA-treated filaments (PKA
and 5 mM ATP), and filaments mock-treated with PKA and 5 mM ATP. Figure 37 shows
mock-treatment did not have a significant effect (P>0.05) on Ca50 compared to untreated
filaments, where PKA treatment produced a significant increase in Ca50. As expected,
PKA treatment and mock treatment did not produce a significant effect on nH. Table A14
summarizes the recovered parameters from Ca2+ titrations. Figure 38 shows only PKA
treatment produced a significant effect on nH and θ50 under both apo and +Ca conditions.
Recovered parameters are listed in Table A15. PKA-mediated TnI Ser-23/24
phosphorylation is responsible for modulating Tn activation.
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Figure 37. Control measurements of PKA treatment of rAc titrated with Ca2+. (A)
Calculated FRET efficiency vs. free Ca2+ for rAc, rAc treated with PKA and ATP
(magenta), mock-treated with ATP (green), and mock-treated with PKA (tan) (250 nM in
Tn in WB). Lines represent fits to the Hill equation. (B) Normalized FRET efficiency.
(C) The recovered Hill coefficients (nH) asymptotic SE from fits in (A). (D) The
recovered concentration of calcium to achieve half maximal activation (Ca50) from fits in
(A) ± SE. *P<0.05 relative to non-treated rAc (n.s. = not significant).
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Figure 38. Control measurements of treatment of reporter filaments with PKA titrated
with S1. (A) Calculated FRET efficiency vs. the relative total concentration of
[S1]/[Actin] for rAc, rAc treated with PKA and ATP (magenta), mock-treated with ATP
(green), and mock-treated with PKA (tan) in WB (apo, dashed lines) and WB
supplemented with 3 mM CaCl2 (+Ca, solid lines). Lines represent fits to the Hill
equation. (B) Normalized FRET efficiency. (C) The recovered Hill coefficients (nH)
asymptotic SE from fits in (A) for apo (open) and +Ca (filled). (D) The recovered
concentration of calcium to achieve half maximal activation (Ca50) from fits in (A) ± SE.
*P < 0.05 relative to non-treated rAc for apo and +Ca (n.s. = not significant).

6.9 S1 binds to rAc with small molecules and PKA treatment
To determine if S1 was binding to rAc filaments under all conditions, SDS-PAGE
was used to assess S1 binding to rAc, and rAc treated with PKA, bepridil, or EGCG. S1
(10 µM) was cosedimented with rAc reconstituted with WT Tn (10 µM in actin) under
apo conditions and with 3 mM CaCl2. Figure 39A shows the SDS-PAGE of the pre-spin,
the supernatant, and the pellet. Densitometry analysis of the S1 and actin band intensities
in the pellet gave percent S1 saturation, seen in Figure 39B. The percent saturation
(>80%) shows S1 binds under all conditions.

6.10 A high throughput single point drug screen
Figure 40 shows the high throughput (HTS) strategy for screening compound
libraries for potential inotropic agents, and finding the EC50 for qualifying compounds.
EC50 is the concentration of compound that produces a half-maximal response.
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Figure 39. SDS-PAGE shows myosin binding with small molecules and PKA
treatment. (A) SDS-PAGE (12%, 29:1) showing the reserved fraction (W), supernatant
(S), and pellet (P) from the cosedimentation of regulated actin (rAc) reconstituted with
WT Tn (10 µM in actin protomer) and S1 (10 µM) in WB. The fraction of S1 bound was
determined using densitometry analysis comparing the band intensities S1 and actin. rAc,
PKA-treated rAc, and rAc supplemented with 200 µM EGCG or bepridil without added
Ca2+ and with 3 mM CaCl2 are shown. Molecular weight markers (M), tropomyosin
(Tm), TnI, TnC, and the two isoforms of the essential light chains (ELC1 and 2) are
resolved. (B) The fraction of S1 bound is shown for rAc (blue), PKA-treated rAc
(magenta), and rAc supplemented with 200 uM EGCG (orange) and bepridil (green)
without added Ca2+ (apo, open) and with 3 mM CaCl2 (filled).
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Figure 40. High throughput screening (HTS) strategy. (A) The FRET efficiency
without added Ca2+ E- was normalized to untreated rAc. The grey rectangle indicates a ±
0.1 threshold for E-, where compounds above the threshold are Ca2+ sensitizing;
compounds below the threshold are Ca2+-desensitizing. (B) EGCG concentrationresponse curve illustrating HTS lead generation. (E-) was measured for different
concentrations of EGCG. Solid line is a fit to the Hill equation with EC50 = 446 nM.
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7 DISCUSSION
Sarcomeric modulators are a promising therapeutic strategy in the treatment of
heart failure that do not require changes in Ca2+ transients. Ca2+ inotropes increase or
decrease the Ca2+ binding affinity of TnC without changing intracellular Ca2+
concentrations, shifting the population of active or inactive Tn that corresponds to a shift
in contracted or relaxed sarcomeres. Insights into the mechanism of action of these
molecules can facilitate informed drug design and development, which could eliminate
many of the negative effects associated with compounds currently used.189-190
A compound does not need to bind directly to TnC to alter Ca2+ sensitivity;
therefore, a drug screen developed in reconstituted thin filaments can potentially resolve
effects from compounds discarded in screens with isolated TnC or Tn alone. Non-specific
interactions would also be reduced. This FRET assay was designed within reconstituted
thin filaments as an in vitro biochemical model28 for muscle activation to directly monitor
the activating structural change in Tn, where the SABS moves off actin and closer to
TnC. A higher FRET efficiency is associated with a higher population of Tn in the active
conformation. FRET provides the relative distances between the donor and acceptor dyes,
positioned, respectively, on TnI189 in the SABS, and TnC127, in the C-lobe of TnC. The
design of this assay was specific for drug screening, where a green-excitable FRET donor
was used to reduce the possibility of photoinactivation of small molecules (drugs) by
blue-shifted excitation wavelengths, e.g. blebbistatin deactivation by exposure to light
below 488 nm.110 While other fluorescence assays in thin filaments have been developed
to monitor Ca2+ sensitivity using changes in TnC conformation,191 this assay was highly
sensitive to the activating structural change between TnC and TnI in reconstituted thin
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filaments. The fraction of active Tn was estimated by monitoring FRET efficiency. The
contributions of Ca2+ and rigor S1 to activate the thin filament were determined, where in
native cardiomyocytes, these contributions would be difficult to resolve. This 2D
screening method was applied to three previously studied compounds thought to alter the
Ca2+ sensitivity of TnC: bepridil, levosimendan, and EGCG. The assay was validated as a
drug screen to identify compounds that bind the thin filament and alter myosin sensitivity
to actin and/or TnC to Ca2+, while also obtaining data suggesting the molecular
mechanisms behind Ca2+- and myosin-dependent activation, and PKA-mediated Ca2+
desensitivity of the thin filament.

7.1 Cooperative activation by Ca2+ is dependent on the presence of
rigor-S1
Ca2+ binding to TnC is a critical step for initiating activation, but cardiac muscle
activates in a highly cooperative process involving both Ca2+ and myosin binding.
Crossbridge formation (S1 binding to actin) not only causes additional myosin binding,
but also increases the Ca2+ sensitivity of TnC. Previous experiments have shown rigor-S1
exerts a Ca2+-sensitization on thin filament activation,49, 136, 192 and full activation can be
achieved by the S1 head alone.193 Rigor-S1 not only sensitized regulated actin to Ca2+,
but also cooperatively activated Tn in a Ca2+-independent manner, consistent with studies
in isolated cardiomyocytes.22 The implications of Tn activating independently of Ca2+
hint at the possibility that Ca2+-dependent Tm movement may not be required for for
myosin crossbridge formation. In the absence of Ca2+, rigor-S1 binding could produce a
conformational change in actin, forcing Tn into the active conformation. However, Ca2+
and S1 together maximally increased the population of active Tn, suggesting Ca2+ alone
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does not maximally activate Tn. These results coincide with those seen by Zhou et al.,
who used anisotropy to show S1 changes the dynamics in the C-terminal region of TnI
independently of Ca2+, but both Ca2+ and S1 are required for maximal activation.82
S1 cooperatively activated thin filaments in a Ca2+-independent manner; Ca2+
cooperatively activated thin filaments only in the absence of S1. Ca2+-induced activation
of rigor-S1-bound thin filaments was negatively cooperative (nH = 0.8 ± 0.1), but S1induced activation of thin filaments in both Ca2+-depleted conditions (nH = 2.9 ± 0.1) and
Ca2+-saturating conditions (nH = 2.8 ± 0.1) was cooperative. The high cooperativity in
S1-dependent activation suggests multiple S1 heads must cooperatively bind to the thin
filament to displace a single SABS. Conversely, the cooperativity of Ca2+ binding was <1
in filaments with a high probability of multiple rigor-S1 heads already bound to actin
(rigor-S1:actin protomer = 1:2.3). This suggests the binding of one Ca2+ molecule
displaced one SABS from actin. Simply stated, when strong crossbridges are bound to
actin, Ca2+ activates the thin filament non-cooperatively; rigor-S1 activates thin filaments
cooperatively, whether or not Ca2+ is bound.
These results suggest actin conformational changes may be responsible for
cooperative activation. When rigor-S1 binds to an actin protomer, conformational
changes in actin may be translated from the SABS to the regulatory head of Tn, through
TnT(T1) to Tm. These translated conformational changes may influence further changes
in actin, allowing for S1 heads to cooperatively bind. Adding Ca2+ to these already semiactivated filaments still produces a conformational change in Tn regulatory head, where
the SABS moves closer to TnC, having already been displaced off actin by S1 binding.
This Ca2+-induced conformational change is not cooperatively translated along the thin
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filament. In the absence of rigor-S1 binding, Ca2+-dependent conformational changes in
the SABS are translated across the thin filament, allowing for cooperative activation (nH
= 1.2± 0.1) by Ca2+.

7.2 Cys84Ser substitution in TnC prevents levosimendan binding
Levosimendan is a Ca2+ sensitizer used in the management of acutely
decompensated heart failure.194-195 Levosimendan binds weakly to the N-lobe of TnC,196197

and exhibits Ca2+-sensitizing effects in skinned muscle fibers,177, 196 and in isolated

TnC and reconstituted Tn.177 There were no effects on the level of Tn activation with
levosimendan, and no changes in Ca2+ sensitivity using this assay. This is most likely due
to the assay design. Native Cys residues in TnC and TnI were removed to covalently
attach fluorescent maleimide probes to engineered Cys on residues 189 and 127 for TnI
and TnC, respectively. In TnC, one of the mutations was Cys84Ser. Levijoki et al.
showed levosimendan increased Ca2+ sensitivity in isolated WT hcTnC; when the point
mutation Cys84Ser was introduced in TnC, there was no change in Ca2+ sensitivity with
levosimendan, indicating Cys84 is necessary for levosimendan binding to the C-lobe of
TnC.177 Schlecht et al. also showed levosimendan did not produce a significant change in
Ca2+ sensitivity using a FRET assay monitoring TnC conformational changes in
reconstituted thin filaments, where their TnC also had the Cys84Ser mutation.191 This
shows a potential limitation in this assay design, where engineered Tn could alter the
binding of small molecules to TnC or TnI compared to native proteins.
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7.3 Bepridil and rigor-S1 promote a stabilized open conformation
of the N-lobe to increase Ca2+ sensitivity
Bepridil is a Ca2+ sensitizer shown to increase maximally activated force and
ATPase activity in isolated myofibrils, and increase the sensitivity of the thin filament for
Ca2+.178 X-ray crystallography studies using isolated TnC,198 and NMR studies of a
TnI/TnC complex199 showed bepridil binds to the N-domain of TnC, stabilizing the open
(active) conformation of TnC.200 This is consistent with the observation that bepridil
increases the population of active Tn, evident by increases in E at both apo and +Ca,
compared to untreated filaments (Figure 35E). This increase in E is similar to the effects
of S1 binding. In the Ca2+ screen, S1 and bepridil equivalently increased Ca2+ sensitivity
(Figure 35F).
The myosin screen was surprising in that there was no evident S1-induced
activation of Tn in filaments treated with bepridil. From Sections 1-3, this author
hypothesized actin-Tm causes a ≈7.4-fold decrease in Ca2+ sensitivity of Tn136 due to the
displacement of the switch region away from the N-lobe of TnC as a result of SABSactin binding. The switch region cannot, therefore, stabilize the open conformation of NTnC, as predicted by the Herzberg model of Tn activation.64 Bepridil is thought to
increase Ca2+ sensitivity by stabilizing the open conformation of the N-lobe by binding to
its hydrophobic pocket. If stabilizing the N-lobe were the main mechanism of action of
bepridil, there should be no reason why myosin has no effect on the conformation of Tn
in the presence of bepridil, particularly because bepridil does not appear to maximally
activate Tn with Ca2+ alone (Figure 36C-D). This suggests myosin and bepridil both
activate Tn using the same mechanism—that is, myosin binding to actin is enough to
push the displaced switch region into the hydrophobic pocket of the N-lobe of TnC,

143
inducing the same effect as bepridil binding. This is evident by the S1-dependent increase
in E, suggesting the SABS may be “pushed” off actin by myosin, and the switch region is
“pushed” towards the N-lobe. The sedimentation experiments showed S1 was still
binding to rAc in the presence of bepridil, suggesting bepridil does not act as an inhibitor
of myosin. Bepridil-dependent increases in myosin ATPase activity and force generation
suggest bepridil is not preventing crossbridge cycling.178 Thus, it is reasonable to expect
when bepridil is bound to the N-lobe of TnC and stabilizing the open conformation,
myosin-induced displacement of the switch region has no further stabilizing effects on
the open conformation. Indeed, the switch region may not be binding at all when bepridil
is bound, as bepridil reduces the affinity of the switch region for the N-lobe ≈3.5-fold.200
This actually supports this author’s hypothesis that the switch region may not bind to the
N-lobe at all in the absence of myosin, as even in the presence of bepridil, there was no
change in the level of Tn activation with Ca2+. If the switch region were binding, the
activation should have decreased with Ca2+ in the presence of bepridil. Bepridil binding
to TnC and myosin binding to actin both act as Ca2+ sensitizers by promoting the open
conformation of the N-lobe: the former does so by directly binding to the hydrophobic
pocket; the latter does so indirectly, by promoting the switch region from binding to the
hydrophobic pocket through some mechanism that may involve myosin-dependent actinTm conformational changes.

7.4 The effect of TnI Ser-23/24 phosphorylation on Tn activation
Phosphorylation of TnI Ser-23/24 increases lusitropy, enabling rapid relaxation
during an increase in heart rate. To gain insights into the mechanistic action behind PKAmediated Ca2+ desensitization of TnC, Ser-23/24 of TnI was phosphorylated using PKA
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treatment. Ser-23/24 phosphorylation facilitates the release of the TnI N-terminal peptide
from the N-lobe of TnC, promoting Ca2+ release from Site II.57 Ward et al. showed the
deletion of residues 1-29 of the N-terminal extension of TnI mimicked the effects of
phosphorylation of Ser-23/24 to reduce Ca2+ sensitivity of myosin ATPase activity,
suggesting phosphorylation eliminates N-TnI and N-TnC interactions.56 PKA treatment
did not dramatically alter the level Tn activation under low and high Ca2+ (Figure 35E)
compared to non-treated filaments, but it did cause a ≈1.4-fold decrease in Ca2+
sensitivity. This suggests conformational changes between TnC/TnI do not affect the
overall architecture of Tn, meaning there are no PKA-dependent allosteric changes
evident in Tn. Since the level of Tn activation remains the same, a decrease in Ca2+
sensitivity may be due to allosterically-induced changes focused in the Ca2+ coordination
at Site II in the N-lobe of TnC.
An NMR study by Hwang et al. on a cTnI(1-73) fragment in complex with cTnC
showed the N-TnI/N-TnC interactions fix the position of the N-lobe in space, and Ser23/24 phosphorylation removes those restricting interactions, allowing N-TnC to move
more freely.58 They suggest when the N-lobe is rigid in space, interactions between the
switch region and N-lobe could be compromised, reducing the level of Tn activation,
meaning more Ca2+ would be required to activate Tn (reduced Ca2+ sensitivity). If what
Hwang et al. suggest is true, the level of active Tn should decreased with Ser-23/24
phosphorylation (i.e., increase the level of SABS bound to actin, drawing the switch
region away from the TnC N-lobe); instead, there was no dramatic change in Tn
activation. The presence of Tm-actin could influence N-lobe dynamics in a way not
evident in a fragmented TnI/TnC complex; additionally, since this dissertation predicts
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Ca2+-dependent switch region binding is eliminated in thin filaments, no change in the
level of Tn activation with PKA treatment is reasonalbe, as a stiffer N-lobe of TnC would
not affect the switch region or SABS of TnI.
It’s interesting to note Hwang et al. proposed the N-terminal extension of cTnI is
a highly dynamic IDR, much like the C-terminal region of TnI (see Sections 1-3); this is
in contrast to an NMR study by Howarth et al. using a cTnI(1-32) peptide, which showed
a more rigid α-helical N-terminal extension that maintains the same structure
independent of Ser-23/24 phosphorylation.201 The presence of potential binding sites
(actin, TnT, TnC, the remaining portion of TnI) could significantly affect the structure
and dynamics of the N-terminal extension, suggesting it may be too early to designate
this region as an IDR. Indeed, Howarth et al. docked their NMR structure of the Nterminal extension onto the Takeda crystal structure,27 showing that when
phosphorylated, residues in the N-terminal extension interact with the inhibitory region
(IR) of TnI, preventing the IR from displacement from actin, subsequently increasing
crossbridge inhibition.
The results from the myosin screen of PKA-treated rAc may support the Howarth
hypothesis. PKA treatment caused a dramatic ≈1.6- and ≈2.9-fold decrease in myosin
sensitivity (θ50 in Table A13) under apo and +Ca conditions, respectively, compared to
untreated filaments. PKA treatment also significantly enhanced cooperativity for myosin
binding. Previous studies using skinned cardiomyocytes showed TnI Ser-23/24
phosphorylation desensitizes force and ATPase to Ca2+;79, 202 this may be due to reduced
crossbridge-mediated activation when TnI is phosphorylated. If the N-terminal extension
is “blocking” the displacement of the IR when phosphorylated, it is reasonable to expect
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more rigor-S/actin binding is required to induce an activating conformational change,
hence why it takes so many myosin molecules to activate Tn in such an extremely
cooperative manner. This also is reasonable when considering the level of active Tn in
PKA-treated rAc was similar to non-treated rAc: Ser-23/24 phosphorylation does not
increase the amount of IRs bound to actin; instead, it works to strengthen the inhibitory
effect of IRs already bound to actin.

7.5 EGCG may destabilize Ca2+-dependent allosteric changes in Tn
A molecular compound specifically targeted to Tn to decrease myofilament
sensitivity to Ca2+ is a potential therapeutic strategy for treating RCM, and other CMs
that cause an increase in myofilament Ca2+ sensitivity. EGCG is a compound found in
green tea203 that reduces myofilament Ca2+ sensitivity in skinned cardiac myofibrils.176 In
mice expressing the RCM mutation TnI(R193H), treatment with EGCG restored
impaired diastolic function.175 NMR studies showed EGCG binds to the hydrophobic
cleft of the C-terminal domain of cTnC in the absence of TnI, and suggested EGCG may
compete with TnI(34-71) binding to C-TnC, potentially weakening the anchor holding
TnC onto the thin filament.204 This is interesting, considering the C-lobe is historically
thought to play only a structural role in Tn;31 there are, however, known CM-causing
mutations in this region,97 suggesting a potential functional target for EGCG. Fuchs et al.
showed EGCG decreases Mg2+ sensitivity for Sites III and IV, which may alter the
conformation of the C-lobe directly and the N-lobe allosterically as the mechanism for
decreased Ca2+ sensitivity.205 Is EGCG destabilizing C-TnC/N-TnI interactions, or is an
allosteric change translated to Site II that facilitates Ca2+ release or decreases the potential
for Ca2+ to bind?
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EGCG treatment caused a ≈3.6-fold decrease in Ca2+ sensitivity. EGCG also
stabilized the inactive Tn state, evident by the sharp decrease in E under Ca2+-depleted
conditions (Figure 35E). This could translate into a larger number of SABS bound to
actin; or into destabilized interactions between the C-TnC/N-TnI, forcing the C-lobe
farther from the SABS. Destabilized interactions would hinder Ca2+-dependent activating
allosteric transitions from being translated to the rest of the Tn complex, effectively
reducing Ca2+ sensitivity. The level of active Tn at saturating Ca2+ was not significantly
different from untreated filaments, suggesting Ca2+ binding can still restore the active
population of Tn to non-treated levels.
In the absence of Ca2+, S1 increased the level of active Tn with EGCG treatment
(E+S1=59.8 ± 0.4%) significantly more than for untreated filaments (E+S1=45.9 ± 0.4%)
(Table A13). The S1-induced change in E (∆ES1=E+S1-E-S1) for non-treated filaments is
22.8%, and for EGCG-treated filaments is a dramatic 47.9%. This suggests EGCG
binding causes conformational changes that promote the inactive conformation of Tn, but
does not alter (and may enhance) the ability of Tn to maximally activate with saturating
S1 only. Ca2+ is not needed to maximally activate Tn. This would be a potential benefit
for RCM treatment with EGCG: hypersensitivity to Ca2+ is reduced without affecting the
ability of the filament to maximally activate. Li et al. showed hypersensitivity to Ca2+
from RCM mutations (including TnIR193H) is not due to altered Ser-23/24 TnI
phosphorylation,174 suggesting changes in SABS due to the R193H mutation enhance
SABS displacement from actin to cause Ca2+ hypersensitivity. Therefore, treatment of
RCM with a molecule that promotes a stabilization of the inactive state of Tn (SABS-
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actin interactions), like EGCG, is a rational strategy; this was already proven viable in
mice in vivo by Zhang et al.175
The mechanism of EGCG-dependent Ca2+ sensitivity may simply be a numbers
game—there are fewer Tn active due to either a displaced C-lobe or enhanced SABS
binding— meaning more Ca2+ has to bind to more Tn to restore the population of active
Tn. Or, destabilized interactions between TnI/TnC prevent a translation of Ca2+dependent activating conformational changes. This explains reduced myofilament Ca2+
sensitivity with EGCG treatment.176 Therefore, EGCG may not actually prevent Ca2+
binding or facilitate Ca2+ release from Site II, therefore not altering the Ca2+ sensitivity of
Site II at all, as Fuchs et al. predicted. Because EGCG dramatically alters the level of Tn
activation and reduces cooperativity of Ca2+ binding, its mechanism of action to induce
Ca2+ desensitivity differs from PKA-mediated TnI Ser-23/24 phosphorylation, which
does not cause a dramatic change in the level of active Tn under Ca2+-depleted conditions
nor any significant changes in cooperativity.

7.6 Ca2+ sensitivity reflects the level of Tn activation under resting
conditions
There was a strong correlation between the Ca2+ sensitivity (pCa50 = -log[Ca2+])
and the FRET efficiency E under Ca2+-depleted conditions for compounds that target Tn
(bepridil and EGCG binding to TnC) and processes directly affecting Tn subunits (PKAmediated Ser-23/24 phosphorylation). S1 was not included, as any effects on the level of
Tn activation are secondary results of S1 binding to actin. A correlation between the
inactive state of Tn, and the state of Tn at non-saturating Ca2+ was observed. Thus, the
state of Tn in the absence of Ca2+ influences or predisposes the behavior of Tn activation.
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A lower E may be due to an increase in the fraction of Tn in the inactive state, and
perturbations that increase the probability that Tn is inactive under relaxing conditions
desensitize Tn to Ca2+. Ca2+ sensitivity may reflect the fraction of active Tn under resting
conditions.
This correlation could be useful for drug screening. Figure 40 shows the proof of
concept for using this assay as a two-point high throughput screen. The assay requires
both the donor emission for rAc-D and –DA filaments. First, the Ca2+-depleted E- would
be determined and normalized to non-treated rAc for thin filaments in the presence of the
compounds, as depicted in Figure 40A. Lead compounds exceeding the threshold (Ca2+
sensitizers) or falling below the threshold (Ca2+ desensitizers) would then undergo
compound titrations to determine the EC50 (the [compound] that incurs a half-maximal
change in E), as seen for ECGC in Figure 40B. Promising compounds could then undergo
Ca2+ and S1 titrations to fully resolve their Ca2+ and myosin-sensing abilities before
undergoing more expensive functional assessments in skinned fibers.

7.7 A drug screening tool—and beyond
Multiple TnI mutations have been implicated in inherited cardiomyopathies.88
This assay would first determine changes in the fraction of active Tn, and then assess
changes in Ca2+ and myosin sensitivity. This assay could be used to assess the effects on
Ca2+- and myosin-dependent activation from numerous mutations troponin, tropomyosin,
actin, and S1 that have been implicated in cardiomyopathies.85, 206 Although altered
molecular binding from the engineered Tn has proven problematic with levosimendan, a
silver lining could be an assessment of altered molecular binding from disease-causing
mutations, relevant in determining if a molecule is an appropriate therapeutic strategy for
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a specific CM as an assessment of the binding ability of therapeutic agents to Tn with
disease-causing mutations in sarcomeric proteins. Few, if any, biochemical thin filament
reconstitution assays have monitored both myosin and Ca2+ sensitivity, in addition to
revealing the fraction of active Tn. This screen could be used to expand insights into the
mechanism of thin filament activation.
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APPENDIX
Calculating the Förster distance (R0). MatLab code for determining R0 for a FRET pair.

%calculation of the J integral.
% units are in M^-1 cm^-1 nm^4
% donor and acceptor are peak normalized
% the x range is in common for donor and acceptor
% numerator
Error using evalin
Undefined function 'Calculating' for input arguments of type 'char'.

load donor emission and acceptor absorption
data
clear all;
donorFileName = 'donor_em';
acceptorFileName = 'acceptor_abs';
%pick integer wavelengths from absorbance
Donor=load(donorFileName);
Acceptor=load(acceptorFileName);
%pick integer wavelengths from absorbance
delta = Acceptor(2,1)-Acceptor(1,1);
pick=1:int32(1/delta):length(Acceptor);
AcceptorPick=Acceptor(pick,:);
donorWavelengthMin=Donor(1,1);
donorWavelengthMax=Donor(end,1);
donorLength = length(Donor);
donorRange = [donorWavelengthMin donorWavelengthMax]
acceptorWavelengthMin=AcceptorPick(1,1);
acceptorWavelengthMax=AcceptorPick(end,1);
acceptorLength = length(AcceptorPick);
acceptorRange = [acceptorWavelengthMin acceptorWavelengthMax]
rangeMin = min([donorWavelengthMin acceptorWavelengthMin]);
rangeMax = max([donorWavelengthMax acceptorWavelengthMax]);
lambda = rangeMin:rangeMax;

%
%len = size(Donor)(1);
donorEm = 0*lambda;
acceptorEx = 0*lambda;

donorOffset=donorWavelengthMin - rangeMin % 500-250
acceptorOffset=acceptorWavelengthMin - rangeMin % 250 - 250
donorEm(donorOffset+1:donorOffset+donorLength) = Donor(1:end,2);

1
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Table A1. Fitting results of rAc-TCSPC measurements of donor-only regulated
actin filaments. Data represent one rAc reconstitution set. The TCSPC histogram of the
FRET donor AF546 (TnI151-189) or ATTO550 (TnI196-211) was fit to a multiexponential decay model convolved with the IRF. Conditions: rAc-D were in working
buffer (apo) or WB supplemented with 3 mM CaCl2 (+Ca).
Donor residue on TnI
151C*AF546

Condition
apo
+Ca
160C*AF546
apo
+Ca
167C*AF546
apo
+Ca
174C*AF546
apo
+Ca
177C*AF546
apo
+Ca
182C*AF546
apo
+Ca
189C*AF546
apo
+Ca
196C*ATTO550
apo
+Ca
200C*ATTO550
apo
+Ca
204C*ATTO550
apo
+Ca
208C*ATTO550
apo
+Ca
211C*ATTO550
apo
+Ca
a
Lifetime (fractional amplitude).
b
Amplitude-weighted mean lifetime.

𝜏Q
0.32 (0.11)
0.33 (0.13)
0.15 (0.14)
0.17 (0.14)
0.25 (0.11)
0.31 (0.10)
0.20 (0.14)
0.15 (0.16)
0.14 (0.18)
0.24 (0.20)
0.11 (0.14)
0.13 (0.15)
0.08 (0.26)
0.12 (0.27)
0.83 (0.16)
0.92 (0.16)
0.66 (0.15)
0.73 (0.18)
0.68 (0.09)
1.64 (0.25)
0.13 (0.16)
0.12 (0.20)
0.59 (0.12)
0.75 (0.11)

Lifetime (ns)a
𝜏+
1.72 (0.16)
1.92 (0.21)
1.45 (0.16)
1.43 (0.17)
1.56 (0.17)
1.71 (0.18)
1.33 (0.20)
1.20 (0.17)
1.11 (0.20)
1.43 (0.26)
1.23 (0.20)
1.26 (0.21)
0.99 (0.18)
1.18 (0.24)
3.64 (0.84)
3.66 (0.84)
3.61 (0.85)
3.72 (0.82)
3.69 (0.91)
3.78 (0.75)
1.27 (0.19)
1.33 (0.20)
3.69 (0.88)
3.72 (0.89)

𝜏@
3.82 (0.73)
3.76 (0.66)
3.75 (0.70)
3.70 (0.69)
3.79 (0.72)
3.79 (0.72)
3.69 (0.66)
3.72 (0.67)
3.61 (0.62)
3.66 (0.54)
3.69 (0.66)
3.67 (0.64)
3.50 (0.56)
3.52 (0.49)

3.54 (0.65)
3.56 (0.60)

𝜏- b
3.10
2.91
2.89
2.81
3.01
3.07
2.73
2.72
2.48
2.40
2.71
2.64
2.16
2.05
3.20
3.22
3.16
3.19
3.41
3.24
2.55
2.44
3.32
3.40

χ2
1.09
0.95
1.05
0.95
1.02
1.01
1.03
1.00
1.05
1.09
1.01
0.98
1.01
1.07
1.08
1.12
1.12
1.03
1.08
1.34
1.01
0.95
1.11
1.06
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Table A2. Fitting results of rAc-TCSPC measurements of donor/acceptor regulated
actin filaments with ATTO655 on TnC residue 35. Data represent one rAc
reconstitution set. The TCSPC histogram of the FRET donor AF546 (TnI151-189) or
ATTO550 (TnI196-211) was fit to a multi-exponential decay model convolved with the
IRF. Conditions: rAc-D were in working buffer (apo) or WB supplemented with 3 mM
CaCl2 (+Ca).
Donor residue on TnI
151C*AF546
160C*AF546
167C*AF546
174C*AF546
177C*AF546
182C*AF546
189C*AF546
196C*ATTO550
200C*ATTO550
204C*ATTO550
208C*ATTO550
211C*ATTO550
a

Condition
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca

Lifetime (fractional amplitude).
Amplitude-weighted mean lifetime.

b

𝜏Q
0.21 (0.26)
0.19 (0.31)
0.13 (0.32)
0.12 (0.38)
0.24 (0.24)
0.18 (0.31)
0.16 (0.35)
0.15 (0.41)
0.14 (0.30)
0.13 (0.34)
0.13 (0.24)
0.12 (0.33)
0.11 (0.31)
0.11 (0.34)
0.17 (0.14)
0.23 (0.24)
0.15 (0.18)
0.16 (0.20)
0.12 (0.11)
0.11 (0.20)
0.11 (0.18)
0.12 (0.26)
0.12 (0.12)
0.13 (0.17)

Lifetime (ns)a
𝜏+
1.17 (0.28)
1.16 (0.28)
0.99 (0.29)
0.86 (0.28)
1.24 (0.29)
1.11 (0.29)
1.00 (0.33)
0.94 (0.32)
1.04 (0.30)
0.95 (0.28)
1.08 (0.31)
0.98 (0.33)
1.00 (0.27)
0.95 (0.32)
1.49 (0.25)
1.47 (0.32)
1.59 (0.19)
1.32 (0.22)
1.27 (0.13)
1.21 (0.21)
1.13 (0.18)
1.08 (0.23)
1.31 (0.15)
1.28 (0.20)

𝜏@
3.29 (0.46)
3.30 (0.41)
3.10 (0.39)
3.11 (0.34)
3.18 (0.47)
3.18 (0.40)
3.07 (0.32)
3.03 (0.27)
3.14 (0.40)
3.01 (0.38)
3.17 (0.45)
3.19 (0.34)
3.16 (0.42)
3.03 (0.34)
3.42 (0.61)
3.39 (0.44)
3.61 (0.63)
3.55 (0.58)
3.50 (0.76)
3.42 (0.59)
3.38 (0.64)
3.19 (0.51)
3.54 (0.73)
3.46 (0.62)

𝜏-8 b
1.91
1.74
1.55
1.35
1.92
1.66
1.36
1.17
1.62
1.46
1.79
1.45
1.63
1.37
2.48
2.0
2.6
2.37
2.84
2.28
2.37
1.90
2.81
2.44

χ2
0.99
1.03
1.05
1.13
1.02
1.06
1.18
1.24
1.04
1.01
1.10
1.19
1.05
1.10
1.13
1.11
1.05
1.10
1.02
1.03
1.15
1.05
1.03
1.03

E
0.38
0.40
0.46
0.52
0.36
0.46
0.50
0.57
0.35
0.39
0.34
0.45
0.25
0.33
0.23
0.38
0.18
0.26
0.17
0.29
0.07
0.22
0.15
0.28
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Table A3. Fitting results of rAc-TCSPC measurements of donor/acceptor regulated
actin filaments with ATTO655 on TnC residue 89. Data represent one rAc
reconstitution set. The TCSPC histogram of the FRET donor AF546 (TnI151-189) or
ATTO550 (TnI196-211) was fit to a multi-exponential decay model convolved with the
IRF. Conditions: rAc-D were in working buffer (apo) or WB supplemented with 3 mM
CaCl2 (+Ca).
Donor residue on TnI
151C*AF546
160C*AF546
167C*AF546
174C*AF546
177C*AF546
182C*AF546
189C*AF546
196C*ATTO550
200C*ATTO550
204C*ATTO550
208C*ATTO550
211C*ATTO550
a

Condition
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca

Lifetime (fractional amplitude).
Amplitude-weighted mean lifetime.

b

𝜏Q
0.19 (0.32)
0.20 (0.37)
0.13 (0.37)
0.14 (0.40)
0.24 (0.27)
0.20 (0.32)
0.14 (0.31)
0.15 (0.28)
0.13 (0.30)
0.15 (0.31)
0.14 (0.24)
0.15 (0.32)
0.11 (0.31)
0.12 (0.38)
0.14 (0.13)
0.18 (0.20)
0.07 (0.21)
0.10 (0.24)
0.12 (0.18)
0.13 (0.25)
0.09 (0.21)
0.14 (0.25)
0.15 (0.11)
0.14 (0.20)

Lifetime (ns)a
𝜏+
1.06 (0.29)
1.04 (0.30)
0.94 (0.30)
0.93 (0.30)
1.18 (0.39)
1.09 (0.33)
1.03 (0.27)
1.01 (0.26)
1.00 (0.29)
0.93 (0.29)
1.11 (0.30)
1.07 (0.33)
0.98 (0.27)
0.95 (0.33)
1.21 (0.18)
1.19 (0.26)
1.23 (0.16)
1.21 (0.20)
1.27 (0.20)
1.16 (0.28)
1.01 (0.19)
1.22 (0.29)
1.27 (0.16)
1.29 (0.24)

𝜏@
3.08 (0.39)
3.10 (0.33)
2.93 (0.33)
3.00 (0.30)
3.05 (0.34)
2.99 (0.35)
3.16 (0.42)
3.05 (0.46)
3.15 (0.41)
3.06 (0.40)
3.27 (0.46)
3.22 (0.35)
3.14 (0.42)
2.96 (0.29)
3.37 (0.69)
3.22 (0.54)
3.63 (0.63)
3.55 (0.56)
3.48 (0.62)
3.30 (0.47)
3.36 (0.60)
3.23 (0.46)
3.49 (0.73)
3.38 (0.56)

𝜏-8 b
1.57
1.41
1.29
1.22
1.56
1.46
1.64
1.70
1.61
1.53
1.87
1.52
1.61
1.23
2.57
2.07
2.50
2.26
2.45
1.91
2.22
1.88
2.78
2.22

χ2
0.96
1.07
1.13
1.06
1.04
1.08
1.02
1.08
1.06
1.05
1.03
1.15
1.08
1.19
1.11
1.02
1.05
1.01
0.95
1.08
1.02
1.06
0.96
1.11

E
0.49
0.52
0.55
0.56
0.48
0.52
0.4
0.38
0.35
0.36
0.31
0.42
0.26
0.4
0.2
0.36
0.21
0.29
0.28
0.41
0.13
0.23
0.16
0.35

156
Table A4. Fitting results of rAc-TCSPC measurements of donor/acceptor regulated
actin filaments with ATTO655 on TnC residue 127. Data represent one rAc
reconstitution set. The TCSPC histogram of the FRET donor AF546 (TnI151-189) or
ATTO550 (TnI196-211) was fit to a multi-exponential decay model convolved with the
IRF. Conditions: rAc-D were in working buffer (apo) or WB supplemented with 3 mM
CaCl2 (+Ca).
Donor residue on TnI
151C*AF546
160C*AF546
167C*AF546
174C*AF546
177C*AF546
182C*AF546

Condition
apo

𝜏Q
0.23 (0.20)

Lifetime (ns)a
𝜏+
1.27 (0.30)

+Ca

0.23 (0.24)

1.23 (0.34)

3.19 (0.42)

1.81

0.99

0.38

apo
+Ca
apo
+Ca
apo
+Ca
apo
+Ca

0.13 (0.19)
0.15 (0.27)
0.24 (0.18)
0.21 (0.22)
0.15 (0.24)
0.15 (0.26)
0.18 (0.20)
0.18 (0.26)

1.09 (0.26)
1.35 (0.35)
1.30 (0.27)
1.14 (0.31)
1.05 (0.30)
1.04 (0.33)
1.16 (0.29)
1.20 (0.28)

3.17 (0.55)
3.40 (0.38)
3.20 (0.55)
3.05 (0.47)
3.02 (0.46)
2.93 (0.41)
3.24 (0.51)
3.17 (0.46)

2.06
1.81
2.16
1.83
1.75
1.59
2.03
1.83

1.04
1.11
0.96
1.03
1.09
1.07
1.06
1.04

0.29
0.36
0.28
0.40
0.36
0.41
0.18
0.24

apo

0.11 (0.20)

1.14 (0.25)

3.45 (0.55)

2.20

1.00

0.19

0.14 (0.20)
0.12 (0.29)
0.12 (0.33)
0.16 (0.17)
0.13 (0.24)
0.04 (0.20)
0.15 (0.18)
0.06 (0.18)
0.12 (0.20)
0.14 (0.22)
0.11 (0.28)
0.17 (0.14)
0.12 (0.20)

1.18 (0.26)
1.01 (0.30)
1.00 (0.32)
1.20 (0.25)
1.07 (0.31)
0.92 (0.11)
1.40 (0.22)
1.13 (0.21)
1.14 (0.23)
1.20 (0.24)
0.97 (0.30)
1.38 (0.20)
1.15 (0.25)

3.47 (0.54)
3.06 (0.41)
2.94 (0.35)
3.13 (0.58)
2.98 (0.44)
3.62 (0.69)
3.43 (0.60)
3.31 (0.61)
3.25 (0.57)
3.35 (0.54)
3.08 (0.42)
3.38 (0.66)
3.24 (0.55)

2.19
1.59
1.39
2.15
1.69
2.61
2.39
2.26
2.14
2.11
1.62
2.54
2.08

1.03
1.16
1.15
1.08
1.05
0.96
1.04
1.04
1.05
1.09
1.07
1.02
1.11

0.17
0.26
0.32
0.33
0.48
0.17
0.25
0.34
0.34
0.17
0.34
0.24
0.39

+Ca
apo
+Ca
196C*ATTO550
apo
+Ca
200C*ATTO550
apo
+Ca
204C*ATTO550
apo
+Ca
208C*ATTO550
apo
+Ca
211C*ATTO550
apo
+Ca
a
Lifetime (fractional amplitude).
b
Amplitude-weighted mean lifetime.
189C*AF546

𝜏@
3.20 (0.50)

𝜏-8 b
2.01

χ2
1.02

E
0.35
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Table A5. Correcting FRET efficiency with the acceptor labeling ratio.
Representative data from separately reconstituted rAc-D (Tn-D, TnI211C*ATTO550)
and rAc-DA (Tn-DA, TnI211C*ATTO550, TnC127C*ATTO655) filaments. The
lifetime of the donor in the absence and presence of an acceptor ( 𝜏- and 𝜏-8 ,
respectively), FRET efficiency E, fa-corrected FRET efficiency Ec, and the calculated
inter-dye distances (R and Rc) are shown.
𝜏-

𝜏-8

E

Ec

R

Rc

Trial

apo

+Ca

apo

+Ca

fa

apo

+Ca

apo

+Ca

apo

+Ca

apo

+Ca

1

3.49

3.44

3.03

2.58

0.49

0.13

0.25

0.27

0.51

8.76

7.69

7.56

6.36

2

3.32

3.4

2.54

2.08

0.85

0.23

0.39

0.28

0.46

7.79

6.90

7.51

6.59

3

3.57

3.53

3.28

2.89

0.33

0.08

0.18

0.25

0.55

9.59

8.23

7.71

6.19

Table A6. Non-corrected and fA-corrected mean FRET efficiencies and inter-dye
distances. Representative data from separately reconstituted rAc-D (Tn-D,
TnI211C*ATTO550) and rAc-DA (Tn-DA, TnI211C*ATTO550, TnC127C*ATTO655)
filaments. The mean FRET efficiency E and fA-corrected FRET efficiency Ec, and
calculated inter-dye distance R and Rc are shown ± SEM (n = 3).
E

Ec

R

Rc

apo

+Ca

apo

+Ca

apo

+Ca

apo

+Ca

0.15±0.06

0.27±0.06

0.26±0.01

0.51±0.03

8.71±0.52

7.61±0.38

7.60±0.06

6.38±0.11
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Table A7. FRET efficiency and inter-dye distance at acceptor position TnC35C. The
average FRET efficiency calculated from the amplitude-weighted mean lifetime of the
donor for rAc-D and DA in WB (apo) and WB supplemented with 3 mM CaCl2 (+Ca),
and calculated inter-dye distance (R) ± SEM from n = 3 experiments are shown.
FRET Efficiency
Donor residue on TnI

R (nm)

apo

+Ca

apo

+Ca

151C*AF546

0.54 ± 0.05

0.55 ± 0.04

5.35 ± 0.20

5.32 ± 0.14

160C*AF546

0.68 ± 0.03

0.77 ± 0.06

4.85 ± 0.10

4.48 ± 0.25

167C*AF546

0.49 ± 0.02

0.66 ± 0.01

5.54 ± 0.08

4.94 ± 0.04

174C*AF546

0.51 ± 0.04

0.58 ± 0.05

5.47 ± 0.15

5.21 ± 0.17

177C*AF546

0.49 ± 0.02

0.57 ± 0.03

5.54 ± 0.09

5.23 ± 0.12

182C*AF546

0.38 ± 0.06

0.53 ± 0.08

6.45 ± 0.26

5.40 ± 0.30

189C*AF546

0.28 ± 0.05

0.42 ± 0.05

7.59 ± 0.32

5.80 ± 0.19

196C*ATTO550

0.27 ± 0.04

0.41 ± 0.09

7.59 ± 0.26

6.85 ± 0.46

200C*ATTO550

0.22 ± 0.02

0.36 ± 0.01

7.90 ± 0.19

7.05 ± 0.08

204C*ATTO550

0.24 ± 0.06

0.34 ± 0.06

7.78 ± 0.41

7.18 ± 0.33

208C*ATTO550

0.25 ± 0.06

0.33 ± 0.04

7.74 ± 0.38

7.21 ± 0.22

211C*ATTO550

0.20 ± 0.01

0.34 ± 0.04

8.06 ± 0.10

7.14 ± 0.20
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Table A8. FRET efficiency and inter-dye distances at acceptor reside TnC89C. The
average FRET efficiency calculated from the amplitude-weighted mean lifetime of the
donor for rAc-D and DA in WB (apo) and WB supplemented with 3 mM CaCl2 (+Ca),
and calculated inter-dye distance (R) ± SEM from n = 3 experiments is shown.
FRET Efficiency
Donor residue on TnI

R (nm)

apo

+Ca

apo

+Ca

151C*AF546

0.58 ± 0.04

0.64 ± 0.04

5.19 ± 0.15

5.00 ± 0.13

160C*AF546

0.71 ± 0.02

0.77 ± 0.04

4.74 ± 0.09

4.50 ± 0.09

167C*AF546

0.60 ± 0.04

0.69 ± 0.01

5.13 ± 0.14

4.82 ± 0.02

174C*AF546

0.54 ± 0.00

0.56 ± 0.03

5.36 ± 0.01

5.29 ± 0.11

177C*AF546

0.47 ± 0.00

0.48 ± 0.04

5.62 ± 0.01

5.58 ± 0.13

182C*AF546

0.36 ± 0.03

0.49 ± 0.06

6.06 ± 0.15

5.54 ± 0.22

189C*AF546

0.28 ± 0.05

0.44 ± 0.05

6.50 ± 0.30

5.73 ± 0.20

196C*ATTO550

0.31 ± 0.03

0.46 ± 0.04

7.30 ± 0.16

6.58 ± 0.19

200C*ATTO550

0.22 ± 0.03

0.46 ± 0.09

7.97 ± 0.24

6.58 ± 0.37

204C*ATTO550

0.36 ± 0.05

0.62 ± 0.06

7.09 ± 0.24

5.87 ± 0.26

208C*ATTO550

0.27 ± 0.06

0.49 ± 0.09

7.62 ± 0.40

6.50 ± 0.42

211C*ATTO550

0.24 ± 0.01

0.45 ± 0.01

7.76 ± 0.10

6.61 ± 0.06
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Table A9. FRET efficiency and inter-dye distances at acceptor reside TnC127C. The
average FRET efficiency calculated from the amplitude-weighted mean lifetime of the
donor for rAc-D and DA in WB (apo) and WB supplemented with 3 mM CaCl2 (+Ca),
and calculated inter-dye distance (R) ± SEM from n = 3 experiments is shown.
FRET Efficiency
Donor residue on TnI

R (nm)

apo

+Ca

apo

+Ca

151C*AF546

0.42 ± 0.01

0.57 ± 0.08

5.81 ± 0.11

5.23 ± 0.28

160C*AF546

0.37 ± 0.04

0.46 ± 0.04

6.04 ± 0.17

5.64 ± 0.13

167C*AF546

0.37 ± 0.02

0.45 ± 0.02

6.03 ± 0.08

5.68 ± 0.06

174C*AF546

0.44 ± 0.01

0.54 ± 0.04

5.72 ± 0.04

5.37 ± 0.13

177C*AF546

0.38 ± 0.02

0.48 ± 0.02

5.96 ± 0.06

5.57 ± 0.08

182C*AF546

0.21 ± 0.01

0.29 ± 0.06

6.89 ± 0.05

6.44 ± 0.30

189C*AF546

0.23 ± 0.04

0.44 ± 0.06

6.79 ± 0.26

5.75 ± 0.22

196C*ATTO550

0.25 ± 0.07

0.46 ± 0.08

7.81 ± 0.53

6.62 ± 0.36

200C*ATTO550

0.27 ± 0.07

0.44 ± 0.08

7.61 ± 0.40

6.71 ± 0.38

204C*ATTO550

0.27 ± 0.07

0.41 ± 0.06

7.70 ± 0.50

6.81 ± 0.28

208C*ATTO550

0.25 ± 0.02

0.38 ± 0.02

7.70 ± 0.17

6.93 ± 0.10

211C*ATTO550

0.26 ± 0.01

0.51 ± 0.03

7.60 ± 0.06

6.38 ± 0.11
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Table A10. Calcium-induced changes in FRET efficiency and inter-dye distance in
Tn within thin filaments. The mean FRET efficiency calculated from the amplitudeweighted mean lifetime of the donor in the presence or absence of an acceptor on TnC
residue 35, 89, or 127 and the calculated inter-dye distance (R) in WB supplemented with
3 mM CaCl2 (+Ca) were subtracted from the mean E or R in WB without Ca2+ (apo). A
positive change in E or a negative change in R indicates a closer proximity of the donor
residue on TnI and acceptor residue on TnC.
Donor residue
151
160
167
174
177
182
189
196
200
204
208
211

∆E for TnC acceptor residue
35C
89C
127C
0.01
0.05
0.16
0.09
0.06
0.10
0.17
0.09
0.09
0.07
0.02
0.09
0.08
0.01
0.10
0.15
0.13
0.07
0.14
0.16
0.21
0.14
0.15
0.20
0.14
0.25
0.16
0.10
0.27
0.15
0.08
0.21
0.13
0.14
0.21
0.24

∆R for TnC acceptor residue (nm)
35C
89C
127C
-0.03
-0.19
-0.58
-0.36
-0.25
-0.40
-0.60
-0.32
-0.35
-0.26
-0.07
-0.35
-0.30
-0.04
-0.39
-0.57
-0.52
-0.45
-0.65
-0.77
-1.05
-0.73
-0.72
-1.19
-0.85
-1.39
-0.90
-0.60
-1.21
-0.89
-0.54
-1.13
-0.77
-0.92
-1.15
-1.22
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Table A11. FRET efficiency and inter-dye distances from steady-state FRET and
theoretically-derived from the MTS molecular model. The experimentally-determined
FRET efficiency calculated from peak emission intensity at 570 nm from the donor in
rAc-D and rAc-DA with acceptor position TnC89C in WB supplemented with 75 mM
KCl and 3 mM CaCl2 (+Ca), and calculated inter-dye distance (R) from n = 1 experiment.
Model-derived E were calculated from Cα distances determined from the MTS model.
Experimental

Model-derived

Donor residue on TnI
151C*AF546

E
0.99

R (nm)
2.56

E
1.00

R (nm)
1.40

160C*AF546

0.99

2.56

0.97

3.00

167C*AF546

0.92

3.66

0.90

3.80

174C*AF546

0.85

4.12

0.81

4.30

177C*AF546

0.75

5.03

0.75

4.60

182C*AF546

0.74

4.62

0.58

5.20

189C*AF546

0.76

4.54

0.37

6.00
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Table A12. Fitting results for Ca2+ titrations of PKA-treated thin filaments, and thin
filaments with PKA treatment, small molecules, and S1. The FRET efficiency vs. free
Ca2+ was fit to the Hill equation to recover estimates for FRET efficiency (%) without
Ca2+ (apo, E-), with 3 mM CaCl2 (+Ca, E+), the Ca2+ concentration that produces halfmaximal activation Ca50, and the Hill coefficient nH. The maximum likelihood estimate ±
asymptotic SE are reported.
Sample
rAc
+DMSO
+bepridil
+levo.
+EGCG
+S1
+PKA

E-

E+

Ca50 (µM)

nH

22.3 ± 0.4
21.7 ± 0.4
26.3 ± 1.1
21.1 ± 0.4
14.5 ± 0.5
36.1 ± 0.5
20.1 ± 0.3

39.3 ± 0.3
40.5 ± 0.4
43.4 ± 0.6
37.3 ± 0.4
41.9 ± 0.8
46.8 ± 0.3
38.0 ± 0.3

1.12 ± 0.09
1.07 ± 0.08
0.53 ± 0.11
1.05 ± 0.08
4.06 ± 0.50
0.54 ± 0.08
1.57 ± 0.09

1.2 ± 0.1
1.2 ± 0.1
0.9 ± 0.2
1.4 ± 0.2
0.9 ± 0.1
0.8 ± 0.1
1.2 ± 0.1

Table A13. Fitting results for S1 titrations of reporter filaments. The calculated
FRET efficiency vs. the fractional binding of S1 to actin was fit to the Hill equation to
recover the FRET efficiency (%) without S1 E-S1, the FRET efficiency with saturating S1
E+S1, the stoichiometry θ = [S1]T/[Actin]T that produces half maximal activation θ50, and
Hill coefficient nH. Maximum likelihood estimate ± asymptotic SE are reported.
Sample
rAc
+Ca

2+

+bepridil
+bepridil +Ca

2+

+EGCG
+EGCG +Ca
+PKA
+PKA +Ca

2+

2+

E-S1
23.1 ± 0.2

E+S1
45.9 ± 0.4

θ50

nH

0.36 ± 0.03

2.9 ± 0.1

43.6 ± 0.2

55.4 ± 0.2

0.20 ± 0.03

2.8 ± 0.2

27.7 ± 1.8

27.7 ± 1.8

45.9 ± 3.1

45.9 ± 3.1

10.5 ± 0.2

58.4 ± 1.1

0.55 ± 0.05

3.3 ± 0.1

36.2 ± 2.2

59.8 ± 0.4

0.32 ± 0.05

2.2 ± 0.1

21.5 ± 0.1

34.5 ± 0.1

0.59 ± 0.01

28.1 ± 2.0

42.0 ± 01

51.6 ± 0.1

0.57 ± 0.01

50.7 ± 6.1
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Table A14. Fitting results for Ca2+ titrations of phosphorylated reporter filaments,
and filaments mock-treated with PKA or ATP. FRET efficiency vs. free Ca2+
concentration were fit to the Hill equation, to recover estimates of FRET efficiency
without Ca2+ (apo, E-), FRET efficiency with 3 mM CaCl2 (+Ca, E+), the Ca2+
concentration that produces half maximal activation Ca50, and the Hill coefficient nH.
Maximum likelihood estimate ± asymptotic SE are reported.
Sample

E+
46.9 ± 0.6

Ca50 (µM)

nH

rAc

E20.4 ± 0.5

2.6 ± 0.2

1.0 ± 0.1

+PKA +ATP

17.8 ± 0.5

44.2 ± 1.5

4.2 ± 1.0

0.7 ± 0.1

+PKA

20.6 ± 0.6

45.4 ± 0.8

2.7 ± 0.4

1.1 ± 0.1

+ATP

20.4 ± 0.6

45.9 ± 0.7

2.4 ± 0.3

1.0 ± 0.1

Table A15. Fitting results for S1 titrations of phosphorylated reporter filaments,
and filaments mock-treated with PKA or ATP. The calculated FRET efficiency vs. the
total fractional binding of S1 to actin was fit to the Hill equation to recover the FRET
efficiency without S1 (apo, E-S1), the FRET efficiency with saturating S1 E+S1, the
fractional binding of [S1]T/[Actin]T that produces half maximal activation θ50, and Hill
coefficient nH. Maximum likelihood estimate ± asymptotic SE are reported.
Sample

E-S1

E+S1

θ50

nH

rAc

20.4 ± 0.3

43.6 ± 0.3

0.27 ± 0.04

3.0 ± 0.2

+Ca2+

41.8 ± 0.3

57.7 ± 0.2

0.20 ± 0.05

2.8 ± 0.4

20.5 ± 0.1

37.5 ± 0.2

0.59 ± 0.02

38.6 ± 8.8

41.2 ± 0.2

55.6 ± 0.1

0.55 ± 0.01

37.0 ± 6.2

+PKA

22.1 ± 0.3

42.8 ± 1.1

0.31 ± 0.05

3.7 ± 0.6

+PKA +Ca2+

42.8 ± 0.4

55.7 ± 0.2

0.16 ± 0.06

3.1 ± 0.6

+ATP

23.9 ± 0.3

46.1 ± 0.4

0.31 ± 0.06

2.6 ± 0.2

44.7 ± 0.2

57.4 ± 0.1

0.21 ± 0.04

3.2 ± 0.4

+PKA +ATP
+PKA +ATP +Ca

+ATP +Ca

2+

2+
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